WO2011029920A1 - Heterocylcic derivatives as inhibitors of glutaminyl cyclase - Google Patents
Heterocylcic derivatives as inhibitors of glutaminyl cyclase Download PDFInfo
- Publication number
- WO2011029920A1 WO2011029920A1 PCT/EP2010/063341 EP2010063341W WO2011029920A1 WO 2011029920 A1 WO2011029920 A1 WO 2011029920A1 EP 2010063341 W EP2010063341 W EP 2010063341W WO 2011029920 A1 WO2011029920 A1 WO 2011029920A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- phenyl
- substituted
- compound
- alkoxy
- Prior art date
Links
- 0 CBc(cc1)cc2c1[n]c(*)n2 Chemical compound CBc(cc1)cc2c1[n]c(*)n2 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the invention relates to novel pyrrolidine derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5).
- QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu * ) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.
- Glutaminyl cyclase catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (pGlu * ) liberating ammonia.
- pGlu * pyroglutamic acid
- Inhibitors of QC are described in WO 2004/098625, WO 2004/098591 , WO 2005/039548, WO 2005/075436, WO 2008/055945, WO 2008/055947, WO 2008/055950, WO2008/065141 , WO 2008/1 10523, WO 2008/128981 , WO 2008/128982, WO 2008/128983, WO 2008/128984, WO 2008/128985, WO 2008/128986, WO 2008/128987 and WO 2010/026212.
- EP 02 01 1 349.4 discloses polynucleotides encoding insect glutaminyl cyclase, as well as polypeptides encoded thereby and their use in methods of screening for agents that reduce glutaminyl cyclase activity. Such agents are useful as pesticides.
- k or " K” and “K D” are binding constants, which describe the binding of an inhibitor to and the subsequent release from an enzyme. Another measure is the “IC 50 " value, which reflects the inhibitor concentration, which at a given substrate concentration results in 50 % enzyme activity.
- DP IV-inhibitor or "dipeptidyl peptidase IV inhibitor” is generally known to a person skilled in the art and means enzyme inhibitors, which inhibit the catalytic activity of DP IV or DP IV-like enzymes.
- DP IV-activity is defined as the catalytic activity of dipeptidyl peptidase IV (DP IV) and DP IV-like enzymes.
- These enzymes are post-proline (to a lesser extent post-alanine, post- serine or post-glycine) cleaving serine proteases found in various tissues of the body of a mammal including kidney, liver, and intestine, where they remove dipeptides from the N- terminus of biologically active peptides with a high specificity when proline or alanine form the residues that are adjacent to the N-terminal amino acid in their sequence.
- post-proline to a lesser extent post-alanine, post- serine or post-glycine
- PEP-inhibitor or "prolyl endopeptidase inhibitor” is generally known to a person skilled in the art and means enzyme inhibitors, which inhibit the catalytic activity of prolyl endopeptidase (PEP, prolyl oligopeptidase, POP).
- PEP-activity is defined as the catalytic activity of an endoprotease that is capable to hydrolyze post proline bonds in peptides or proteins where the proline is in amino acid position 3 or higher counted from the N-terminus of a peptide or protein substrate.
- QC as used herein comprises glutaminyl cyclase (QC) and QC-like enzymes. QC and QC-like enzymes have identical or similar enzymatic activity, further defined as QC activity. In this regard, QC-like enzymes can fundamentally differ in their molecular structure from QC.
- QC-like enzymes are the glutaminyl-peptide cyclotransferase-like proteins (QPCTLs) from human (GenBank NM_017659), mouse (GenBank BC058181 ), Macaca fascicularis (GenBank AB168255), Macaca mulatta (GenBank XM_001 1 10995), Canis familiaris (GenBank XM_541552), Rattus norvegicus (GenBank XM_001066591 ), Mus musculus (GenBank BC058181 ) and Bos taurus (GenBank BT026254).
- QPCTLs glutaminyl-peptide cyclotransferase-like proteins
- QC activity is defined as intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (pGlu * ) or of N-terminal L-homoglutamine or L- ⁇ - homoglutamine to a cyclic pyro-homoglutamine derivative under liberation of ammonia. See therefore schemes 1 and 2.
- Scheme 1 Cyclization of glutamine by QC
- EC as used herein comprises the activity of QC and QC-like enzymes as glutamate cyclase (EC), further defined as EC activity.
- EC activity as used herein is defined as intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid (pGlu * ) by QC. See therefore scheme 3.
- QC-inhibitor "glutaminyl cyclase inhibitor” is generally known to a person skilled in the art and means enzyme inhibitors, which inhibit the catalytic activity of glutaminyl cyclase (QC) or its glutamyl cyclase (EC) activity.
- the subject method and medical use utilize an agent with an I C 50 for QC inhibition of 10 ⁇ or less, more preferably of 1 ⁇ or less, even more preferably of 0.1 ⁇ or less or 0.01 ⁇ or less, or most preferably 0.001 ⁇ or less.
- I ndeed, inhibitors with K, values in the lower micromolar, preferably the nanomolar and even more preferably the picomolar range are contemplated.
- active agents are described herein, for convenience, as "QC inhibitors", it will be understood that such nomenclature is not intending to limit the subject of the invention to a particular mechanism of action.
- the QC inhibitors of the subject method or medical use will be small molecules, e.g., with molecular weights of 500 g/mole or less, 400 g/mole or less, preferably of 350 g/mole or less, and even more preferably of 300 g/mole or less and even of 250 g/mole or less.
- subject refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
- therapeutically effective amount means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.
- pharmaceutically acceptable embraces both human and veterinary use: For example the term “pharmaceutically acceptable” embraces a veterinarily acceptable compound or a compound acceptable in human medicine and health care.
- alkyl denotes a C 1 - 12 alkyl group, suitably a Ci -8 alkyl group, e.g. Ci -6 alkyl group, e.g. Ci -4 alkyl group.
- Alkyl groups may be straight chain or branched. Suitable alkyl groups include, for example, methyl, ethyl, propyl (e.g. n-propyl and isopropyl), butyl (e.g n-butyl, iso-butyl, sec- butyl and tert-butyl), pentyl (e.g. n-pentyl), hexyl (e.g.
- alk for example in the expressions "alkoxy”, "haloalkyl” and “thioalkyl” should be interpreted in accordance with the definition of "alkyl”.
- alkoxy groups include methoxy, ethoxy, propoxy (e.g. n-propoxy), butoxy (e.g. n-butoxy), pentoxy (e.g. n-pentoxy), hexoxy (e.g. n-hexoxy), heptoxy (e.g.
- n-heptoxy n-heptoxy
- octoxy e.g. n-octoxy
- exemplary thioalkyl groups include methylthio-.
- exemplary haloalkyl groups include fluoroalkyl e.g. CF 3 .
- alkenyl denotes a C 2- i 2 alkenyl group, suitably a C 2 -6 alkenyl group, e.g. a C 2-4 alkenyl group, which contains at least one double bond at any desired location and which does not contain any triple bonds.
- Alkenyl groups may be straight chain or branched.
- Exemplary alkenyl groups including one double bond include propenyl and butenyl.
- Exemplary alkenyl groups including two double bonds include pentadienyl, e.g. (1 E, 3E)-pentadienyl.
- alkynyl denotes a C 2- i 2 alkynyl group, suitably a C 2 -6 alkynyl group, e.g. a C 2-4 alkynyl group, which contains at least one triple bond at any desired location and may or may not also contain one or more double bonds.
- Alkynyl groups may be straight chain or branched.
- Exemplary alkynyl groups include propynyl and butynyl.
- alkylene denotes a chain of formula -(CH 2 ) n - wherein n is an integer e.g. 2- 5, unless specifically limited.
- cycloalkyl denotes a C 3- io cycloalkyl group (i.e. 3 to 10 ring carbon atoms), more suitably a C 3- 8 cycloalkyl group, e.g. a C 3- 6 cycloalkyl group.
- exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
- a most suitable number of ring carbon atoms is three to six.
- cycloalkenyl denotes a C 5- io cycloalkenyl group (i .e. 5 to 1 0 ring carbon atoms), more suitably a C 5 -s cycloalkenyl group e.g. a C 5- 6 cycloalkenyl group.
- exemplary cycloalkenyl groups include cyclopropenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl.
- a most suitable number of ring carbon atoms is five to six.
- Carbocyclyl denotes any ring system in which all the ring atoms are carbon and which contains between three and twelve ring carbon atoms, suitably between three and ten carbon atoms and more suitably between three and eight carbon atoms.
- Carbocyclyl groups may be saturated or partially unsaturated, but do not include aromatic rings. Examples of carbocyclyl groups include monocyclic, bicyclic, and tricyclic ring systems, in particular monocyclic and bicyclic ring systems. Other carbocylcyl groups include bridged ring systems (e.g. bicyclo[2.2.1 ]heptenyl).
- a specific example of a carbocyclyl group is a cycloalkyl group. A further example of a carbocyclyl group is a cycloalkenyl group.
- heterocyclyl refers to a carbocyclyl group wherein one or more (e.g. 1 , 2 or 3) ring atoms are replaced by heteroatoms selected from N, S and O.
- a specific example of a heterocyclyl group is a cycloalkyl group (e.g. cyclopentyl or more particularly cyclohexyl) wherein one or more (e.g. 1 , 2 or 3, particularly 1 or 2, especially 1 ) ring atoms are replaced by heteroatoms selected from N, S or O.
- heterocyclyl groups containing one hetero atom include pyrrolidine, tetrahydrofuran and piperidine, and exemplary heterocyclyl groups containing two hetero atoms include morpholine and piperazine.
- a further specific example of a heterocyclyl group is a cycloalkenyl group (e.g. a cyclohexenyl group) wherein one or more (e .g . 1 , 2 or 3 , particularly 1 or 2, especially 1 ) ring atoms are replaced by heteroatoms selected from N, S and O.
- An example of such a group is dihydropyranyl (e.g. 3,4-dihydro-2H-pyran-2-yl-).
- aryl denotes a C 6- 12 aryl group, suitably a C 6- io aryl group, more suitably a C 6- 8 aryl group.
- Aryl groups will contain at least one aromatic ring (e.g. one, two or three rings).
- An example of a typical aryl group with one aromatic ring is phenyl.
- An example of a typical aryl group with two aromatic rings is naphthyl.
- heteroaryl denotes an aryl residue, wherein one or more (e.g. 1 , 2, 3, or 4, suitably 1 , 2 or 3) ring atoms are replaced by heteroatoms selected from N, S and O, or else a 5-membered aromatic ring containing one or more (e.g. 1 , 2, 3, or 4, suitably 1 , 2 or 3) ring atoms selected from N, S and O.
- exemplary monocyclic heteroaryl groups having one heteroatom include: five membered rings (e.g. pyrrole, furan, thiophene); and six membered rings (e.g.
- pyridine such as pyridin-2-yl, pyridin-3-yl and pyridin-4-yl
- exemplary monocyclic heteroaryl groups having two heteroatoms include: five membered rings (e.g. pyrazole, oxazole, isoxazole, thiazole, isothiazole, imidazole, such as imidazol-1 -yl, imidazol-2-yl imidazol-4-yl); six membered rings (e.g. pyridazine, pyrimidine, pyrazine).
- Exemplary monocyclic heteroaryl groups having three heteroatoms include: 1 ,2,3- triazole and 1 ,2,4-triazole.
- Exemplary monocyclic heteroaryl groups having four heteroatoms include tetrazole.
- Exemplary bicyclic heteroaryl groups include: indole (e.g. indol-6-yl), benzofuran, benzthiophene, quinoline, isoquinoline, indazole, benzimidazole, benzthiazole, quinazoline and purine.
- alkylaryl unless specifically limited, denotes an aryl residue which is connected via an alkylene moiety e.g. a Ci -4 alkylene moiety.
- amino refers to the group -NH 2 .
- phenyl substituted by phenyl refers to biphenyl.
- ww * denotes a single bond where the stereochemistry is not defined.
- benzimidazol l When benzimidazol l is shown as benzimidazol-5-yl, which is represented as:
- the processes for the preparation of the compounds according to the invention give rise to a mixture of stereoisomers
- these isomers may be separated by conventional techniques such as preparative chromatography.
- the compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution.
- the compounds may, for example, be resolved into their components enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p- toluoyl-l-tartaric acid followed by fractional crystallization and regeneration of the free base.
- the compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column.
- salts and solvates of the compounds of formula (I) and physiologically functional derivatives thereof which are suitable for use in medicine are those wherein the counter-ion or associated solvent is pharmaceutically acceptable.
- salts and solvates having non- pharmaceutically acceptable counter-ions or associated solvents are within the scope of the present invention , for example, for use as intermediates in the preparation of other compounds and their pharmaceutically acceptable salts and solvates.
- Suitable salts according to the invention include those formed with both organic and inorganic acids or bases.
- Pharmaceutically acceptable acid addition salts include those formed from hydrochloric, hydrobromic, sulfuric, nitric, citric, tartaric, phosphoric, lactic, pyruvic, acetic, trifluoroacetic, triphenylacetic, sulfamic, sulfanilic, succinic, oxalic, fumaric, maleic, malic, mandelic, glutamic, aspartic, oxaloacetic, methanesulfonic, ethanesulfonic, arylsulfonic (for example p-toluenesulfonic, benzenesulfonic, naphthalenesulfonic or naphthalenedisulfonic), salicylic, glutaric, gluconic, tricarballylic, cinnamic, substituted cinnamic (for example, phenyl
- Pharmaceutically acceptable base salts include ammonium salts, alkali metal salts such as those of sodium and potassium, alkaline earth metal salts such as those of calcium and magnesium and salts with organic bases such as dicyclohexylamine and /V-methyl-D-glucamine.
- some of the crystalline forms of the compounds may exist as polymorphs and as such are intended to be included in the present invention.
- some of the compounds may form solvates with water (i.e. hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.
- the compounds, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.
- the present invention further includes within its scope prodrugs of the compounds of this invention.
- prodrugs will be functional derivatives of the compounds which are readily convertible in vivo into the desired therapeutically active compound.
- the term “administering” shall encompass the treatment of the various disorders described with prodrug versions of one or more of the claimed compounds, but which converts to the above specified compound in vivo after administration to the subject. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
- any of the processes for preparation of the compounds of the present invention it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991 , fully incorporated herein by reference.
- the protecting groups may be removed at a convenient subsequent stage using methods known from the art.
- a protecting group or protective group is introduced into a molecule by chemical modification of a functional group in order to obtain chemoselectivity in a subsequent chemical reaction.
- Protecting groups are e.g. alcohol protecting groups, amine protecting groups, carbonyl protecting groups, carboxylic acid protecting groups and phosphate protecting groups.
- alcohol protecting groups are acetyl (Ac), benzoyl (Bz), benzyl (Bn, Bnl) ⁇ - methoxyethoxymethyl ether (MEM), mimethoxytrityl [bis-(4-methoxyphenyl)phenylmethyl, DMT], methoxymethyl ether (MOM), methoxytrityl [(4-methoxyphenyl)diphenylmethyl, MMT), p-methoxybenzyl ether (PMB), methylthiomethyl ether, pivaloyl (Piv), tetrahydropyranyl (TH P), trityl (triphenylmethyl , Tr), silyl ethers (such as trimethylsilyl ether (TMS), tert- butyldimethylsi ly I ether (TB D MS), ie/f-butyldimethylsilyloxymethyl ether (TOM), and triisopropylsilyl ether
- Suitable amine protecting groups are selected from carbobenzyloxy (Cbz), p-methoxybenzyl carbonyl (Moz or MeOZ), ie f-butyloxycarbonyl (BOC), 9-fluorenylmethyloxycarbonyl (FMOC), acetyl (Ac), benzoyl (Bz), benzyl (Bn), p-methoxybenzyl (PMB), 3,4- dimethoxybenzyl (DMPM), p-methoxyphenyl (PMP), tosyl (Ts), and other sulfonamides (Nosyl & Nps).
- Suitable carbonyl protecting groups are selected from acetals and ketals, acylals and dithianes.
- Suitable crboxylic acid protecting groups are selected from methyl esters, benzyl esters, tert- butyl esters, silyl esters, orthoesters, and oxazoline.
- phosphate protecting groups are 2-cyanoethyl and methyl (Me)
- composition is intended to encompass a product comprising the claimed compounds in the therapeutically effective amounts, as well as any product which results, directly or indirectly, from combinations of the claimed compounds.
- Carriers and Additives for galenic formulations may advantageously include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like;
- suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like.
- Carriers which can be added to the mixture, include necessary and inert pharmaceutical excipients, including, but not limited to, suitable binders, suspending agents, lubricants, flavorants, sweeteners, preservatives, coatings, disintegrating agents, dyes and coloring agents.
- Soluble polymers as targetable drug carriers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxyethylaspartamide-phenol, or polyethyleneoxidepolyllysine substituted with palmitoyl residue.
- the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polyactic acid, polyepsilon caprolactone, polyhydroxy butyeric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
- Suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or betalactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
- Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
- any of aforesaid heteroaryl groups may optionally be substituted by one or more groups selected from Ci -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 haloalkyl, -Ci_ 6thioalkyl, -SOCi -4 alkyl, -S0 2 Ci -4 alkyl, Ci -6 alkoxy-, -0-C 3-8 cycloalkyl, C 3-8 cycloalkyl, - S0 2 C 3-8 cycloalkyl, -SOC 3-6 cycloalkyl, C 3-6 alkenyloxy-, C 3-6 alkynyloxy-, -C(0)Ci -6 alkyl, - C(0)OCi -6 alkyl, Ci- 6 alkoxy-Ci- 6 alkyl-, nitro, halogen, cyano, hydroxyl, -C(0)OH, -NH 2 , - NHCi -4 alkyl,
- carbocyclyl groups may optionally be substituted by one or more groups selected from Ci -4 alkyl, oxo, halogen and Ci -4 alkoxy;
- R 2 represents H , Ci -8 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, -Ci -4 alkylaryl, -Ci_ 4alkylheteroaryl, -Ci -4 alkylcarbocyclyl or -Ci -4 alkylheterocyclyl;
- any of aforesaid aryl and heteroaryl groups may optionally be substituted by one or more groups selected from Ci -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 haloalkyl, -Ci_ 6thioalkyl, -SOCi -4 alkyl, -S0 2 Ci -4 alkyl, Ci -6 alkoxy-, -0-C 3-8 cycloalkyl, C 3-8 cycloalkyl, - S0 2 C 3-8 cycloalkyl, -SOC 3-6 cycloalkyl, C 3-6 alkenyloxy-, C 3-6 alkynyloxy-, -C(0)Ci -6 alkyl, - C(0)OCi -6 alkyl, Ci- 6 alkoxy-Ci- 6 alkyl-, Ci- 6 alkoxy-Ci- 6 alkoxy-, nitro, halogen, haloCi.
- 6alkyl haloCi -6 alkoxy, cyano, hydroxyl, -C(0)OH, -NH 2 , -NHCi -4 alkyl, -N(Ci -4 alkyl)(Ci. 4alkyl), -N(Ci -4 alkyl)(Ci -4 alkyl)-N(Ci -4 alkyl)(Ci -4 alkyl), -Ci -4 alkyl-N(Ci -4 alkyl)(Ci -4 alkyl), - Ci -4 alkoxy-N(Ci -4 alkyl)(Ci -4 alkyl), -N(C 3-8 cycloalkyll)(C 3-8 cycloalkyl), -N(-Ci -6 alkyl-Ci.
- R 2 represents phenyl substituted by phenyl, phenyl substituted by a monocyclic heteroaryl group, phenyl substituted by phenoxy, phenyl substituted by heterocyclyl, phenyl substituted by heterocyclyl wherein said heterocyclyl is substituted by phenyl, phenyl substituted by -0-Ci -4 alkyl-heterocyclyl, phenyl substituted by benzyloxy, phenyl substituted by carbocyclyl, phenyl substituted by carbocyclyl wherein said carbocyclyl is substituted by heterocyclyl, phenyl substituted by -O-carbocyclyl, heterocyclyl substituted by phenyl, carbocyclyl substituted by phenyl, phenyl fused to carbocyclyl, phenyl fused to heterocyclyl, -Ci -4 alkyl(phenyl substituted by phenyl), -C
- any of aforesaid phenyl, benzyloxy and heteroaryl groups may optionally be substituted by one or more groups selected from Ci -4 alkyl, halogen and Ci -4 alkoxy, and in which any of aforesaid carbocyclyl and heterocyclyl groups may optionally be substituted by one or more groups selected from methyl, phenyl, oxo, halogen, hydroxyl and Ci -4 alkoxy;
- R 3 represents H, -Ci -4 alkyl or aryl
- aryl may optionally be substituted by one or more groups selected from Ci -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 haloalkyl, -Ci -6 thioalkyl, -SOCi -4 alkyl, - S0 2 Ci -4 alkyl, Ci -6 alkoxy-, -0-C 3-8 cycloalkyl, C 3-8 cycloalkyl, -S0 2 C 3 - 8 cycloalkyl, -SOC 3- 6 cycloalkyl, C 3-6 alkenyloxy-, C 3-6 alkynyloxy-, -C(0)Ci -6 alkyl, -C(0)OCi -6 alkyl, Ci -6 alkoxy- Ci -6 alkyl-, nitro, halogen , cyano, hydroxyl , -C(0)OH, -NH 2 , -NHCi -4 alkyl,
- R 2 and R 3 are joined to form a carbocyclyl ring which is optionally substituted by one or more Ci -2 alkyl groups; or R 2 and R 3 are joined to form a carbocyclyl ring which is fused to phenyl, wherein aforesaid carbocyclyl and/or phenyl may optionally be substituted by one or more groups selected from Ci -4 alkyl, halogen and Ci -4 alkoxy;
- R 2 and R 3 are joined to form a carbocyclyl ring which is fused to monocyclic heteroaryl, wherein aforesaid carbocyclyl and/or heteroaryl may optionally be substituted by one or more groups selected from Ci -4 alkyl, halogen and Ci -4 alkoxy;
- Z represents -N-R 4 , O or CH R 10 , such that when X represents O or S, Z must represent CHR 10 ;
- X and Z represent two adjacent carbon atoms of a phenyl ring which is fused in that position and which is optionally substituted by one or more halogen or Ci -2 alkyl groups;
- R 4 represents H, -Ci -8 alkyl, -C(0)Ci -6 alkyl or -NH 2 ;
- R 7 and R 8 independently represent H, -Ci -4 alkyl or aryl
- aryl may be optionally substituted by Ci -6 alkyl, C 2-6 alkenyl, C 2- 6 alkynyl, Ci -6 haloalkyl, -Ci -6 thioalkyl, -SOCi -4 alkyl, -S0 2 Ci -4 alkyl, Ci -6 alkoxy-, -0-C 3- scycloalkyl, C 3-8 cycloalkyl, -S0 2 C 3-8 cycloalkyl, -SOC 3-6 cycloalkyl, C 3-6 alkenyloxy-, C 3- 6 alkynyloxy-, -C(0)Ci -6 alkyl, -C(0)OCi -6 alkyl, Ci- 6 alkoxy-Ci- 6 alkyl-, nitro, halogen, cyano, hydroxyl, -C(0)OH, -NH 2 , -NHCi -4 alkyl, -N(Ci -4
- R 9 and R 10 independently represent H or methyl
- any of aforesaid heteroaryl groups may optionally be substituted by one or more grou ps selected from Ci -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 haloalkyl, -Ci_ 6thioalkyl, -SOCi -4 alkyl, -S0 2 Ci -4 alkyl, Ci -6 alkoxy-, -0-C 3-8 cycloalkyl, C 3-8 cycloalkyl, - S0 2 C 3-8 cycloalkyl, -SOC 3-6 cycloalkyl, C 3-6 alkenyloxy-, C 3-6 alkynyloxy-, -C(0)Ci -6 alkyl, -
- carbocyclyl groups may optionally be substituted by one or more groups selected from Ci -4 alkyl, oxo, halogen and Ci -4 alkoxy;
- R 2 represents H , Ci -8 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, -Ci -4 alkylaryl, -Ci_ 4alkylheteroaryl, -Ci -4 alkylcarbocyclyl or -Ci -4 alkylheterocyclyl;
- any of aforesaid aryl and heteroaryl groups may optionally be substituted by one or more groups selected from Ci -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 haloalkyl, -Ci_ 6thioalkyl, -SOCi -4 alkyl, -S0 2 Ci -4 alkyl , Ci -6 alkoxy-, -0-C 3-8 cycloalkyl, C 3-8 cycloalkyl, -
- R 2 represents phenyl substituted by phenyl, phenyl substituted by a monocyclic heteroaryl group, phenyl substituted by phenoxy, phenyl substituted by heterocyclyl, phenyl substituted by -0-Ci -4 alkyl-heterocyclyl, phenyl substituted by benzyloxy, phenyl fused to carbocyclyl, phenyl fused to heterocyclyl, -Ci -4 alkyl(phenyl substituted by phenyl), -
- any of aforesaid phenyl, benzyloxy and heteroaryl groups may optionally be substituted by one or more groups selected from Ci -4 alkyl, halogen and Ci -4 alkoxy, and in which any of aforesaid carbocyclyl and heterocyclyl groups may optionally be substituted by one or more groups selected from methyl, phenyl, oxo, halogen and Ci_ 4alkoxy;
- R 3 represents H, -Ci -4 alkyl or aryl
- aryl may optionally be substituted by one or more groups selected from Ci -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 haloalkyl, -Ci -6 thioalkyl, -SOCi -4 alkyl, -
- Ci -4 alkyl Ci -6 alkoxy-, -0-C 3-8 cycloalkyl, C 3-8 cycloalkyl, -S0 2 C 3 - 8 cycloalkyl, -SOC 3- 6 cycloalkyl, C 3-6 alkenyloxy-, C 3-6 alkynyloxy-, -C(0)Ci -6 alkyl, -C(0)OCi -6 alkyl, Ci -6 alkoxy- Ci -6 alkyl-, nitro, halogen, cyano, hydroxyl, -C(0)OH, -NH 2 , -NHCi -4 alkyl, -N(Ci_ 4alkyl)(Ci -4 alkyl), -C(0)N(Ci -4 alkyl)(Ci -4 alkyl), -C(0)NH 2 , -C(0)NH(Ci -4 alkyl) and, - C(0)NH(C 3- iocycloalkyl);
- R 2 and R 3 are joined to form a carbocyclyl ring which is optionally substituted by one or more Ci -2 alkyl groups;
- R 2 and R 3 are joined to form a carbocyclyl ring which is fused to phenyl, wherein aforesaid carbocyclyl and/or phenyl may optionally be substituted by one or more groups selected from Ci -4 alkyl, halogen and Ci -4 alkoxy;
- R 2 and R 3 are joined to form a carbocyclyl ring which is fused to monocyclic heteroaryl, wherein aforesaid carbocyclyl and/or heteroaryl may optionally be substituted by one or more groups selected from Ci -4 alkyl, halogen and Ci -4 alkoxy;
- Z represents -N-R 4 , O or CH R 10 , such that when X represents O or S, Z must represent
- X and Z represent two adjacent carbon atoms of a phenyl ring which is fused in that position and which is optionally substituted by one or more halogen or Ci -2 alkyl groups;
- R 4 represents H, -Ci -8 alkyl, -C(0)d -6 alkyl or -NH 2 ;
- R 7 and R 8 independently represent H, -Ci -4 alkyl or aryl
- aryl may be optionally substituted by Ci -6 alkyl, C 2-6 alkenyl, C 2- 6 alkynyl, Ci -6 haloalkyl, -Ci -6 thioalkyl, -SOCi -4 alkyl, -S0 2 Ci -4 alkyl, Ci -6 alkoxy-, -0-C 3- scycloalkyl, C 3-8 cycloalkyl, -S0 2 C 3 - 8 cycloalkyl, -SOC 3-6 cycloalkyl, C 3-6 alkenyloxy-, C 3- 6 alkynyloxy-, -C(0)Ci -6 alkyl, -C(0)OCi -6 alkyl, Ci- 6 alkoxy-Ci- 6 alkyl-, nitro, halogen, cyano, hydroxyl, -C(0)OH, -NH 2 , -NHCi -4 alkyl, -N(Ci)
- R 9 and R 10 independently represent H or methyl
- carbocyclyl and heterocyclyl When carbocyclyl and heterocyclyl are substituted, they are typically substituted by 1 or 2 substituents (e.g. 1 substitent). Typically the substituent is methyl. More typically carbocyclyl and heterocyclyl groups are unsubstituted.
- aryl and heteroaryl When aryl and heteroaryl are substituted, they are typically substituted by 1 , 2 or 3 (e.g. 1 or 2) substituents.
- Substituents for aryl and heteroaryl are selected from Ci -6 alkyl (e.g. methyl), C 2-6 alkenyl (e.g. buten-3-yl), C 2-6 alkynyl (e.g. butyn-3-yl), Ci -6 haloalkyl (e.g. fluoromethyl, trifluoromethyl), -C 1-6 thioalkyl (e.g. -S-methyl), -SOCi -4 alkyl (e.g. -SOmethyl), -S0 2 Ci -4 alkyl (e.g.
- Ci -6 alkoxy- e.g. methoxy, ethoxy
- -0-C 3-8 cycloalkyl e.g. -O-cyclopentyl
- C 3-8 cycloalkyl e.g. cyclopropyl, cyclohexyl
- -S0 2 C 3-8 cycloalkyl e.g. -S0 2 cyclohexyl
- -SOC 3- 6 cycloalkyl e.g. -SOcyclopropyl
- C 3-6 alkenyloxy- e.g. -O-buten-2-yl
- C 3-6 alkynyloxy- e.g.
- - O-buten-2-yl -C(0)d -6 alkyl (e.g. -C(O)ethyl), -C(0)OCi -6 alkyl (e.g. -C(O)O-methyl), Ci_ 6 alkoxy-Ci- 6 alkyl- (e.g. methoxy-ethyl-), nitro, halogen (e.g. fluoro, chloro, bromo), cyano, hydroxyl, -C(0)OH, -NH 2 , -NHCi -4 alkyl (e.g. -NHmethyl), -N(C 1-4 alkyl)(C 1-4 alkyl) (e.g.
- substituents will be selected from Ci -6 alkyl (e.g. methyl), Ci -6 haloalkyl (e.g. Ci -6 fluoroalkyl, e.g. CF 3 ), Ci -6 alkoxy (e.g. OMe), halogen and hydroxy.
- R 1 represents heteroaryl
- examples include monocyclic (e.g. 5 and 6 membered) and bicyclic (e.g. 9 and 10 membered, particularly 9 membered) heteroaryl rings, especially rings containing nitrogen atoms (e.g. 1 or 2 nitrogen atoms).
- a suitable bicyclic heteroaryl ring is a 9-membered heteroaryl ring containing 1 or 2 nitrogen atoms, especially a benzene ring fused to a 5-membered ring containing one or two nitrogen atoms (e.g. 1 H-benzoimidazolyl). Most suitably the point of attachment is through a benzene ring, e.g. the group is 1 H- benzoimidazol-5-yl.
- Aforementioned heteroaryl groups may either be unsubstituted (which is more typical) or may suitably be substituted by one or more (e.g. 1 or 2) substituents selected from alkyl (e.g. Ci -4 alkyl such as Me), alkoxy- (e.g. Ci -4 alkoxy- such as OMe) and halogen (e.g. F).
- alkyl e.g. Ci -4 alkyl such as Me
- alkoxy- e.g. Ci -4 alkoxy- such as OMe
- halogen e.g. F
- R 1 represents -C 3 - 8 carbocyclyl-heteroaryl
- examples of carbocyclyl include cycloalkyl (e.g. cyclohexyl) and cycloalkenyl (e.g. cyclohexenyl)
- heteroaryl groups include monocyclic (e.g.
- heteroaryl groups may either be unsubstituted (which is more typical) or may suitably be substituted by one or more (e.g. 1 or 2) substituents selected from alkyl (e.g. Ci -4 alkyl such as Me), alkoxy- (e.g. Ci -4 alkoxy- such as OMe) and halogen (e.g. F).
- alkyl e.g. Ci -4 alkyl such as Me
- alkoxy- e.g. Ci -4 alkoxy- such as OMe
- halogen e.g. F
- a suitable heteroaryl group is imidazol-1 -yl.
- An exemplary - C 3-8 carbocyclyl-heteroaryl group is 3-imidazol-1 -yl-cyclohexyl-.
- examples of C 2-6 alkenyl include C 2-4 alkenyl, in particular propenyl and examples of heteroaryl groups include monocyclic (e.g. 5 or 6 membered, particularly 5 membered) rings especially rings containing nitrogen atoms e.g. 1 or 2 nitrogen atoms.
- Aforementioned heteroaryl groups may either be unsubstituted (which is more typical) or may suitably be substituted by one or more (e.g. 1 or 2) substituents selected from alkyl (e.g. Ci -4 alkyl such as Me), alkoxy- (e.g. Ci -4 alkoxy- such as OMe) and halogen (e.g. F).
- a suitable heteroaryl group is imidazolyl, particularly imidazol-1 -yl .
- An exemplary -alkenylheteroaryl group is 3-imidazol-1 -yl-prop-2-enyk
- examples of Ci -6 alkyl include Ci -5 alkyl or Ci -4 alkyl, especially C 2-5 alkyl or C 2-4 alkyl, in particular propyl
- examples of heteroaryl groups include monocyclic (e.g. 5 or 6 membered, particularly 5 membered) rings especially rings containing nitrogen atoms e.g. 1 or 2 nitrogen atoms.
- Aforementioned heteroaryl groups may either be unsubstituted (which is most typical) or may suitably be substituted by one or more (e.g. 1 or 2) substituents selected from alkyl (e.g. Ci -4 alkyl such as Me), alkoxy- (e.g.
- a suitable heteroaryl group is imidazol-1 -yl.
- a particularly suitable -alkylheteroaryl group is 3-imidazol-1 -yl-propyk
- R 1 represents -Ci -6 alkylheteroaryl
- examples wherein alkyl is branched include:
- R 1 heteroaryl groups include a 5-membered ring containing 2 or 3 nitrogen atoms, which ring may optionally be substituted (e.g. in particular by one or two groups, such as methyl, for example:
- heteroaryl groups shown above may also be present as part of a larger R 1 function such as -C 3 - 8 carbocyclyl-heteroaryl, -C 2 - 6 alkenylheteroaryl or -Ci -6 alkylheteroaryl.
- Wh en R 2 represents -Ci -8 alkyl, examples include methyl, ethyl, propyl (e.g. n-propyl, isopropyl), butyl (e.g. n-butyl- sec-butyl, isobutyl and tert-butyl), pentyl (e.g. n-pentyl, 3,3,- dimethylpropyl), hexyl, heptyl and octyl.
- aryl may typically represent phenyl.
- exemplary substituted phenyl groups include 3-methylphenyl-, 2,3-dichlorophenyl-, 2,3- difluorophenyl-, 2,4-dichlorophenyl-, 2,4-difluororophenyl-, 2,4-dimethoxyphenyl-, 2,4- dimethylphenyl-, 2,4-bis(trifluoromethyl)phenyl-, 2,4,6-trifluorophenyl-, 2,4,6-trimethylphenyl-, 2,6-dichlorophenyl-, 2,6-difluorophenyl-, 2,6-dimethoxyphenyl-, 2,6-difluoro-4- (methoxy)phenyl-, 2-isopropyl-6-methylphenyl-, 3-(cyclopentyloxy)-4-methoxyphenyl-, 3,4,5- trimethoxyphenyl-, 3,
- R 2 may represent unsubstituted phenyl-.
- substituted phenyl groups include 2,3,4- trifluorophenyl, 2,3-difluoro-4-methylphenyl, 2-bromo-4-fluorophenyl-, 2-bromo-5- fluorophenyl-, 2-chlorophenyl-, 2-fluorophenyl-, 2-fluoro-5-(trifluoromethyl)phenyl-, 2-hydroxy- 3-methoxyphenyl-, 2-hydroxy-5-methylphenyl-, 3-chlorophenyl-, 3-fluorophenyl-, 3-fluoro-4- (trifluoromethyl)phenyl-, 3-fluoro-5-(trifluoromethyl)phenyl-, 2-fluoro-4-(trifluoromethyl)phenyl- , 3-fluoro-4-(methoxy)phenyl-, 3-hydroxy-4-methoxyphenyl-, 4-bromo-2-fluoropheny
- R 2 represents optionally substituted aryl and aryl represents naphthyl
- examples include unsubstituted naphthyl (e.g. naphthalen-1 -yl, naphthalen-2-yl, naphthalen-3-yl) as well as substituted naphthyl (e.g. 4-methyl-naphthalen-2-yl-, 5-methyl-naphthalen-3-yl-, 7- methyl-naphthalen-3-y- and 4-fluoro-naphthalen-2-yl-).
- unsubstituted naphthyl e.g. naphthalen-1 -yl, naphthalen-2-yl, naphthalen-3-yl
- substituted naphthyl e.g. 4-methyl-naphthalen-2-yl-, 5-methyl-naphthalen-3-yl-, 7- methyl-naphthalen-3-y- and 4-fluoro-naphthalen-2-
- R 2 represents optionally substituted heteroaryl
- examples include monocyclic rings (e.g. 5 or 6 membered rings) and bicyclic rings (e.g. 9 or 10 membered rings) which may optionally be substituted.
- Example 5 membered rings include pyrrolyl (e.g. pyrrol-2-yl) and imidazolyl (e.g. 1 H-imidazol-2-yl or 1 H-imidazol-4-yl), pyrazolyl (e.g. 1 H-pyrazol-3-yl), furanyl (e.g. furan-2-yl), thiazolyl (e.g. thiazol-2-yl), thiophenyl (e.g.
- Example 6 membered rings include pyridinyl (e.g. pyridin-2-yl and pyridin-4-yl). Specific substituents that may be mentioned are one or more e.g. 1 , 2 or 3 groups selected from halogen, hydroxyl, alkyl (e.g. methyl) and alkoxy- (e.g. methoxy-).
- Example substituted 5 membered rings include 4,5-dimethyl-furan-2-yl-, 5-hydroxymethyl-furan-2-yl-, 5-methyl- furan-2-yl- and 6-methyl-pyridin-2-yk
- An example substituted 6-membered ring is 1 -oxy- pyridin-4-yk
- Example 9 membered rings include 1 H-indolyl (e.g. 1 H-indol-3-yl, 1 H-indol-5- yl), benzothiophenyl (e.g. benzo[b]thiophen-3-yl, particularly 2-benzo[b]thiophen-3-yl), benzo[1 ,2,5]-oxadiazolyl (e.g.
- Example 10 membered rings include quinolinyl (e.g.quinolin-3-yl, quinolin-4-yl, quinolin-8-yl). Specific substituents that may be mentioned are one or more e.g. 1 , 2 or 3 groups selected from halogen, hydroxyl, alkyl (e.g. methyl) and alkoxy- (e.g. methoxy-).
- Example substituted 9-membered rings include 1 -methyl-1 H-indol-3-yl, 2-methyl-1 H-indol-3-yl, 6-methyl-1 H-indol-3-yl.
- Example substituted 10 membered rings include 2-chloro-quinolin-3-yl, 8-hydroxy-quinolin-2-yl, oxo- chromenyl (e.g. 4-oxo-4H-chromen-3-yl) and 6-methyl-4-oxo-4H-chromen-3-yl.
- R 2 represents carbocyclyl
- examples include cycloalkyi and cycloalkenyl.
- examples of cycloalkyi include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
- Examples of cycloalkenyl include cyclohexenyl (e.g. cyclohex-2-enyl, cyclohex-3-enyl).
- substituted carbocyclyl examples include 2-methyl-cyclohexyl-, 3-methyl-cyclohexyl-, 4-methyl- cyclohexyl-, 2-methyl-cyclohex-2-enyl, 2-methyl-cyclohex-3-enyl, 3-methyl-cyclohex-3-enyl, 3-methyl-cyclohex-3-enyl.
- R 2 represents heterocyclyl (which may optionally be substituted)
- examples include tetrahydrofuranyl, morpholinyl, piperdinyl, 3,4-dihydro-2H-pyranyl, pyrrolidinyl, methyltetrahydrofuranyl- (e.g. 5-methyltetrahydrofuran-2-yl-).
- R 2 represents -Ci -4 alkylaryl
- examples include -alkyl(substituted phenyl) e.g. in which phenyl is substituted by one or more groups selected from alkyl, fluoroalkyl, halogen and alkoxy (e.g. methyl, trifluoromethyl, tert-butyl, chloro, fluoro and methoxy) and, for example, alkyl is Ci -4 alkyl.
- Another specific group is -alkyl(bicyclic aryl) e.g. wherein bicyclic aryl is optionally substituted naphthyl.
- a further specific group is benzyl.
- Wh e n R 2 represents -Ci -4 alkylheteroaryl in which heteroaryl is optionally substituted, examples include methylheteroaryl and -ethylheteroaryl (e.g. 1 -heteroarylethyl- and 2- heteroarylethyl-), -propylheteroaryl and -butylheteroaryl in which heteroaryl is optionally substituted.
- -alkylheteroaryl groups include pyridinylmethyl-, N-methyl- pyrrol-2-methyl- N-methyl-pyrrol-2-ethyl-, N-methyl-pyrrol-3-methyl-, N-methyl-pyrrol-3-ethyl-, 2-methyl-pyrrol-1 -methyl-, 2-methyl-pyrrol-1 -ethyl-, 3-methyl-pyrrol-1 -methyl-, 3-methyl- pyrrol-1 -ethyl-, 4-pyridino-methyl-, 4-pyridino-ethyl-, 2-(thiazol-2-yl)-ethyl-, 2-ethyl-indol-1 - methyl-, 2-ethyl-indol-1 -ethyl-, 3-ethyl-indol-1 -methyl-, 3-ethyl-indol-1 -ethyl-, 4-methyl-pyridin-
- R 2 represents -Ci -4 alkyl-carbocyclyl (which may optionally be substituted)
- examples include -methyl-cyclopentyl, -methyl-cyclohexyl, -ethyl-cyclohexyl, -propyl-cyclohexyl, - methyl-cyclohexenyl, -ethyl-cyclohexenyl, -methyl(4-methylcyclohexyl) and -propyl (3- methylcyclyohexyl).
- R 2 represents -Ci -4 alkylheterocyclyl (which may optionally be substituted); examples include -methyl-tetrahydrofuranyl (e.g. -methyl-tetrahydrofuran-2-yl, -methyl-tetrahydrofuran-
- R 2 represents phenyl substituted by phenyl or phenyl substituted by a monocyclic heteroaryl group, in which any of aforesaid phenyl and heteroaryl groups may optionally be substituted, typically the phenyl ring connected directly to the nitrogen atom is unsubstituted and the terminal phenyl ring or the monocyclic heteroaryl ring is optionally substituted by one, two or three substitutents (e.g. one or two, e.g. one). Typically the terminal phenyl or monocyclic heteroaryl group is unsubstituted.
- the terminal phenyl or monocyclic heteroaryl group substitutes the other phenyl group at the 4-position.
- R 2 represents phenyl substituted by phenyl in which any of aforesaid phenyl groups may optionally be substituted, examples include -biphenyl-4-yl.
- R 2 represents phenyl substituted by a monocyclic heteroaryl group, in which any of aforesaid phenyl and heteroaryl groups may optionally be substituted, examples include 4- (oxazol-5-yl)phenyk
- R 2 represents phenyl substituted by benzyloxy in which any of aforesaid phenyl and benzyloxy groups may optionally be substituted
- examples include 4-benzyloxy-phenyl-, 4-(3- methylbenzyloxy)phenyl- and 4-(4-methylbenzyloxy)phenyk
- R 2 represents optionally substituted phenyl fused to optionally substituted carbocyclyl
- examples include indanyl (e.g. indan-4-yl-, 2-methyl-indan-4-yl-), indenyl and tetralinyl.
- R 2 represents optionally substituted phenyl fused to optionally substituted heterocyclyl
- examples include benzo[1 ,3]dioxo-4-yl- and 2,3-dihydro-benzo[1 ,4]dioxin-4-yk
- R 2 represents -Ci -4 alkyl(phenyl substituted by phenyl)
- examples include biphenyl-4-yl- methyk
- examples include 4-(oxazol-5-yl)phenyl-methyk
- R 2 represents -Ci -4 alkyl(phenyl substituted by benzyloxy) in which any of aforesaid phenyl and benzyloxy groups may optionally be substituted
- examples include 4-benzyloxy- phenyl-methyk 4-(3-methylbenzyloxy)phenyl-methyl- and 4-(4-methylbenzyloxy)phenyl- methyk
- examples include indanyl-methyl- (e.g.
- R 2 represents -Ci -4 alkyl(optionally substituted phenyl fused to optionally substituted heterocyclyl); examples include benzo[1 ,3]dioxo-4-yl-methyl- and 2,3-dihydro- benzo[1 ,4]dioxin-4-yl-methyl-.
- Wh en R 3 represents -Ci -4 alkyl, examples include methyl, ethyl, propyl (e.g. n-propyl, isopropyl) and butyl (e.g. n-butyl- sec-butyl, isobutyl and tert-butyl).
- aryl may typically represent phenyl.
- exemplary substituted phenyl groups include 2,4-dichlorophenyl-, 2,4-difluororophenyl-, 2,4- dimethoxyphenyl-, 2,4-dimethylphenyl-, 2,4-bis(trifluoromethyl)phenyl-, 2,4,6-trifluorophenyl-, 2,4,6-trimethylphenyl-, 2,6-dichlorophenyl-, 2,6-difluorophenyl-, 2,6-dimethoxyphenyl-, 2- isopropyl-6-methylphenyl-, 3-(cyclopentyloxy)-4-methoxyphenyl-, 3,4,5-trimethoxyphenyl-, 3,4-dimethoxyphenyl-, 3,4-dichlorophenyl-, 3,4-dimethylphenyl-, 3,4,5-trifluorophenyl-, 3,5- bis(
- R 3 may represents unsubstituted phenyl-.
- substituted phenyl groups include 2-bromo-4- fluorophenyl-, 2-bromo-5-fluorophenyl-, 2-chlorophenyl-, 2-fluoro-5-(trifluoromethyl)phenyl-, 2-hydroxy-3-methoxyphenyl-, 2-hydroxy-5-methylphenyl-, 3-chlorophenyl-, 3-fluoro-4- (trifluoromethyl)phenyl-, 3-hydroxy-4-methoxyphenyl-, 4-chloro-3-(trifluoromethyl)phenyl-, 4- chlorophenyl-, 4-fluorophenyl- and 4-propoxyphenyl-.
- examples include cycloalkyi (e.g. cyclopropyl, cyclopentyl and cyclohexyl) and cycloalkenyl (e.g. cyclohexenyl).
- cycloalkyi e.g. cyclopropyl, cyclopentyl and cyclohexyl
- cycloalkenyl e.g. cyclohexenyl
- R 2 and R 3 are joined to form a carbocyclyl ring which is fused to phenyl; examples include indanyl (e.g. indan-2-yl) and tetralinyl.
- R 2 and R 3 are joined to form a carbocyclyl ring which is fused to monocyclic heteroaryl; examples include 5-membered carbocyclyl fused to 6-membered heteroaryl, 6-membered carbocyclyl fused to 6-membered heteroaryl, 5-membered carbocyclyl fused to 5-membered heteroaryl and 6-membered carbocyclyl fused to 5-membered heteroaryl.
- the monocyclic heteroaryl to which carbocyclyl is fused contains at least one heteroatom (e.g. one, two or three heteroatoms, e.g. one or two, e.g. one heteroatom).
- R 4 represents -Ci -8 alkyl examples include methyl, ethyl, propyl (e.g. n-propyl, isopropyl), butyl (e.g. n-butyl- sec-butyl, isobutyl and tert-butyl), pentyl (e.g. n-pentyl, 3,3,- dimethylpropyl), hexyl, heptyl and octyl.
- propyl e.g. n-propyl, isopropyl
- butyl e.g. n-butyl- sec-butyl, isobutyl and tert-butyl
- pentyl e.g. n-pentyl, 3,3,- dimethylpropyl
- hexyl heptyl and octyl.
- R 4 represents -C(0)Ci -6 alkyl; examples include -C(0)Ci -4 alkyl such as -C(0)methyl, - C(0)ethyl, -C(0)propyl and -C(0)butyl.
- R 1 represents heteroaryl or -Ci -6 alkylheteroaryl.
- R 1 represents heteroaryl. I n a further embodiment, R 1 represents unsubstituted heteroaryl or heteroaryl optionally substituted by one or more Ci -6 alkyl (e.g. methyl), halogen (e.g. fluorine) or Ci -6 haloalkyl (e.g. trifluoromethyl) groups. In another embodiment, R 1 represents -Ci -6 alkylheteroaryl.
- R 1 when R 1 represents heteroaryl, R 1 suitably represents bicyclic heteroaryl, especially 9- membered bicyclic heteroaryl. More suitably, R 1 represents a bicyclic heteroaryl ring system and in particular a phenyl ring fused with a 5 membered heteroaryl ring containing one or more (e.g. one or two, suitably one, more suitably two) nitrogen atoms or a pyridine ring fused with a 5-membered heteroaryl ring containing one or more (e.g. one or two, suitably one, more suitably two) nitrogen atoms.
- R 1 represents bicyclic heteroaryl, preferably the heteroaryl group does not contain S atoms.
- R 1 represents a phenyl ring fused to a 5-membered heteroaryl ring, preferably R 1 is linked to the core of formula (I) through the phenyl ring.
- R 1 represents a pyridine ring fused to a 5-membered heteroaryl ring, preferably R 1 is linked to the core of formula (I) through the pyridine ring.
- R 1 represents unsubstituted heteroaryl.
- R 1 suitably represents 1 H-benzoimidazolyl or imidazo[1 ,2-a]pyridine, particularly 1 H-benzoimidazolyl, especially 1 H-benzoimidazol-5-yl.
- heteroaryl is suitably monocyclic heteroaryl, especially 5-membered monocyclic heteroaryl. More suitably, when R 1 represents -Ci_ 6 alkylheteroaryl, heteroaryl is suitably a 5 membered heteroaryl ring containing one or more (e.g. one or two, suitably one, more suitably two) nitrogen atoms. When R 1 represents -Ci_ 6 alkylheteroaryl, preferably the heteroaryl group does not contain S atoms. When R 1 represents -Ci -6 alkylheteroaryl, heteroaryl represents substituted or unsubstituted imidazolyl.
- R 1 represents -Ci -6 alkylheteroaryl
- heteroaryl suitably represents substituted or unsubstituted imidazoly-1 -yl.
- R 1 represents -Ci -6 alkylheteroaryl and heteroaryl is substituted imidazoly-1 -yl
- imidazoly-1 -yl is suitably substituted by methyl.
- R 1 represents
- A represents an unbranched Ci -6 alkylene chain (e.g. an unbranched Ci -5 alkylene chain, e.g. an unbranched Ci -4 alkylene chain, e.g. an unbranched Ci -3 alkylene chain) or A represents a branched Ci -6 alkylene chain (e.g. wherein the one or more (e.g. one or two) branches consist of one or more (e.g. one or two) methyl groups at the same or different positions) or A represents (CH 2 )aCR 5 R 6 (CH 2 )b and
- R 11 , R 12 and R 13 independently represent H or Ci -2 alkyl.
- R 1 represents
- B represents a bond, -CH 2 -, -CH 2 -CH 2 -, -CH(Me)-, -CH(Me)-CH 2 - or -CH 2 -CH(Me)- and
- R 14 and R 15 independently represent H, Ci -2 alkyl (e.g. methyl), halogen (e.g. fluorine) or d -6 haloalkyl (e.g. trifluoromethyl).
- R 1 represents
- C represents a bond, -CH 2 -, -CH 2 -CH 2 -, -CH(Me)-, -CH(Me)-CH 2 - or -CH 2 -CH(Me) and
- R 16 and R 17 independently represent H, Ci -2 alkyl (e.g. methyl), halogen (e.g. fluorine) or Ci_ haloalkyl (e.g. trifluoromethyl).
- R 1 represents
- D represents a bond, -CH 2 -, -CH 2 -CH 2 -, -CH(Me)-, -CH(Me)-CH 2 - or -CH 2 -CH(Me)- and
- R 18 and R 19 independently represent H, Ci -2 alkyl (e.g. methyl), halogen (e.g. fluorine) or Ci -6 haloalkyl (e.g. trifluoromethyl);
- R 1 represents
- R 14 represents H and R 15 represents H .
- R 14 represents H and R 15 represents Ci -2 alkyl.
- R 14 represents Ci -2 alkyl and R 15 represents H.
- R 14 represents methyl and R 15 represents H.
- R 14 represents H or methyl and R 15 represents Ci -2 alkyl (e.g. methyl) or halogen (e.g. fluorine).
- B represents a bond, -CH 2 - or -CH 2 CH 2 -. In one embodiment B represents a bond. In another embodiment, B represents -CH 2 -. In a third embodiment, B represents -CH 2 CH 2 -.
- R 1 represents
- R 11 suitably represents H
- R 12 suitably represents H or methyl.
- R 13 suitably represents H or methyl.
- R 12 represents H and R 13 represents methyl. In another embodiment, R 12 represents methyl and R 13 represents H . I n a third embodiment, R 12 represents H and R 13 represents H.
- A represents an unbranched C 2-5 alkylene chain.
- A represents -(CH 2 ) 2 -.
- A represents -(CH 2 )3-.
- A represents -(CH 2 )4-.
- A represents -(CH 2 )5-. More suitably A represents -(CH 2 ) 2 -, -(CH 2 ) 4 - or -(CH 2 ) 5 -.
- A represents -(CH 2 ) 3 -.
- A represents -(CH 2 ) 4 -.
- Alternatively A represents a branched C 2-5 alkylene chain.
- A does not represent -(CH 2 ) 3 -.
- A represents a C 2-5 alkylene chain, which is substituted by two alkylene substituents at the same position wherein the two alkylene substituents are joined to each other to form a C 3-5 spiro-cycloalkyl group
- the spiro-cycloalkyl group is suitably C 3 spiro-cycloalkyl.
- R 16 represents H and R 17 represents H .
- R 16 represents H and R 17 represents Ci -2 alkyl.
- R 16 represents Ci -2 alkyl and R 17 represents H.
- R 16 represents H or methyl and R 17 represents Ci -2 alkyl (e.g. methyl) or halogen (e.g. fluorine).
- C represents a bond, -CH 2 - or -CH 2 CH 2 -.
- C represents a bond.
- C represents -CH 2 -.
- C represents -CH 2 CH 2 -.
- R 18 represents H and R 19 represents H .
- R 18 represents H and R 19 represents Ci -2 alkyl.
- R 18 represents Ci -2 alkyl and R 19 represents H.
- R 14 represents H or methyl and R 15 represents Ci -2 alkyl (e.g. methyl) or halogen (e.g. fluorine).
- D represents a bond, -CH 2 - or -CH 2 CH 2 -. In one embodiment D represents a bond. In another embodiment, D represents -CH 2 -. In a third embodiment, D represents -CH 2 CH 2 -.
- R 1 represents
- R 1 represents
- R 2 represents H , Ci -8 alkyl, C 3-8 cycloalkyl, -Ci -4 alkylcarbocyclyl, aryl, heteroaryl, heterocyclyl, -Ci -4 alkylaryl, phenyl substituted by phenyl, phenyl substituted by phenoxy, phenyl substituted by heterocyclyl wherein said heterocyclyl group is optionally substituted by a methyl or phenyl group, phenyl substituted by carbocyclyl, phenyl substituted by carbocyclyl wherein said carbocyclyl is substituted by heterocyclyl, phenyl substituted by -O- carbocyclyl, heterocyclyl substituted by phenyl, carbocyclyl substituted by phenyl, -Ci_ 4 alkyl(phenyl substituted by a monocyclic heterocyclyl group), -Ci -4 alkyl(phenyl substituted by an -Ci
- R 2 represents H, Ci -8 alkyl, C 3-8 cycloalkyl, aryl, heteroaryl, -Ci -4 alkylaryl, phenyl substituted by phenyl, phenyl substituted by phenoxy, phenyl substituted by heterocyclyl wherein said heterocyclyl group is optionally substituted by a methyl or phenyl group, phenyl substituted by -0-Ci -4 alkyl-heterocyclyl or phenyl fused to heterocyclyl, the aforesaid aryl, heteroaryl, phenyl and heterocyclyl groups optionally being substituted.
- R 2 represents Ci -8 alkyl, C 3-8 cycloalkyl, aryl, heteroaryl, -Ci -4 alkylaryl, phenyl substituted by phenyl, phenyl substituted by phenoxy, phenyl substituted by heterocyclyl wherein said heterocyclyl group is optionally substituted by a methyl or phenyl group, phenyl substituted by -0-Ci -4 alkyl-heterocyclyl or phenyl fused to heterocyclyl, the aforesaid aryl, heteroaryl, phenyl and heterocyclyl groups optionally being substituted.
- R 2 represent H.
- R 2 represents Ci -8 alkyl.
- R 2 suitably represents i-propyl or t-butyl.
- R 2 represents carbocyclyl.
- R 2 suitably represents cyclohexyl.
- I n on e em bod i m ent R 2 represents -Ci -4 alkylcarbocyclyl.
- R 2 suitably represents -CH 2 -cyclohexyl.
- R 2 represents optionally substituted aryl.
- R 2 suitably represents optionally substituted phenyl or napthyl.
- R 2 represents phenyl optionally substituted by one or more groups selected from Ci -6 alkyl (e.g. methyl), Ci -6 alkoxy (e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or isopropyloxy), hydroxyl, haloCi -6 alkyl (e.g. trifluoromethyl), haloCi -6 alkoxy (e.g. tetrafluoroethyloxy), halogen (e.g. chlorine or fluorine), Ci- 6 alkoxy-Ci- 6 alkyl- (e.g.
- Ci -6 alkoxy-Ci -6 alkoxy- e.g. -0-(CH 2 ) 2 -OMe
- -N(Ci -4 alkyl)(Ci -4 alkyl)-N(Ci -4 alkyl)(Ci. 4 alkyl) e.g. -N(Me)-(CH 2 ) 2 -N(Me) 2
- -N(C 1-4 alkyl)(C 1-4 alkyl) e.g. -N(ethyl)(ethyl)
- -N(C 3- 8 cycloalkyll)(C 3 - 8 cycloalkyl) e.g.
- R 2 represents phenyl optionally substituted by one or more groups selected from Ci -6 alkyl (e.g. methyl), Ci -6 alkoxy (e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or isopropyloxy), haloCi -6 alkyl (e.g. trifluoromethyl), haloCi -6 alkoxy (e.g. tetrafluoroethyloxy) or halogen (e.g. chlorine or fluorine).
- Ci -6 alkyl e.g. methyl
- Ci -6 alkoxy e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or isopropyloxy
- haloCi -6 alkyl e.g. trifluoromethyl
- haloCi -6 alkoxy e.g. tetrafluoroethyloxy
- halogen e.g. chlorine or fluorine
- R 2 represents phenyl optionally substituted by one or more groups selected from Ci -6 alkoxy (e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or isopropyloxy). In a still yet further embodiment, R 2 represents phenyl optionally substituted by a propoxy group.
- R 2 represents optionally substituted phenyl
- R 2 suitably represents 3-methylphenyl, 2- methoxyphenyl, 3-methoxyphenyl, 3,4-dimethoxyphenyl, 4-methoxyphenyl, 4-ethoxyphenyl, 4-propoxyphenyl, 4-butoxyphenyl, 4-pentoxyphenyl, 4-isopropyloxyphenyl, 4- tetrafluoroethyloxyphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,6- dichlorophenyl, 2,3-dichlorophenyl, 3,4-dichlorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4- fluorophenyl, 2,6-difluorophenyl, 2,3-difluorophenyl, 3,4-difluorophenyl, 3-chloro-5- fluorophenyl, 3,5-difluorophen
- R 2 represents -Ci- 4 alkylaryl, the aforesaid aryl optionally being substituted.
- R 2 represents -Ci -4 alkylaryl
- R 2 suitably represents benzyl optionally substituted by one or more Ci -6 alkoxy (e.g. methoxy) or halogen (e.g. chlorine or fluorine) g rou ps .
- Wh en R 2 represents optionally substituted benzyl, R 2 suitably represents 4- methoxybenzyl, 4-chlorobenzyl or 4-fluorobenzyl.
- R 2 represents optionally substituted benzyl
- R 2 also suitably represents 4-propoxybenzyl or 4-isopropoxybenzyl.
- R 2 represents unsubstituted benzyl.
- Wh en R 2 represents -Ci -4 alkylaryl, R 2 suitably represents -C(H)(Me)-phenyl.
- Wh e n R 2 represents -Ci -4 alkylaryl, R 2 suitably represents -(CH 2 )2-phenyl.
- R 2 represents optionally substituted heteroaryl.
- R 2 suitably represents optionally substituted thiophenyl.
- R 2 represents unsubstituted thiophenyl.
- R 2 represents optionally substituted heterocyclyl.
- R 2 represents optionally substituted heteroaryl
- R 2 suitably represents unsubstituted dihydrobenzodioxinyl or piperidinyl substituted by a -C(0)Ci -6 alkyl (i.e. -COMe) group.
- R 2 represents phenyl substituted by phenyl, the aforesaid phenyl groups optionally being substituted.
- R 2 represents phenyl substituted by phenyl, the aforesaid phenyl groups optionally being substituted
- R 2 suitably represents phenyl substituted by 3- phenyl, phenyl substituted by 4-phenyl, phenyl substituted by 3-(3-chlorophenyl), phenyl substituted by 4-(3-chlorophenyl), phenyl substituted by 4-(3,4-dichlorophenyl) or 3- fluorophenyl substituted by 4-phenyl.
- R 2 when R 2 represents phenyl substituted by phenyl, R 2 suitably represents unsubstituted phenyl substituted by unsubstituted phenyl.
- R 2 represents optionally substituted phenyl substituted by optionally substituted phenoxy.
- R 2 suitably represents phenyl substituted by 4-phenoxy.
- R 2 represents optionally substituted phenyl substituted by optionally substituted heterocyclyl.
- R 2 represents optionally substituted phenyl substituted by optionally substituted heterocyclyl
- R 2 suitably represents 3-chlorophenyl substituted by 4- morpholinyl, phenyl substituted by 4-piperazinyl substituted by 4N-methyl, , 2-chlorophenyl substituted by 6-piperazinyl substituted by 4N-ethyl, phenyl substituted by pyrrolidinyl, phenyl substituted by piperidinyl substituted by 4N-methyl, phenyl substituted by tetrahydropyranyl or phenyl substituted by morpholinyl.
- R 2 represents optionally substituted phenyl substituted by optionally substituted heterocyclyl.
- R 2 suitably represents 3-chlorophenyl substituted by 4- morpholinyl, phenyl substituted by 4-piperazinyl substituted by 4N-methyl, phenyl substituted by 4-piperazinyl substituted by 4N-phenyl, phenyl substituted by 3-piperazinyl substituted by 4N-phenyl or 2-chlorophenyl substituted by 6-piperazinyl substituted by 4N-ethyl.
- R 2 represents optionally substituted phenyl substituted by heterocyclyl wherein said heterocyclyl is substituted by phenyl.
- R 2 represents optionally substituted phenyl substituted by heterocyclyl wherein said heterocyclyl is substituted by phenyl
- R 2 suitably represents phenyl substituted by 4-piperazinyl substituted by 4N-phenyl, phenyl substituted by 3-piperazinyl substituted by 4N-phenyl.
- R 2 represents optionally substituted phenyl substituted by optionally substituted carbocyclyl wherein said carbocyclyl is substituted by optionally substituted heterocyclyl.
- R 2 represents optionally substituted phenyl substituted by optionally substituted carbocyclyl wherein said carbocyclyl is substituted by optionally substituted heterocyclyl
- R 2 suitably represents phenyl substituted by carbocyclyl (i.e. cyclohexyl) substituted by heterocyclyl (i.e. morpholinyl).
- R 2 represents optionally substituted phenyl substituted by -0-C-i -4 alkyl- heterocyclyl.
- R 2 represents optionally substituted phenyl substituted by -0-Ci -4 alkyl- heterocyclyl
- R 2 suitably represents phenyl substituted by 4-0-(CH 2 )2-morpholinyl, 4-0- (CH 2 )3-morpholinyl, 2-0-(CH 2 )2-morpholinyl or 4-0-(CH 2 )2-piperazinyl.
- R 2 represents optionally substituted phenyl substituted by optionally substituted carbocyclyl.
- R 2 represents optionally substituted phenyl substituted by optionally substituted carbocyclyl
- R 2 suitably represents phenyl substituted by C 3- 8 cycloalkyl (such as cyclohexyl) wherein said C 3 - 8 cycloalkyl may be optionally substituted by one or more oxo, halogen (i.e. fluorine), hydroxyl or Ci -4 alkoxy (i.e. methoxy) groups.
- R 2 represents optionally substituted phenyl substituted by -O- carbocyclyl.
- R 2 represents optionally substituted phenyl substituted by -O-carbocyclyl
- R 2 suitably represents unsubstituted phenyl substituted by an -0-C 3- 8 cycloalkyl group (i.e. - O-cyclohexyl).
- R 2 represents optionally substituted heterocyclyl substituted by optionally substituted phenyl.
- R 2 represents optionally substituted heterocyclyl substituted by optionally substituted phenyl
- R 2 suitably represents unsubstituted piperidinyl substituted by unsubstituted phenyl.
- R 2 represents optionally substituted carbocyclyl substituted by optionally substituted phenyl.
- R 2 suitably represents unsubstituted C 3- 8 cycloalkyl (i.e. cyclohexyl) substituted by unsubstituted phenyl.
- R 2 represents optionally substituted phenyl fused to optionally substituted heterocyclyl.
- R 2 suitably represents benzo-1 ,3-dioxolanyl, 4- methoxy(benzo-1 ,3-dioxolanyl), 6-methoxy(benzo-1 ,3-dioxolanyl), 2,2-difluoro(benzo-1 ,3- dioxolanyl) or benzo-1 ,4-dioxanyl.
- R 2 represents -Ci -4 alkyl(phenyl substituted by a monocyclic heterocyclyl group).
- R 2 suitably represents benzyl substituted by morpholinyl.
- R 2 represents -Ci -4 alkyl(phenyl substituted by an -O-carbocyclyl group).
- R 2 suitably represents benzyl substituted by an -O-carbocyclyl group (i.e. -O-cyclohexyl).
- R 3 represents H or R 2 and R 3 are joined to form a carbocyclyl ring which is fused to phenyl. Most suitably R 3 represents H.
- R 4 represents H, -Ci -8 alkyl or -C(0)Ci -6 alkyl. More suitably R 4 represents H or -Ci_ 8 alkyl, e.g. H or methyl. Most suitably R 4 represents H.
- X represents O, S or CR 7 R 8 or X and Z represent two adjacent carbon atoms of a phenyl ring which is fused in that position and is optionally substituted by one or more halogen or Ci -2 alkyl groups.
- X represents O, S or CR 7 R 8 .
- R 7 and R 8 both represent hydrogen or -Ci -4 alkyl, or one of R 7 and R 8 represents hydrogen and the other represents -Ci -4 alkyl or an optionally substituted aryl group.
- R 7 and R 8 represents a group, said group is suitably methyl.
- R 7 and R 8 represents an optionally substituted aryl group, said group is suitably unsubstituted phenyl or phenyl substituted by 4-propoxy.
- R 7 and R 8 both represent hydrogen.
- R 7 and R 8 both represent -Ci -4 alkyl.
- one of R 7 and R 8 represents hydrogen and the other represents -Ci_ 4 alkyl (e.g. methyl).
- one of R 7 and R 8 represents hydrogen and the other represents an optionally substituted aryl group (e.g. unsubstituted phenyl or phenyl substituted by a Ci -6 alkoxy group).
- Z represents -N-R 4 (e.g. -NH or -N-NH 2 ), O or CHR 10 (e.g. CH 2 or CH- methyl), or X and Z represent two adjacent carbon atoms of a phenyl ring which is fused in that position and is optionally substituted by one or more halogen or Ci -2 alkyl groups.
- Z represents -NH.
- Z represents -N-NH 2 .
- Z represents O.
- Z represents CH 2 .
- Z represents CH-methyl.
- I n a further embodiment, X represents CH 2 , Y represents C 0 and Z represents -NH.
- R 1 suitably represents 1 H-benzo[d]imidazolyl or 1 H-imidazo[1 ,2-a]pyridinyl.
- Wh en X represents CR 7 R 8
- Z represents -N-R 4
- R 2 suitably represents:
- Ci-8 alkyl (such as t-butyl);
- carbocyclyl such as cyclohexyl
- Ci -6 alkyl e.g. methyl
- Ci -6 alkoxy such as methoxy, ethoxy, propoxy, butoxy, pentoxy or isopropoxy
- halogen such as fluorine or chlorine
- haloCi -6 alkyl such as trifluoromethyl
- haloCi -6 alkoxy groups such as trifluoromethoxy
- optionally substituted phenyl fused to optionally substituted heterocyclyl such as 4- methoxybenzo[d][1 ,3]dioxol-6-yl, 2,2-difluorobenzo[d][1 ,3]dioxol-5-yl or 2,3- dihydrobenzo[b][1 ,4]dioxin-6-yl);
- optionally substituted phenyl substituted by optionally substituted heterocyclyl such as phenyl substituted by -0-(CH 2 )2-morpholinyl or phenyl substituted by -0-(CH 2 )3- morpholinyl;
- optionally substituted phenyl substituted by optionally substituted phenyl or optionally substituted phenyl substituted by optionally substituted heterocyclyl (such as optionally substituted phenyl substituted by morpholinyl, optionally substituted phenyl substituted by piperazinyl substituted by phenyl or optionally substituted phenyl substituted by piperazinyl substituted by ethyl).
- X represents CR 7 R 8
- Z represents -N-R 4
- R 3 suitably represents hydrogen.
- Y represents CH R 9 and Z represents -N-R 4 .
- R 1 suitably represents 1 H-benzo[d]imidazolyl.
- R 2 suitably represents phenyl optionally substituted by one or more halogen atoms (such as unsubstituted phenyl or 2,3,5-trifluorophenyl).
- R 3 suitably represents hydrogen.
- R 1 suitably represents 1 H-benzo[d]imidazolyl or 1 H-imidazo[1 ,2-a]pyridinyl.
- R 2 suitably represents:
- Ci-8 alkyl (such as i-propyl);
- phenyl optionally substituted by one or more halogen (such as fluorine or chlorine), Ci-6 alkoxy (such as propoxy) or haloCi -6 alkyl groups (such as trifluoromethyl);
- halogen such as fluorine or chlorine
- Ci-6 alkoxy such as propoxy
- haloCi -6 alkyl groups such as trifluoromethyl
- optionally substituted phenyl fused to optionally substituted heterocyclyl such as 2,3- dihydrobenzo[b][1 ,4]dioxin-6-yl or benzo[d][1 ,3]dioxol-6-yl);
- optionally substituted phenyl substituted by optionally substituted heterocyclyl such as phenyl substituted by -0-(CH 2 )2-piperazinyl or -0-(CH 2 )2-morpholinyl;
- optionally substituted phenyl substituted by optionally substituted phenyl or optionally substituted phenyl substituted by optionally substituted heterocyclyl (such as optionally substituted phenyl substituted by piperazinyl substituted by phenyl or optionally substituted phenyl substituted by piperazinyl substituted by methyl).
- R 3 suitably represents hydrogen.
- X represents CR 7 R 8
- Y represents CH R 9 and Z represents CHR 10
- X represents CH 2
- Y represents CH 2
- Z represents CH 2 .
- R 1 suitably represents 1 H-benzo[d]imidazolyl.
- Wh e n X represents CR 7 R 8 , Y represents CHR 9 and Z represents CHR 10 , R 2 suitably represents: hydrogen;
- phenyl optionally substituted by one or more halogen (such as fluorine or chlorine), Ci-6 alkoxy (such as methoxy); or
- optionally substituted -Ci -4 alkylaryl such as unsubstituted benzyl and benzyl substituted a halogen atom, such as fluorine or chlorine or a Ci -6 alkoxy, such as methoxy).
- R 3 suitably represents hydrogen.
- R 1 suitably represents 1 H-benzo[d]imidazolyl.
- R 2 suitably represents: phenyl optionally substituted by one or more halogen (such as fluorine or chlorine); optionally substituted naphthyl (such as unsubstituted naphthyl);
- optionally substituted phenyl substituted by optionally substituted phenoxy; or optionally substituted heteroaryl (such as unsubstituted thiophenyl).
- R 3 suitably represents hydrogen.
- R 1 suitably represents 1 H- benzo[d]imidazolyl.
- R 2 suitably represents optionally substituted phenyl or optionally substituted phenyl substituted by optionally substituted phenoxy.
- R 3 suitably represents hydrogen.
- X represents CR 7 R 8
- X represents CH 2
- R 1 suitably represents 1 H-benzo[d]imidazolyl.
- R 2 suitably represents:
- phenyl optionally substituted by one or more halogen (such as fluorine), Ci -6 alkoxy (such as methoxy or propoxy); or
- optionally substituted phenyl fused to optionally substituted heterocyclyl such as 2,3- dihydrobenzo[b][1 ,4]dioxin-6-yl.
- R 3 suitably represents hydrogen.
- R 1 suitably represents 1 H-benzo[d]imidazolyl.
- R 2 suitably represents:
- phenyl optionally substituted by one or more halogen (such as fluorine or chlorine), Ci-6 alkoxy (such as methoxy or propoxy);
- optionally substituted phenyl fused to optionally substituted heterocyclyl such as benzo[d][1 ,3]dioxol-6-yl
- R 3 suitably represents hydrogen
- X represents -0-CH 2 -
- Y represents CO and Z represents CHR 10 .
- X represents -0-CH 2 -
- Y represents CO and Z represents CH 2 (see e.g. Example 93).
- X represents -0-CH 2 -
- Y represents CO and Z represents CH R 10
- R 1 suitably represents 1 H-benzo[d]imidazolyl.
- X represents -0-CH 2 -
- Y represents CO and Z represents CH R 10
- R 2 suitably represents phenyl optionally substituted by a Ci -6 alkoxy (such as propoxy).
- R 3 suitably represents hydrogen.
- X represents -CH 2 -CH 2 -
- Y represents CO
- Z represents O.
- R 1 suitably represents 1 H-benzo[d]imidazolyl or 1 H-imidazo[1 ,2-a]pyridinyl.
- R 2 suitably represents phenyl optionally substituted by a Ci -6 alkoxy (such as propoxy).
- R 3 suitably represents hydrogen.
- the compound of formula (I) is a compound selected from Examples 1 to 235. In a further embodiment, the compound of formula (I) is a compound selected from Examples 1 to 147. In a yet further embodiment, the compound of formula (I) is a compound selected from Examples 12 to 14.
- R 2 , R 3 , X, Y and Z are as defined above for compounds of formula (I).
- the process typically involves reacting a compound of formula (I I) with a compound of formula R 1 -L in which L represents a leaving group e.g. a halogen atom such as iodine.
- L represents a leaving group e.g. a halogen atom such as iodine.
- Process (b) typically comprises hydrogenation under suitable conditions, such as PdC, 10% on charcoal at 4 bar at 40°C for 4 hours.
- suitable conditions such as PdC, 10% on charcoal at 4 bar at 40°C for 4 hours.
- Process (c) typically comprises hydrogenation under suitable conditions, such as PdC, 10% on charcoal at 1 -2 bar at room temperature overnight. A non-limiting example of the methodology of process (c) is described in Method 10 herein. (d) preparing a compound of formula (I) wherein R represents hydrogen, Y represents CO, Z represents -N-R 4 and X represent compound of formula (V):
- Process (d) typically comprises reaction with a suitable reagent, such as a compound of formula LCOL' in which L and L' represent leaving groups.
- a suitable reagent such as a compound of formula LCOL' in which L and L' represent leaving groups.
- An example reagent is carbonyldiimidazole which may be employed in the presence of a suitable solvent such as dichloromethane.
- Process (e) typically comprises the use of a suitable reagent, such as an activated formic acid derivative e.g. triethyl-ortho formate under suitable conditions, such as reflux followed by reduction e.g. with sodium borohydride.
- a suitable reagent such as an activated formic acid derivative e.g. triethyl-ortho formate under suitable conditions, such as reflux followed by reduction e.g. with sodium borohydride.
- suitable conditions such as reflux followed by reduction e.g. with sodium borohydride.
- Process (f) typically comprises treatment of the compound of formula (IV) with an activated formic acid derivative, such as triethyl orthoformate.
- an activated formic acid derivative such as triethyl orthoformate.
- Process (g) is essentially a dehydration reaction which typically comprises the use of suitable reagents, such as trifluoroacetic acid, triethylsilane and sodium bicarbonate.
- suitable reagents such as trifluoroacetic acid, triethylsilane and sodium bicarbonate.
- a non-limiting example of the methodology of process (g) is described in Method 1 1 herein.
- (h) typically comprises the use of suitable reagents such as Lawesson's Reagent.
- suitable reagents such as Lawesson's Reagent.
- a non- limiting example of the methodology of process (h) is described in Method 9 herein.
- Typical alkylating agents include compounds of formula R 4 -L wherein L is a leaving group such as iodine and typical alkanoylating agents include activated acids such as compounds of formula R 4 -L wherein L is a leaving group such as halogen (e.g. chlorine) or a corresponding acid anhydride.
- interconversion of compounds of formula (I) examples include interconversion of a compound of formula (I) wherein Y represents CO to a compound of formula (I) wherein Y represents CS.
- Such an interconversion may typically comprise the use of suitable reagents, such as toluol and Lawesson's Reagent.
- suitable reagents such as toluol and Lawesson's Reagent.
- Novel intermediates are claimed as an aspect of the present invention.
- Therapeutic uses are claimed as an aspect of the present invention.
- Physiological substrates of QC (EC) in mammals are, e.g. amyloid beta-peptides (3-40), (3- 42), (1 1 -40 and (1 1 -42), ABri, ADan, Gastrin, Neurotensin, FPP, CCL 2, CCL 7, CCL 8, CCL 16, CCL 18, Fractalkine, Orexin A, [Gln 3 ]-glucagon(3-29), [Gln 5 ]-substance P(5-1 1 ) and the peptide QYNAD.
- Table 1 Amino acid sequences of physiological active peptides with an N-terminal glutamine residue, which are prone to be cyclized to final pGlu
- Gly-Tyr-Glu-Val-His-His-Gln-Lys- neurodegeneration e.g. in
- Gly-Tyr-Glu-Val-His-His-Gln-Lys- neurodegeneration e.g. in
- Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser- neurodegeneration e.g. in Asn-Lys-Gly-Ala-lle-lle-Gly-Leu-Met- Alzheimer's Disease, Familial Val-Gly-Gly-Val-Val-lle-Ala British Dementia, Familial
- Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser- neurodegeneration e.g. in Asn-Lys-Gly-Ala-lle-lle-Gly-Leu-Met- Alzheimer's Disease, Familial Val-Gly-Gly-Val-Val British Dementia, Familial
- ADan EASNCFA IRHFENKFAV ETLIC Pyroglutamated form plays a
- FPP QEP amide A tripeptide related to thyrotrophin releasing hormone (TRH), is found in seminal plasma. Recent evidence obtained in vitro and in vivo showed that FPP plays an i m porta nt role i n regu lati ng sperm fertility.
- TRH QHP amide TRH functions as a regulator of the biosynthesis of TSH in the
- GnRH QHWSYGL RP(G) amide Stimulates the secretion of gonadotropins; it stimulates the
- CCL16 small QPKVPEW VNTPSTCCLK Shows chemotactic activity for inducible cytokine YYEKVLPRRL WGYRKALNC lymphocytes and monocytes A16
- HLPAIIFVTK RNREVCTNPN but not neutrophils. Also shows
- Recombinant SCYA16 shows chemotactic activity for monocytes and THP-1 monocytes, but not for resting lymphocytes and neutrophils. Induces a calcium flux in THP-1 cells that were desensitized by prior expression to RANTES.
- CCL8 small QPDSVSI PITCCFNVIN Chemotactic factor that attracts inducible cytokine RKIPIQRLES YTRITNIQCP monocytes, lymphocytes, A8) KEAVIFKTKR GKEVCADPKE basophils and eosinophils. May
- RWVRDSMKHL DQIFQNLKP play a role in neoplasia
- This protein can bind heparin.
- CCL2 (MCP-1 , small QPDAINA PVTCCYNFTN Chemotactic factor that attracts inducible cytokine RKISVQRLAS YRRITSSKCP monocytes and basophils but A2) KEAVIFKTIV AKEICADPKQ not neutrophils or eosinophils.
- CCL18 small QVGTNKELC CLVYTSWQIP Chemotactic factor that attracts inducible cytokine QKFIVDYSET SPQCPKPGVI lymphocytes but not monocytes A18
- LLTKRGRQIC ADPNKKWVQK or granulocytes. May be
- naive T lymphocytes toward dendritic cells and activated macrophages in lymph nodes, has chemotactic activity for naive T cells, CD4+ and CD8+ T cells and thus may play a role in both humoral and cell-mediated immunity responses.
- VGTELFRVPP VSTAATWQSS migration processes at the
- APHQPGPSLW AEAKTSEAPS endothelium binds to CX3CR1 .
- CCL7 small QPVGINT STTCCYRFIN Chemotactic factor that attracts inducible cytokine KKIPKQRLES YRRTTSSHCP monocytes and eosinophils, but
- Orexin A (Hypocretin- QPLPDCCRQK TCSCRLYELL Neuropeptide that plays a 1 ) HGAGNHAAGI LTL significant role in the regulation of food intake and sleep-
- Orexin-A binds to both 0X1 R and OX2R with a high affinity.
- Substance P RPK PQQFFGLM Belongs to the tachykinins.
- Tachykinins are active peptides which excite neurons, evoke behavioral responses, are potent vasodilators and secretagogues, and contract (directly or indirectly) many smooth muscles.
- QYNAD Gln-Tyr-Asn-Ala-Asp Acts on voltage-gated sodium channels.
- Glutamate is found in positions 3, 1 1 and 22 of the amyloid ⁇ -peptide.
- the mutation from glutamic acid (E) to glutamine (Q) in position 22 has been described as the so called Dutch type cerebroarterial amyloidosis mutation.
- the ⁇ -amyloid peptides with a pyroglutamic acid residue in position 3, 1 1 and/or 22 have been described to be more cytotoxic and hydrophobic than the amyloid ⁇ -peptides 1 - 40(42/43) (Saido T.C. 2000 Medical Hypotheses 54(3): 427-429).
- the multiple N-terminal variations e.g. Abeta(3-40), Abeta(3-42), Abeta(1 1 -40) and Abeta (1 1 -42) can be generated by the ⁇ -secretase enzyme ⁇ -site amyloid precursor protein- cleaving enzyme (BACE) at different sites (Huse J.T. et al. 2002 J. Biol. Chem. 277 (18): 16278-16284), and/or by aminopeptidase or dipeptidylaminopeptidase processing from the full lenght peptides Abeta(1 -40) and Abeta(1 -42). In all cases, cyclization of the then N- terminal occuring glutamic acid residue is catalyzed by QC.
- BACE ⁇ -secretase enzyme ⁇ -site amyloid precursor protein- cleaving enzyme
- Transepithelial transducing cells particularly the gastrin (G) cell, co-ordinate gastric acid secretion with the arrival of food in the stomach.
- G gastrin
- Biosynthetic precursors and intermediates are putative growth factors; their products, the amidated gastrins, regulate epithelial cell proliferation, the differentiation of acid-producing parietal cells and histamine-secreting enterochromaffin-like (ECL) cells, and the expression of genes associated with histamine synthesis and storage in ECL cells, as well as acutely stimulating acid secretion.
- Gastrin also stimulates the production of members of the epidermal growth factor (EGF) family, which in turn inhibit parietal cell function but stimulate the growth of surface epithelial cells.
- Plasma gastrin concentrations are elevated in subjects with Helicobacter pylori, who are known to have increased risk of duodenal ulcer disease and gastric cancer (Dockray, G.J. 1999 J Physiol 15 315-324).
- the peptide hormone gastrin, released from antral G cells is known to stimulate the synthesis and release of histamine from ECL cells in the oxyntic mucosa via CCK-2 receptors. The mobilized histamine induces acid secretion by binding to the H(2) receptors located on parietal cells.
- gastrin in both its fully amidated and less processed forms (progastrin and glycine-extended gastrin), is also a growth factor for the gastrointestinal tract. It has been established that the major trophic effect of amidated gastrin is for the oxyntic mucosa of stomach, where it causes increased proliferation of gastric stem cells and ECL cells, resulting in increased parietal and ECL cell mass. On the other hand, the major trophic target of the less processed gastrin (e.g. glycine-extended gastrin) appears to be the colonic mucosa (Koh, T.J. and Chen, D. 2000 Regul Pept 9337- 44).
- Neurotensin is a neuropeptide implicated in the pathophysiology of schizophrenia that specifically modulates neurotransmitter systems previously demonstrated to be misregulated in this disorder.
- Clinical studies in which cerebrospinal fluid (CSF) NT concentrations have been measured revealed a subset of schizophrenic patients with decreased CSF NT concentrations that are restored by effective antipsychotic drug treatment.
- CSF cerebrospinal fluid
- Considerable evidence also exists concordant with the involvement of NT systems in the mechanism of action of antipsychotic drugs.
- the behavioral and biochemical effects of centrally administered NT remarkably resemble those of systemically administered antipsychotic drugs, and antipsychotic drugs increase NT neurotransmission. This concatenation of findings led to the hypothesis that NT functions as an endogenous antipsychotic.
- FPP Fertilization promoting peptide
- TRH thyrotrophin releasing hormone
- FPP and adenosine have been shown to stimulate cAMP production in uncapacitated cells but inhibit it in capacitated cells, with FPP receptors somehow interacting with adenosine receptors and G proteins to achieve regulation of AC. These events affect the tyrosine phosphorylation state of various proteins, some being important in the initial "switching on”, others possibly being involved in the acrosome reaction itself.
- Calcitonin and angiotensin II also found in seminal plasma, have similar effects in vitro on uncapacitated spermatozoa and can augment responses to FPP. These molecules have similar effects in vivo, affecting fertility by stimulating and then maintaining fertilizing potential.
- CCL2 (MCP-1 ), CCL7, CCL8, CCL1 6, CCL18 and fractalkine play an important role in pathophysiological conditions, such as suppression of proliferation of myeloid progenitor cells, neoplasia, inflammatory host responses, cancer, psoriasis, rheumatoid arthritis, atherosclerosis, vasculitis, humoral and cell-mediated immunity responses, leukocyte adhesion and migration processes at the endothelium, inflammatory bowel disease, restenosis, pulmonary fibrosis, pulmonary hypertention , liver fibrosis, liver cirrhosis, n eph rosclerosi s , ventricu lar rem od el i ng , h ea rt fa i l u re , a rteri opathy after orga n transplantations and failure of vein grafts.
- pancreatitis Bossetia, M., et al., (2005) Am.J Physiol Gastrointest.Liver Physiol 288, G1259-G1265); Alzheimer's disease (Yamamoto, M., et al., (2005) Am.J Pathol. 166, 1475-1485); lung fibrosis (Inoshima, I ., et al., (2004) Am.J Physiol Lung Cell Mol. Physiol 286, L1038-L1044); renal fibrosis (Wada, T., et al., (2004) J Am. Soc. Nephrol.
- MCP-1 might also play a role in gestosis (Katabuchi, H., et al., (2003) Med Electron Microsc. 36, 253-262), as a paracrine factor in tumor development (Ohta, M., et al., (2003) Int.J Oncol. 22, 773-778; Li, S., et al., (2005) J Exp.Med 202, 617-624), neuropathic pain (White, F. A., et al., (2005) Proc. Natl.
- MCP-1 levels are increased in CSF of AD patients and patients showing mild cognitive impairment (MCI) (Galimberti, D., et al., (2006) Arch. Neurol. 63, 538-543). Furthermore, MCP-1 shows an increased level in serum of patients with MCI and early AD (Clerici, F., et al., (2006) Neurobiol. Aging 27, 1763-1768).
- MCI mild cognitive impairment
- Several cytotoxic T lymphocyte peptide-based vaccines against hepatitis B, human immunodeficiency virus and melanoma were recently studied in clinical trials.
- One interesting melanoma vaccine candidate alone or in combination with other tumor antigens, is the decapeptide ELA.
- This peptide is a Melan-A MART-1 antigen immunodominant peptide analog, with an N-terminal glutamic acid. It has been reported that the amino group and gamma-carboxylic group of glutamic acids, as well as the amino group and gamma- carboxamide group of glutamines, condense easily to form pyroglutamic derivatives. To overcome this stability problem, several peptides of pharmaceutical interest have been developed with a pyroglutamic acid instead of N-terminal glutamine or glutamic acid, without loss of pharmacological properties.
- Orexin A is a neuropeptide that plays a significant role in the regulation of food intake and sleep-wakefulness, possibly by coordinating the complex behavioral and physiologic responses of these complementary homeostatic functions. It plays also a role in the homeostatic regulation of energy metabolism, autonomic function, hormonal balance and the regulation of body fluids.
- QYNAD is a substrate of the enzyme glutaminyl cyclase (QC, EC 2.3.2.5), which is also present in the brain of mammals, especially in human brain. Glutaminyl cyclase catalyzes effectively the formation of pEYNAD from its precursor QYNAD.
- the present invention provides the use of the compounds of formula (I) for the preparation of a medicament for the prevention or alleviation or treatment of a disease selected from the group consisting of mild cognitive impairment, Alzheimer's disease, Familial British Dementia, Familial Danish Dementia, neurodegeneration in Down Syndrome, Huntington's disease, Kennedy's disease, ulcer disease, duodenal cancer with or w/o Helicobacter pylori infections, colorectal cancer, Zolliger-Ellison syndrome, gastric cancer with or without Helicobacter pylori infections, pathogenic psychotic conditions, schizophrenia, infertility, neoplasia, inflammatory host responses, cancer, malign metastasis, melanoma, psoriasis, rheumatoid arthritis, atherosclerosis, pancreatitis, restenosis, impaired humoral and cell-mediated immune responses, leukocyte adhesion and migration processes in the endothelium, impaired food intake, impaired sleep-wake
- the administration of a QC inhibitor according to the present invention can lead to suppression of male fertility.
- the present invention provides the use of inhibitors of QC (EC) activity in combination with other agents, especially for the treatment of neuronal diseases, artherosclerosis and multiple sclerosis.
- the present invention also provides a method of treatment of the aforementioned diseases comprising the administration of a therapeutically active amount of at least one compound of formula (I) to a mammal, preferably a human.
- said method and corresponding uses are for the treatment of a disease selected from the group consisting of mild cognitive impairment, Alzheimer's disease, Familial British Dementia, Familial Danish Dementia, neurodegeneration in Down Syndrome, Parki nson 's d isease an d Chorea H u ntin gton , com prisi ng the ad m i n istration of a therapeutically active amount of at least one compound of formula (I) to a mammal, preferably a human.
- a disease selected from the group consisting of mild cognitive impairment, Alzheimer's disease, Familial British Dementia, Familial Danish Dementia, neurodegeneration in Down Syndrome, Parki nson 's d isease an d Chorea H u ntin gton , com prisi ng the ad m i n istration of a therapeutically active amount of at least one compound of formula (I) to a mammal, preferably
- the present invention provides a method of treatment and corresponding uses for the treatment of rheumatoid arthritis, atherosclerosis, pancreatitis and restenosis.
- the present invention provides a composition, preferably a pharmaceutical composition, comprising at least one QC inhibitor optionally in combination with at least one other agent selected from the group consisting of nootropic agents, neuroprotectants, antiparkinsonian drugs, amyloid protein deposition inhibitors, beta amyloid synthesis inhibitors, antidepressants, anxiolytic drugs, antipsychotic drugs and anti-multiple sclerosis drugs.
- at least one QC inhibitor optionally in combination with at least one other agent selected from the group consisting of nootropic agents, neuroprotectants, antiparkinsonian drugs, amyloid protein deposition inhibitors, beta amyloid synthesis inhibitors, antidepressants, anxiolytic drugs, antipsychotic drugs and anti-multiple sclerosis drugs.
- said QC inhibitor is a compound of formula (I) of the present invention.
- the aforementioned other agent is selected from the group consisting of beta-amyloid antibodies, vaccines, cysteine protease inhibitors, PEP-inhibitors, LiCI, acetylcholinesterase (AChE) inhibitors, PIMT enhancers, inhibitors of beta secretases, inhibitors of gamma secretases, inhibitors of aminopeptidases, preferably inhibitors of dipeptidyl peptidases, most preferably DP IV inhibitors; inhibitors of neutral endopeptidase, inhibitors of Phosphodiesterase-4 (PDE-4), TNFalpha inhibitors, muscarinic M 1 receptor antagonists, NMDA receptor antagonists, sigma-1 receptor inh ibitors, h istamine H3 antagonists, immunomodulatory agents, immunosuppressive agents, MCP-1 antagonists or an agent selected from the group consisting of antegren (natalizumab), Neurelan (f
- the other agent may be, for example, an anti-anxiety drug or antidepressant selected from the group consisting of
- Benzodiazepines e.g. alprazolam, chlordiazepoxide, clobazam, clonazepam, clorazepate, diazepam, fludiazepam, loflazepate, lorazepam, methaqualone, oxazepam, prazepam, tranxene,
- alprazolam chlordiazepoxide
- clobazam clonazepam
- clorazepate diazepam
- fludiazepam fludiazepam
- loflazepate lorazepam
- methaqualone oxazepam
- prazepam tranxene
- SSRI's Selective serotonin re-uptake inhibitors
- Tricyclic antidepressants e.g. amitryptiline, clomipramine, desipramine, doxepin, imipramine
- Azapirones e.g. buspirone, tandopsirone
- Serotonin-norepinephrine reuptake inhibitors e.g. venlafaxine, duloxetine
- NRI's Norepinephrine reuptake inhibitors (NRI's), e.g. reboxetine,
- NPY-receptor ligands NPY agonists or antagonists.
- the other agent may be, for example, an anti-multiple sclerosis drug selected from the group consisting of
- dihydroorotate dehydrogenase inhibitors e.g. SC-12267, teriflunomide, MNA-715, HMR-1279 (syn. to HMR-1715, MNA-279),
- autoimmune suppressant e.g. laquinimod
- antibodies e.g. AGT-1 , anti-granulocyte-macrophage colony-stimulating factor (GM- CSF) monoclonal antibody, Nogo receptor modulators, ABT-874, alemtuzumab (CAMPATH), anti-OX40 antibody, CNTO-1275, DN-1921 , natalizumab (syn. to AN- 100226, Antegren, VLA-4 Mab), daclizumab (syn. to Zenepax, Ro-34-7375, SMART anti-Tac), J-695, priliximab (syn. to Centara, CEN-000029, cM-T412), MRA, Dantes, anti-IL-12-antibody,
- AGT-1 anti-granulocyte-macrophage colony-stimulating factor (GM- CSF) monoclonal antibody
- Nogo receptor modulators ABT-874, alemtuzumab (CAMPATH), anti-OX40 antibody
- PNA peptide nucleic acid
- interferon alpha e.g. Alfaferone, human alpha interferon (syn. to Omniferon, Alpha Leukoferon),
- interferon beta e.g. Frone, interferon beta-1 a like Avonex, Betron (Rebif), interferon beta analogs, interferon beta-transferrin fusion protein, recombinant interferon beta- l b like Betaseron,
- peptides e.g. AT-008, AnergiX.MS, Immunokine (alpha-lmmunokine-NNS03), cyclic peptides like ZD-7349,
- sCD8 soluble CD8
- TNF-alpha e.g. BLX-1002, thalidomide, SH-636,
- TNF antagonists e.g. solimastat, lenercept (syn. to RO-45-2081 , Tenefuse), onercept
- TNF alpha e.g. etanercept (syn. to Enbrel, TNR-001 )
- CD28 antagonists e.g. abatacept
- CCR1 chemokine receptor-1
- AMPA receptor antagonists e.g. ER-167288-01 and ER-099487, E-2007, talampanel
- potassium channel blockers e.g. fampridine
- oligonucleotides e.g. EN-101
- z antisense oligonucleotides, e.g. EN-101
- IgLC free immunoglobulin light chain
- apoptosis inducing antigens e.g. Apogen MS
- alpha-2 adrenoceptor agonist e.g. tizanidine (syn. to Zanaflex, Ternelin, Sirdalvo, Sirdalud, Mionidine),
- topoisomerase II modulators e.g. mitoxantrone hydrochloride
- adenosine deaminase inhibitor e.g. cladribine (syn. to Leustatin, Mylinax, RWJ- 26251 ),
- interleukin-10 e.g. ilodecakin (syn. to Tenovil, Sch-52000, CSIF)
- interleukin-12 antagonists e.g. lisofylline (syn. to CT-1501 R, LSF, lysofylline), hh) Ethanaminum, e.g. SRI-62-834 (syn. to CRC-8605, NSC-614383),
- immunomodulators e.g. SAIK-MS, PNU-156804, alpha-fetoprotein peptide (AFP), IPDS,
- retinoid receptor agonists e.g. adapalene (syn. to Differin, CD-271 ),
- TGF-beta e.g. GDF-1 (growth and differentiation factor 1 ),
- TGF-beta-2 e.g. BetaKine
- MMP inhibitors e.g. glycomed
- nn) phosphodiesterase 4 (PDE4) inhibitors e.g. RPR-122818,
- purine nucleoside phosphorylase inhibitors e.g. 9-(3-pyridylmethyl)-9-deazaguanine, peldesine (syn. to BCX-34, TO-200),
- alpha-4/beta-1 integrin antagonists e.g. ISIS-104278,
- CD49d alpha4 integrin
- cytokine-inducing agents e.g. nucleosides, ICN-17261 ,
- heat shock protein vaccines e.g. HSPPC-96
- neuregulin growth factors e.g. GGF-2 (syn. to neuregulin, glial growth factor 2), vv) cathepsin S - inhibitors,
- bropirimine analogs e.g. PNU-56169, PNU-63693,
- Monocyte chemoattractant protein-1 inhibitors e.g. benzimidazoles like MCP-1 inhibitors, LKS-1456, PD-064036, PD-064126, PD-084486, PD-172084, PD-172386.
- the present invention provides pharmaceutical compositions e.g. for parenteral, enteral or oral administration, comprising at least one QC inhibitor, optionally in combination with at least one of the other aforementioned agents. These combinations provide a particularly beneficial effect. Such combinations are therefore shown to be effective and useful for the treatment of the aforementioned diseases. Accordingly, the invention provides a method for the treatment of these conditions.
- the method comprises either co-administration of at least one QC inhibitor and at least one of the other agents or the sequential administration thereof.
- Co-administration includes administration of a formulation, which comprises at least one QC inhibitor and at least one of the other agents or the essentially simultaneous administration of separate formulations of each agent.
- Beta-amyloid antibodies and compositions containing the same are described, e.g. in WO/2009/065054, WO/2009/056490, WO/2009/053696, WO/2009/033743, WO/2007/1 13172, WO/2007/022416, WO 2006/137354, WO 2006/1 18959, WO 2006/1031 16, WO 2006/095041 , WO 2006/081 171 , WO 2006/066233, WO 2006/066171 , WO 2006/066089 , WO 2006/066049 , WO 2006/0551 78 , WO 2006/046644 , WO 2006/039470, WO 2006/036291 , WO 2006/026408, WO 2006/016644, WO 2006/014638, WO 2006/01 4478 , WO 2006/008661 , WO 2005/1 23775, WO 2005/1 20571 , WO 2005/105998, WO 2005/08
- beta-amyloid antibodies are ACU-5A5, huC091 (Acumen/Merck); PF- 4360365, RI-1014, RI-1219, RI-409, RN-1219 (Rinat Neuroscience Corp (Pfizer Inc)); the nanobody therapeutics of Ablynx/Boehringer Ingelheim; beta-amyloid-specific humanized monoclonal antibodies of Intellect Neurosciences/IBL; m266, m266.2 (Eli Lilly & Co.); AAB- 02 (Elan); bapineuzumab (Elan); BAN-2401 (Bioarctic Neuroscience AB); ABP-102 (Abiogen Pharma SpA); BA-27, BC-05 (Takeda); R-1450 (Roche); ESBA-212 (ESBATech AG); AZD- 3102 (AstraZeneca) and beta-amyloid antibodies of Mindset BioPharmaceuticals Inc.
- antibodies which recognize the N-terminus of the ⁇ peptide.
- a suitable antibody, which recognizes the ⁇ - ⁇ -Terminus is, for example Acl-24 (AC Immune SA).
- Monoclonal antibodies against beta-amyloid peptide are disclosed in WO 2007/068412, WO/2008/156621 and WO/2010/012004. Respective chimeric and humanized antibodies are disclosed in WO 2008/01 1348 and WO/2008/060364.
- Vaccine composition for treating an amyloid-associated disease is disclosed in WO/2002/096937, WO/2005/014041 , WO 2007/06841 1 , WO/2007/097251 , WO/2009/029272, WO/2009/054537, WO/2009/090650 WO/2009/095857, WO/2010/016912, WO/2010/01 1947, WO/2010/01 1999, WO/2010/044464.
- Suitable vaccines for treating an amyloid-associated disease are, e.g. Affitopes AD-01 and AD-02 (GlaxoSmithKline), ACC-01 and ACC-02 (Elan/Wyeth), CAD-106 (Novartis / Cytos Biotechnology),
- Suitable cysteine protease inhibitors are inhibitors of cathepsin B.
- Inhibitors of cathepsin B and compositions containing such inhibitors are described, e.g. in WO/2008/077109, WO/2007/038772, WO 2006/060473 , WO 2006/042 1 03 , WO 2006/039807 , WO 2006/021413, WO 2006/021409, WO 2005/097103, WO 2005/007199, WO2004/084830, WO 2004/078908, WO 2004/026851 , WO 2002/094881 , WO 2002/027418, WO 2002/021509, WO 1998/046559, WO 1996/021655.
- PIMT enhancers are 10-aminoaliphatyl-dibenz[b, f] oxepines described in WO 98/15647 and WO 03/057204, respectively. Further useful according to the present invention are modulators of PIMT activity described in WO 2004/039773.
- Inhibitors of beta secretase and compositions containing such inhibitors are described, e.g. in WO/2010/094242, WO/2010/058333, WO/2010/021680, WO/2009/108550, WO/2009/042694, WO/2008/054698, WO/2007/051333, WO/2007/021793, WO/2007/019080, WO/2007/019078, WO/2007/01 1810, WO03/059346, WO2006/099352, WO2006/078576, WO2006/060109, WO2006/057983, WO2006/057945, WO2006/055434, WO2006/044497, WO2006/034296, WO2006/034277, WO2006/029850, WO2006/026204, WO2006/014944, WO2006/014762, WO2006/002004, US 7, 109,217, WO2005/1 13484,
- beta secretase inhibitors for the purpose of the present invention are WY-25105 (Wyeth); Posiphen, (+)-phenserine (TorreyPines / NIH); LSN-2434074, LY- 2070275, LY-2070273, LY-2070102 (Eli Lilly & Co.); PNU-159775A, PNU-178025A, PNU- 17820A, PNU-33312, PNU-38773, PNU-90530 (Elan / Pfizer); KMI-370, KMI-358, kmi-008 (Kyoto University); OM-99-2, OM-003 (Athenagen Inc.); AZ-12304146 (AstraZeneca / Astex); GW-840736X (GlaxoSmithKline pic), DNP-004089 (De Novo Pharmaceuticals Ltd.) and CT- 21 166 (CoMentis Inc.).
- Inhibitors of gamma secretase and compositions containing such inhibitors are described, e.g. in WO/2010/090954, WO/2009/01 1851 , WO/2009/008980, WO/2008/147800, WO/2007/084595, WO2005/008250, WO2006/004880, US 7,122,675, US 7,030,239, US 6,992,081 , US 6,982,264, WO2005/097768, WO2005/028440, WO2004/101562, US 6,756,51 1 , US 6,683,091 , WO03/066592, WO03/014075, WO03/013527, WO02/36555, WO01/53255, US 7,109,217, US 7,101 ,895, US 7,049,296, US 7,034,182, US 6,984,626, WO2005/040126, WO2005/030731 , WO2005/014553, US 6,8
- Suitable gamma secretase inhibitors for the purpose of the present invention are GSI-953, WAY-GSI-A, WAY-GSI-B (Wyeth); MK-0752, MRK-560, L-852505, L-685-458, L-852631 , L- 852646 (Merck & Co. Inc.); LY-450139, LY-41 1575, AN-37124 (Eli Lilly & Co.); BMS- 299897, BMS-433796 (Bristol-Myers Squibb Co.); E-2012 (Eisai Co. Ltd.); EHT-0206, EHT- 206 (ExonHit Therapeutics SA); NGX-555 (TorreyPines Therapeutics Inc.) and Semagacestat (Eli Lilly).
- DP IV-inhibitors and compositions containing such inhibitors are described, e.g. in US6,01 1 ,155; US6, 107,317; US6,1 10,949; US6, 124,305; US6, 172,081 ; W099/61431 , W099/67278, W099/67279, DE19834591 , WO97/40832, WO95/15309, W098/19998, WO00/07617, WO99/38501 , W099/46272, WO99/38501 , WO01/68603, WO01/40180, WO01/81337, WO01/81304, WO01/55105, WO02/02560, WO01/34594, WO02/38541 , WO02/083128, WO03/072556, WO03/002593, WO03/000250, WO03/000180, WO03/000181 , EP1258476,
- Suitable DP IV-inhibitors for the purpose of the present invention are for example Sitagliptin, des-fluoro-sitagliptin (Merck & Co. Inc.); vildagliptin, DPP-728, SDZ-272-070 (Novartis) ; ABT-279, ABT-341 (Abbott Laboratories); denagliptin, TA-6666 (GlaxoSmithKline pic); SYR- 322 (Takeda San Diego Inc.); talabostat (Point Therapeutics Inc.); Ro-0730699, R-1499, R- 1438 (Roche Holding AG); FE-99901 1 (Ferring Pharmaceuticals); TS-021 (Taisho Pharmaceutical Co.
- GRC-8200 (Glenmark Pharmaceuticals Ltd.); ALS-2-0426 (Alantos Pharmaceuticals Holding Inc.); ARI-2243 (Arisaph Pharmaceuticals Inc.); SSR-162369 (Sanofi-Synthelabo); MP-513 (Mitsubishi Pharma Corp.); DP-893, CP-867534-01 (Pfizer Inc.); TSL-225, TMC-2A (Tanabe Seiyaku Co.
- PHX-1 149 Phenomenix Corp.
- saxagliptin Bristol-Myers Squibb Co.
- PSN-9301 ((OSI) Prosidion), S-40755 (Servier)
- KRP- 104 ActivX Biosciences Inc.
- sulphostin Zaidan Hojin
- KR-62436 Korea Research Institute of Chemical Technology
- P32/98 Probiodrug AG
- Bl-A, Bl-B Boehringer Ingelheim Corp.
- SK-0403 Sawa Kagaku Kenkyusho Co. Ltd.
- NNC-72-2138 Novo Nordisk A/S.
- dipeptide-like compounds disclosed in WO 99/61431 , e.g. N-valyl prolyl, O-benzoyl hydroxylamine, alanyl pyrrolidine, isoleucyl thiazolidine like L-allo-isoleucyl thiazolidine, L- threo-isoleucyl pyrrolidine and salts thereof, especially the fumaric salts, and L-allo-isoleucyl pyrrolidine and salts thereof;
- prodrugs of DP IV-inhibitors disclosed in WO 99/67278 and WO 99/67279; and (v) glutaminyl based DP IV-inhibitors, disclosed in WO 03/072556 and WO 2004/099134.
- Suitable beta amyloid synthesis inhibitors for the purpose of the present invention are for example Bisnorcymserine (Axonyx Inc.); (R)-flurbiprofen (MCP-7869; Flurizan) (Myriad Genetics); nitroflurbiprofen (NicOx); BGC-20-0406 (Sankyo Co. Ltd.) and BGC-20-0466 (BTG pic), RQ-00000009 (RaQualia Pharma Inc).
- Suitable amyloid protein deposition inhibitors for the purpose of the present invention are for example SP-233 (Samaritan Pharmaceuticals); AZD-103 (Ellipsis Neurotherapeutics Inc.); AAB-001 (Bapineuzumab), AAB-002, ACC-001 (Elan Corp pic ); Colostrinin (ReGen Therapeutics pic); Tramiprosate (Neurochem); AdPEDI-(amyloid-beta1 -6)1 1 ) (Vaxin Inc.); MPI-127585, MPI-423948 (Mayo Foundation); SP-08 (Georgetown University); ACU-5A5 (Acumen / Merck); Transthyretin (State University of New York); PTI-777, DP-74, DP 68, Exebryl (ProteoTech Inc.); m266 (Eli Lilly & Co.); EGb-761 (Dr.
- Suitable PDE-4 inhibitors for the purpose of the present invention are for example Doxofylline (Instituto Biologico Chemioterapica ABC SpA.); idudilast eye drops, tipelukast, ibudilast (Kyorin Pharmaceutical Co.
- a preferred PDE-4-inhibitor is Rolipram.
- MAO inhibitors and compositions containing such inhibitors are described, e.g. in WO2006/091988, WO2005/007614, WO2004/089351 , WO01/26656, WO01/12176, WO99/57120, W099/571 19, W099/13878, WO98/40102, WO98/01 157, WO96/20946, WO94/07890 and W092/21333.
- Suitable MAO-inhibitors for the purpose of the present invention are for example Linezolid (Pharmacia Corp.); RWJ-416457 (RW Johnson Pharmaceutical Research Institute); budipine (Altana AG); GPX-325 (BioResearch Ireland); isocarboxazid; phenelzine; tranylcypromine; indantadol (Chiesi Farmaceutici SpA.); moclobemide (Roche Holding AG); SL-25.1 131 (Sanofi-Synthelabo); CX-1370 (Burroughs Wellcome Co.); CX-1 57 (Kren itsky Pharmaceuticals Inc.); desoxypeganine (HF Arzneiffenforschung GmbH & Co.
- Suitable histamine H3 antagonists for the purpose of the present invention are, e.g. ABT- 239, ABT-834 (Abbott Laboratories); 3874-H1 (Aventis Pharma); UCL-2173 (Berlin Free University), UCL-1470 (BioProjet, Societe Civile de für); DWP-302 (Daewoong Pharmaceutical Co Ltd); GSK-189254A, GSK-207040A (GlaxoSmithKline Inc.); cipralisant, GT-2203 (Gliatech Inc.); Ciproxifan (INSERM), 7S,2S-2-(2-Aminoethyl)-1 -(1 H-imidazol-4- yl)cyclopropane (Hokkaido University); JNJ-17216498, JNJ-5207852 (Johnson & Johnson); NNC-0038-0000-1049 (Novo Nordisk A/S); and Sch-79687 (Schering-Plough).
- PEP inhibitors and compositions containing such inhibitors are described , e.g. in J P 01042465, JP 03031298, JP 04208299, WO 00/71 144, US 5,847,155; JP 09040693, JP 10077300, JP 05331072, JP 05015314, WO 95/15310, WO 93/00361 , EP 0556482, JP 06234693, JP 01068396, EP 0709373, US 5,965,556, US 5,756,763, US 6, 121 ,31 1 , JP 63264454, JP 64000069, JP 63162672, EP 0268190, EP 0277588, EP 0275482, US 4,977,180, US 5,091 ,406, US 4,983,624, US 5,1 12,847, US 5,100,904, US 5,254,550, US 5,262,431 , US 5,340,832, US 4,956,380, EP 0303434, JP 030564
- Suitable prolyl endopeptidase inhibitors for the purpose of the present invention are, e.g. Fmoc-Ala-Pyrr-CN, Z-Phe-Pro-Benzothiazole (Probiodrug), Z-321 (Zeria Pharmaceutical Co Ltd.); ONO-1603 (Ono Pharmaceutical Co Ltd); JTP-4819 (Japan Tobacco Inc.) and S-17092 (Servier).
- NPY neuropeptide Y
- NPY mimetic NPY mimetic
- NPY agonist or antagonist NPY ligand of the NPY receptors.
- Preferred according to the present invention are antagonists of the NPY receptors.
- Suitable ligands or antagonists of the NPY receptors are 3a, 4,5,9b-tetrahydro-1 h- benz[e]indol-2-yl amine-derived compounds as disclosed in WO 00/68197.
- NPY receptor antagonists which may be mentioned include those disclosed in European patent applications EP 0 614 91 1 , EP 0 747 357, EP 0 747 356 and EP 0 747 378; international patent applications WO 94/17035, WO 97/1991 1 , WO 97/19913, WO 96/12489, WO 97/19914, WO 96/22305, WO 96/40660, WO 96/12490, WO 97/09308, WO 97/20820, WO 97/20821 , WO 97/20822, WO 97/20823, WO 97/19682, WO 97/25041 , WO 97/34843, WO 97/46250, WO 98/03492, WO 98/03493, WO 98/03494 and WO 98/07420; WO 00/30674, US patents Nos.
- NPY antagonists include those compounds that are specifically disclosed in these patent documents. More preferred compounds include amino acid and non-peptide-based NPY antagonists.
- Amino acid and non-peptide-based NPY antagonists which may be mentioned include those disclosed in European patent applications EP 0 614 91 1 , EP 0 747 357, EP 0 747 356 and EP 0 747 378; international patent applications WO 94/17035, WO 97/1991 1 , WO 97/19913, WO 96/12489, WO 97/19914, WO 96/22305, WO 96/40660, WO 96/12490, WO 97/09308, WO 97/20820, WO 97/20821 , WO 97/20822, WO 97/20823, WO 97/19682, WO 97/25041 , WO 97/34843, WO 97/46250, WO 98/03492, WO 98/03493, WO 98/03494, WO 98/07420 and WO 99/15498 ; US patents Nos. 5,552,41 1
- Particularly preferred compounds include amino acid-based NPY antagonists.
- Amino acid-based compounds which may be mentioned include those disclosed in international patent applications WO 94/17035, WO 97/1991 1 , WO 97/19913, WO 97/19914 or, preferably, WO 99/15498.
- Preferred amino acid-based NPY antagonists include those that are specifically disclosed in these patent documents, for example BIBP3226 and, especially, (R)-N2- (diphenylacetyl)-(R)-N-[1 -(4-hydroxy- phenyl) ethyl] arginine amide (Example 4 of international patent application WO 99/15498).
- M1 receptor agonists and compositions containing such inhibitors are described, e.g. in WO2004/087158, WO91/10664.
- Suitable M1 receptor antagonists for the purpose of the present invention are for example CDD-0102 (Cognitive Pharmaceuticals); Cevimeline (Evoxac) (Snow Brand Milk Products Co.
- Acetylcholinesterase inhibitors and compositions containing such inhibitors are described, e .g . i n WO2006/071 274 , WO2006/070394 , WO2006/040688 , WO2005/092009 , WO2005/079789, WO2005/039580, WO2005/027975, WO2004/084884, WO2004/037234, WO2004/032929, WO03/101458, WO03/091220, WO03/082820, WO03/020289, WO02/32412, WO01/85145, WO01/78728, WO01/66096, WO00/02549, WO01/00215, WO00/15205, WO00/23057, WO00/33840, WO00/30446, WO00/23057, WO00/15205, WO00/09483, WO00/07600, WO00/02549, W099
- Suitable acetylcholinesterase inhibitors for the purpose of the present invention are for example Donepezil (Eisai Co. Ltd.); rivastigmine (Novartis AG); (-)-phenserine (TorreyPines Therapeutics); ladostigil (Hebrew University of Jerusalem); huperzine A (Mayo Foundation); galantamine (Johnson & Johnson); Memoquin (Universita di Bologna); SP-004 (Samaritan Pharmaceuticals Inc.); BGC-20-1259 (Sankyo Co.
- NMDA receptor antagonists and compositions containing such inhibitors are described, e.g. in WO2006/094674, WO2006/058236, WO2006/058059, WO2006/010965, WO2005/000216, WO2005/102390, WO2005/079779, WO2005/079756, WO2005/072705, WO2005/070429, WO2005/055996, WO2005/035522, WO2005/009421 , WO2005/000216, WO2004/092189, WO2004/039371 , WO2004/028522, WO2004/009062, WO03/010159, WO02/072542, WO02/34718, WO01/98262, WO01/94321 , WO01/92204, WO01/81295, WO01/32640, WO01/10833, WO01 /10831 , WO00/5671 1 , WO00/
- Suitable NMDA receptor antagonists for the purpose of the present invention are for example Memantine (Merz & Co. GmbH); topiramate (Johnson & Johnson); AVP-923 (Neurodex) (Center for Neurologic Study); EN-3231 (Endo Pharmaceuticals Holdings Inc.); neramexane (MRZ-2/579) (Merz and Forest); CNS-5161 (CeNeS Pharmaceuticals Inc.); dexanabinol (HU- 21 1 ; Sinnabidol; PA-5021 1 ) (Pharmos); EpiCept NP-1 (Dalhousie University); indantadol (V- 3381 ; CNP-3381 ) (Vernalis); perzinfotel (EAA-090, WAY-126090, EAA-129) (Wyeth); RGH- 896 (Gedeon Richter Ltd.); traxoprodil (CP-101606), besonprodil (PD-196860, CI-1041 ) (P
- the present invention relates to combination therapies useful for the treatment of atherosclerosis, restenosis or arthritis, administering a QC inhibitor in combination with another therapeutic agent selected from the group consisting of inhibitors of the angiotensin converting enzyme (ACE); angiotensin II receptor blockers; diuretics; calcium channel blockers (CCB); beta-blockers; platelet aggregation inhibitors; cholesterol absorption modulators; HMG-Co-A reductase inhibitors; high density lipoprotein (HDL) increasing compounds; renin inhibitors; IL-6 inhibitors; antiinflammatory corticosteroids; antiproliferative agents; nitric oxide donors; inhibitors of extracellular matrix synthesis; growth factor or cytokine signal transduction inhibitors; MCP-1 antagonists and tyrosine kinase inhibitors providing beneficial or synergistic therapeutic effects over each monotherapy component alone.
- ACE angiotensin converting enzyme
- CB calcium channel blockers
- beta-blockers beta-blockers
- Angiotensin II receptor blockers are understood to be those active agents that bind to the AT1 -receptor subtype of angiotensin II receptor but do not result in activation of the receptor. As a consequence of the blockade of the AT1 receptor, these antagonists can, e.g. be employed as antihypertensive agents.
- Suitable angiotensin II receptor blockers which may be employed in the combination of the present invention include AT-i receptor antagonists having differing structural features, preferred are those with non-peptidic structures.
- AT-i receptor antagonists having differing structural features, preferred are those with non-peptidic structures.
- AT1 -receptor antagonists are those agents that have been approved and reached the market, most preferred is valsartan, or a pharmaceutically acceptable salt thereof.
- the interruption of the enzymatic degradation of angiotensin to angiotensin II with ACE inhibitors is a successful variant for the regulation of blood pressure and thus also makes available a therapeutic method for the treatment of hypertension.
- a suitable ACE inhibitor to be employed in the combination of the present invention is, e.g. a compound selected from the group consisting alacepril, benazepril, benazeprilat; captopril, ceronapril, cilazapril, delapril, enalapril, enaprilat, fosinopril, imidapril, lisinopril, moveltopril, perindopril, quinapril, ramipril, spirapril , temocapril and trandolapril, or in each case, a pharmaceutically acceptable salt thereof.
- Preferred ACE inhibitors are those agents that have been marketed, most preferred are benazepril and enalapril.
- a diuretic is, for example, a thiazide derivative selected from the group consisting of chlorothiazide, hydrochlorothiazide, methylclothiazide, and chlorothalidon.
- the most preferred diuretic is hydrochlorothiazide.
- a diuretic furthermore comprises a potassium sparing diuretic such as amiloride or triameterine, or a pharmaceutically acceptable salt thereof.
- the class of CCBs essentially comprises dihydropyridines (DHPs) and non-DHPs, such as diltiazem-type and verapamil-type CCBs.
- DHPs dihydropyridines
- non-DHPs such as diltiazem-type and verapamil-type CCBs.
- a CCB useful in said combination is preferably a DHP representative selected from the group consisting of amlodipine, felodipine, ryosidine, isradipine, lacidipine, nicardipine, nifedipine, niguldipine, niludipine, nimodipine, nisoldipine, nitrendipine and nivaldipine, and is preferably a non-DHP representative selected from the group consisting of flunarizine, prenylamine, diltiazem, fendiline, gallopamil, mi
- Preferred CCBs comprise amlodipine, diltiazem, isradipine, nicardipine, nifedipine, nimodipine, nisoldipine, nitrendipine and verapamil or, e.g. dependent on the specific CCB, a pharmaceutically acceptable salt thereof.
- DHP is amlodipine or a pharmaceutically acceptable salt thereof, especially the besylate.
- An especially preferred representative of non-DHPs is verapamil or a pharmaceutically acceptable salt, especially the hydrochloride, thereof.
- Beta-blockers suitable for use in the present invention include beta-adrenergic blocking agents (beta-blockers), which compete with epinephrine for beta-adrenergic receptors and interfere with the action of epinephrine.
- beta-blockers are selective for the beta-adrenergic receptor as compared to the alpha-adrenergic receptors, and so do not have a significant alpha-blocking effect.
- Suitable beta-blockers include compounds selected from acebutolol, atenolol, betaxolol, bisoprolol, carteolol, carvedilol, esmolol, labetalol, metoprolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol and timolol.
- beta- blocker is an acid or base or otherwise capable of forming pharmaceutically acceptable salts or prodrugs
- these forms are considered to be encompassed herein, and it is understood that the compounds may be administered in free form or in the form of a pharmaceutically acceptable salt or a prodrug, such as a physiologically hydrolyzable and acceptable ester.
- metoprolol is suitably administered as its tartrate salt
- propranolol is suitably administered as the hydrochloride salt
- Platelet aggregation inhibitors include PLAVIX® (clopidogrel bisulfate), PLETAL® (cilostazol) and aspirin.
- Cholesterol absorption modulators include ZETIA® (ezetimibe) and KT6-971 (Kotobuki Pharmaceutical Co. Japan).
- HMG-Co-A reductase inhibitors also called beta-hydroxy-beta-methylglutaryl-co-enzyme-A reductase inhibitors or statins
- statins are understood to be those active agents which may be used to lower lipid levels including cholesterol in blood.
- the class of HMG-Co-A reductase inhibitors comprises compounds having differing structural features.
- the compounds which are selected from the group consisting of atorvastatin, cerivastatin , fluvastatin, lovastatin , pitavastatin, pravastatin, rosuvastatin and simvastatin, or in each case, a pharmaceutically acceptable salt thereof.
- HMG-Co-A reductase inhibitors are those agents, which have been marketed, most preferred is atorvastatin, pitavastatin or simvastatin, or a pharmaceutically acceptable salt thereof.
- HDL-increasing compounds include, but are not limited to, cholesterol ester transfer protein (CETP) inhibitors.
- CETP inhibitors include JTT705 disclosed in Example 26 of U .S. Patent No. 6,426,365 issued July 30, 2002, and pharmaceutically acceptable salts thereof.
- Inhibition of interleukin 6 mediated inflammation may be achieved indirectly through regulation of endogenous cholesterol synthesis and isoprenoid depletion or by direct inhibition of the signal transduction pathway utilizing interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor/antibody, tyrosine kinase inhibitors/antibodies, serine/threonine kinase inhibitors/antibodies, mitogen-activated protein (MAP) kinase inhibitors/antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors/antibodies, Nuclear factor kappaB (N F-KB) inhibitors/antibodies, ⁇ kinase (IKK) inhibitors/antibodies, activator protein-1 (AP-1 ) inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial
- Suitable antiproliferative agents are cladribine, rapamycin, vincristine and taxol.
- a suitable inhibitor of extracellular matrix synthesis is halofuginone.
- a suitable growth factor or cytokine signal transduction inhibitor is, e.g. the ras inhibitor R1 15777.
- a suitable tyrosine kinase inhibitor is tyrphostin.
- Suitable renin inhibitors are described, e.g. in WO 2006/1 16435.
- a preferred renin inhibitor is aliskiren, preferably in the form of the hemi-fumarate salt thereof.
- MCP-1 antagonists may, e.g. be selected from anti-MCP-1 antibodies, preferably monoclonal or humanized monoclonal antibodies, MCP-1 expression inhibitors, CCR2-antagonists, TNF- alpha inhibitors, VCAM-1 gene expression inhibitors and anti-C5a monoclonal antibodies.
- MCP-1 antagonists and compositions containing such inhibitors are described , e.g.
- Suitable MCP-1 antagonists are, for instance, C-243 (Telik Inc.); NOX-E36 (Noxxon Pharma AG); AP-761 (Actimis Pharmaceuticals Inc.); ABN-912, NIBR-177 (Novartis AG); CC-1 1006 (Celgene Corp.); SSR-150106 (Sanofi-Aventis); MLN-1202 (Millenium Pharmaceuticals Inc.); AGI-1067, AGIX-4207, AGI-1096 (AtherioGenics Inc.); PRS-21 1095, PRS-21 1092 (Pharmos Corp.); anti-C5a monoclonal antibodies, e.g.
- neutrazumab G2 Therapies Ltd.
- AZD-6942 AstraZeneca pic
- 2-mercaptoimidazoles Johnson & Johnson
- TEI-E00526, TEI-6122 Deltagen
- RS-504393 Roche Holding AG
- anti-MCP-1 monoclonal antibodies Johnson & Johnson.
- Combinations of QC-inhibitors with MCP-1 antagonists may be useful for the treatment of inflammatory diseases in general, including neurodegenerative diseases.
- Combinations of QC-inhibitors with MCP-1 antagonists are preferred for the treatment of Alzheimer's disease.
- the QC inhibitor is combined with one or more compounds selected from the following group:
- PF-4360365 m266, bapineuzumab, R-1450, Posiphen, (+)-phenserine, MK-0752, LY- 450139, E-2012, (R)-flurbiprofen, AZD-103, AAB-001 (Bapineuzumab), Tramiprosate, EGb- 761 , TAK-070, Doxofylline, theophylline, cilomilast, tofimilast, roflumilast, tetomilast, tipelukast, ibudilast, HT-0712, MEM-1414, oglemilast, Linezolid, budipine, isocarboxazid, phenelzine, tranylcypromine, indantadol, moclobemide, rasagiline, ladostigil, safinamide, ABT-239, ABT-834, GSK-189254A, Ci
- a QC inhibitor preferably a QC inhibitor of formula (I), more preferably a QC inhibitor selected from any one of examples 1 -235, in combination with Atorvastatin for the treatment and/or prevention of artherosclerosis,
- a QC inhibitor preferably a QC inhibitor of formula (I), more preferably a QC inhibitor selected from any one of examples 1 -235, i n com bi nation with immunosuppressive agents, preferably rapamycin for the prevention and/or treatment of restenosis,
- a QC inhibitor preferably a QC inhibitor of formula (I), more preferably a QC inhibitor selected from any one of examples 1 -235, i n com bi nation with immunosuppressive agents, preferably paclitaxel for the prevention and/or treatment of restenosis,
- a QC inhibitor preferably a QC inhibitor of formula (I), more preferably a QC inhibitor selected from any one of examples 1 -235, in combination with AChE inhibitors, preferably Donepezil, for the prevention and/or treatment of Alzheimer's disease,
- a QC inhibitor preferably a QC inhibitor of formula (I), more preferably a QC inhibitor selected from any one of examples 1 -235, i n com bi nation with interferones, preferably Aronex, for the prevention and/or treatment of multiple sclerosis,
- a QC inhibitor preferably a QC inhibitor of formula (I), more preferably a QC inhibitor selected from any one of examples 1 -235, i n com bi nation with interferones, preferably betaferon, for the prevention and/or treatment of multiple sclerosis,
- a QC inhibitor preferably a QC inhibitor of formula (I), more preferably a QC inhibitor selected from any one of examples 1 -235, i n com bi nation with interferones, preferably Rebif, for the prevention and/or treatment of multiple sclerosis
- a QC inhibitor preferably a QC inhibitor of formula (I), more preferably a QC inhibitor selected from any one of examples 1 -235, in combination with Copaxone, for the prevention and/or treatment of multiple sclerosis,
- a QC inhibitor preferably a QC inhibitor of formula (I ), more preferably a QC inhibitor selected from any one of examples 1 -235, i n com bi nation with dexamethasone, for the prevention and/or treatment of restenosis, a QC inhibitor, preferably a QC inhibitor of formula (I), more preferably a QC inhibitor selected from any one of examples 1 -235, i n com bi nation with dexamethasone, for the prevention and/or treatment of atherosclerosis,
- a QC inhibitor preferably a QC inhibitor of formula (I), more preferably a QC inhibitor selected from any one of examples 1 -235, i n com bi nation with dexamethasone, for the prevention and/or treatment of rheumatid arthritis
- a QC inhibitor preferably a QC inhibitor of formula (I), more preferably a QC inhibitor selected from any one of examples 1 -235, in combination with HMG-Co-A- reductase inhibitors, for the prevention and/or treatment of restenosis, wherein the HMG-Co-A-reductase in h i bitor is selected from atorvastati n , cerivastati n , fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin, a QC inhibitor, preferably a QC inhibitor of formula (I), more preferably a QC inhibitor selected from any one of examples 1 -235, in combination with HMG
- a QC inhibitor preferably a QC inhibitor of formula (I), more preferably a QC inhibitor selected from any one of examples 1 -235, in combination with amyloid- beta antibodies for the prevention and/or treatment of mild cognitive impairment, wherein the amyloid-beta antibody is Acl-24,
- a QC inhibitor preferably a QC inhibitor of formula (I), more preferably a QC inhibitor selected from any one of examples 1 -235, in combination with amyloid- beta antibodies for the prevention and/or treatment of Alzheimer's disease, wherein the amyloid-beta antibody is Acl-24,
- a QC inhibitor preferably a QC inhibitor of formula (I), more preferably a QC inhibitor selected from any one of examples 1 -235, in combination with amyloid- beta antibodies for the prevention and/or treatment of neurodegeneration in Down Syndrome, wherein the amyloid-beta antibody is Acl-24,
- a QC inhibitor preferably a QC inhibitor of formula (I), more preferably a QC inhibitor selected from any one of examples 1-235, in combination with beta- secretase in hibitors for the prevention and/or treatment of m ild cognitive impairment, wherein the beta-secretase inhibitor is selected from WY-25105, GW- 840736X and CTS-21 166,
- a QC inhibitor preferably a QC inhibitor of formula (I), more preferably a QC inhibitor selected from any one of examples 1-235, in combination with beta- secretase inhibitors for the prevention and/or treatment of Alzheimer's disease, wherein the beta-secretase inhibitor is selected from WY-25105, GW-840736X and CTS-21 166,
- a QC inhibitor preferably a QC inhibitor of formula (I), more preferably a QC inhibitor selected from any one of examples 1-235, in combination with beta- secretase inhibitors for the prevention and/or treatment of neurodegeneration in
- beta-secretase inhibitor is selected from WY-25105, GW-840736X and CTS-21 166,
- a QC inhibitor preferably a QC inhibitor of formula (I), more preferably a QC inhibitor selected from any one of examples 1 -235, in combination with gamma- secretase in hibitors for the prevention and/or treatment of m ild cognitive impairment, wherein the gamma-secretase inhibitor is selected from LY-450139, LY-41 1575 and AN-37124,
- a QC inhibitor preferably a QC inhibitor of formula (I), more preferably a QC inhibitor selected from any one of examples 1 -235, in combination with gamma- secretase inhibitors for the prevention and/or treatment of Alzheimer's disease, wherein the gamma-secretase inhibitor is selected from LY-450139, LY-41 1575 and AN-37124,
- a QC inhibitor preferably a QC inhibitor of formula (I), more preferably a QC inhibitor selected from any one of examples 1 -235, in combination with gamma- secretase inhibitors for the prevention and/or treatment of neurodegeneration in
- gamma-secretase inhibitor is selected from LY- 450139, LY-41 1575 and AN-37124.
- Such a combination therapy is in particular useful for AD, FAD, FDD and neurodegeneration in Down syndrome as well as atherosclerosis, rheumatoid arthritis, restenosis and pancreatitis.
- Such combination therapies might result in a better therapeutic effect (less proliferation as well as less inflammation, a stimulus for proliferation) than would occur with either agent alone.
- At least one compound of formula (I) optionally in combination with at least one of the other aforementioned agents can be used as the active ingredient(s).
- the active ingredient(s) is intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending of the form of preparation desired for administration, e.g., oral or parenteral such as intramuscular.
- a pharmaceutical carrier may take a wide variety of forms depending of the form of preparation desired for administration, e.g., oral or parenteral such as intramuscular.
- any of the usual pharmaceutical media may be employed.
- suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like;
- suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated or enteric coated by standard techniques.
- the carrier will usually comprise sterile water, though other ingredients, for example, for purposes such as aiding solubility or for preservation, may be included.
- injectable suspensions may also prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed.
- the pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful and the like, an amount of the active ingredient(s) necessary to deliver an effective dose as described above.
- compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, suppository, teaspoonful and the like, from about 0.03 mg to 100 mg/kg (preferred 0.1 - 30 mg/kg) and may be given at a dosage of from about 0.1 - 300 mg/kg per day (preferred 1 - 50 mg/kg per day) of each active ingredient or combination thereof.
- the dosages may be varied depending upon the requirement of the patients, the severity of the condition being treated and the compound being employed. The use of either daily administration or post-periodic dosing may be employed.
- compositions are in unit dosage forms from such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, autoinjector devices or suppositories; for oral parenteral , intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation.
- the composition may be presented in a form suitable for once- weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection.
- a pharmaceutical carrier e.g.
- a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof.
- preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective dosage forms such as tablets, pills and capsules.
- This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of each active ingredient or combinations thereof of the present invention.
- the tablets or pills of the compositions of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
- the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
- the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release.
- enteric layers or coatings such materials including a number of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
- Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone or gelatin.
- the pharmaceutical composition may contain between about 0.01 mg and 100 mg, preferably about 5 to 50 mg, of each compound, and may be constituted into any form suitable for the mode of administration selected.
- Carriers include necessary and inert pharmaceutical excipients, including, but not limited to, binders, suspending agents, lubricants, flavorants, sweeteners, preservatives, dyes, and coatings.
- Compositions suitable for oral administration include solid forms, such as pills, tablets, caplets, capsules (each including immediate release, timed release and sustained release formulations), granules, and powders, and liq u id forms, such as solutions, syru ps , el ixi rs, em ulsions, and suspensions.
- Forms useful for parenteral administration include sterile solutions, emulsions and suspensions.
- compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
- compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal skin patches well known to those of ordinary skill in that art.
- the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
- the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
- suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or betalactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
- Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
- the liquid forms in suitable flavored suspending or dispersing agents such as the synthetic and natural gums, for example, tragacanth, acacia, methyl-cellulose and the like.
- suitable flavored suspending or dispersing agents such as the synthetic and natural gums, for example, tragacanth, acacia, methyl-cellulose and the like.
- sterile suspensions and solutions are desired.
- Isotonic preparations which generally contain suitable preservatives are employed when intravenous administration is desired.
- the compounds or combinations of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
- Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
- Compounds or combinations of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled.
- the compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers.
- Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxyethylaspartamid-ephenol, or polyethyl eneoxidepolyllysine substituted with palmitoyl residue.
- the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polyactic acid, polyepsilon caprolactone, polyhydroxy butyeric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
- biodegradable polymers useful in achieving controlled release of a drug, for example, polyactic acid, polyepsilon caprolactone, polyhydroxy butyeric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
- Compounds or combinations of this invention may be administered in any of the foregoing compositions and according to dosage regimens established in the art whenever treatment of the addressed disorders is required.
- the daily dosage of the products may be varied over a wide range from 0.01 to 1 .000 mg per mammal per day.
- the compositions are preferably provided in the form of tablets containing, 0.01 , 0.05, 0.1 , 0.5, 1 .0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250 and 500 milligrams of each active ingredient or combinations thereof for the symptomatic adjustment of the dosage to the patient to be treated.
- An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.1 mg/kg to about 300 mg/kg of body weight per day.
- the range is from about 1 to about 50 mg/kg of body weight per day.
- the compounds or combinations may be administered on a regimen of 1 to 4 times per day.
- Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular compound used, the mode of administration, the strength of the preparation, the mode of administration, and the advancement of disease condition. In addition, factors associated with the particular patient being treated, including patient age, weight, diet and time of administration, will result in the need to adjust dosages.
- the invention also provides a process for preparing a pharmaceutical composition
- a pharmaceutical composition comprising at least one compound of formula (I), optionally in combination with at least one of the other aforementioned agents and a pharmaceutically acceptable carrier.
- compositions are preferably in a unit dosage form in an amount appropriate for the relevant daily dosage.
- Suitable dosages, including especially unit dosages, of the the compounds of the present invention include the known dosages including unit doses for these compounds as described or referred to in reference text such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31 st Edition page 341 and pages cited therein) or the above mentioned publications.
- the urea was taken up in a mixture of AcOH and cone, aqueous HCI (40/1 , v/v) and kept under reflux for 1 h. The solvent was removed and the remains were re-dissolved in MeOH and little HCI was added (1 -2%). The solution was subjected to hydrogenation (PdC, 10% on charcoal, 4 bar, 40°C) for 4h. The catalyst was removed by filtration through a pad of CELITE ® . The solvent was removed and purified by means of preparative HPLC.
- the product (1 equiv.) obtained from step B was dissolved in dichloromethane and the solution was cooled down to 0°C. Tosylchloride (1 .05 equiv.) and triethylamine (1 .4 equiv.) were added to the solution. The reaction was allowed to adopt ambient temperature and was stirred for 14 hours before the reaction mixture was transferred into water. The mixture was extracted three times by means of dichloromethane. The combined organic layers were washed with brine, dried (Na 2 S0 4 ), filtered and the solvent was removed under reduced pressure. The product was purified by FPLC using a hexane-ethyl acetate gradient (0-»30%).
- step C The product obtained from step C (1 equiv.) was dissolved in DMF and sodium azide (1 .5 equiv.) was added. The reaction was stirred for 2 hours at 70 °C. The reaction was cooled down to ambient temperature, before water was added and the mixture was extracted three times with 60 ml. ethyl acetate. The combined organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The product was purified via FPLC using hexane-ethyl acetate gradient (0->30%).
- step D The product obtained from step D was dissolved in ethanol.
- the mixture was purged with argon, loaded with palladium on activated carbon (10%) and the mixture was hydrogenated using an autoclave for 14 hours at ambient temperature and 4 bar hydrogen pressure.
- the catalyst was filtered off through a pad of CELITE ® and the filtrate was concentrated under reduced pressure.
- the product firstly appears as a colorless oil and crystallizes after a few minutes.
- the crude product obtained from the hydrogenation was dissolved in ethanol and p- anisaldehyde (1 .2 equiv.) was added to the solution.
- the reaction was stirred for 5 hours at ambient temperature, before the reaction was cooled down to 0°C and sodium borohydride (2.4 equiv.) was added.
- step E The cru de materia l obtai ned from step E was d issolved in d ich lorometha ne and trifluoroacetic acid (20% V/V) was added. The reaction was stirred until the complete consumption of the starting material (TLC control). Toluol was added and the solvents and the trifluoroacetic acid were removed under reduced pressure.
- step G The product obtained from step G was dissolved in triethyl orthoformate and the reaction was stirred for 30 minutes at reflux. After cooling the excess of triethyl orthoformate was removed under reduced pressure and the remains were dissolved in trifluoroacetic acid. The reaction was stirred for 14 hours at ambient temperature. The TFA was removed under reduced pressure and the residue was re-dissolved in buffer (pH7) and three times extracted by means of dichloromethane. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. The final product was purified by means of FPLC using a methanol-chloroform gradient (0->10%).
- the mixture was then poured on ice/ammonia (containing 12 mL of a 25% NH 3 solution in case of 4 mmol starting material).
- the aqueous layer was extracted 3 times by means of CH 2 CI 2 the organic phases were combined, dried, filtrated and the solvent was removed. The remains were re-dissolved in concentrated HCI and kept at 40°C overnight. Water was added and the solution was neutralized by adding NaOH.
- the aqueous phase was extracted three times by means of CH 2 CI 2 , thereafter the organic phases were combined and dried. The solvent was removed and the remains were taken up in triethyl-ortho formate. The mixture was kept under reflux for 1 h.
- T-butyl hypochlorite (3 eq) was added to a stirred solution of benzyl carbamate (3 eq) 0.4M aqueous sodium hydroxide in 1 -propanol at 0°C and stirred for 1 5min .
- a solution of (DHQ) 2 PHAL (0.05 eq) in 1 -propanol was added.
- the corresponding define (1 eq)) in 1 - propanol followed by potassium osmate dihydrate (100mg, 0.025eq) and the reaction mixture was stirred for 2h at room temperature.
- the reaction mixture was quenched into saturated sodium sulphite solution and extracted with ethyl acetate (3x40ml_).
- step B The product obtained from step B was dissolved in a 0.2 M solution of sodium hydroxide in methanol. The reaction was stirred at reflux until the TLC control indicated complete consumption. The solvent was removed under reduced pressure and ethyl acetate was added. The organic layer was washed with brine, dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. The product was purified via FPLC using a heptane-ethyl acetate gradient (0->100%).
- the product obtained from the copper(l)-catalyzed coupling was dissolved in triethyl orthoformate and the reaction was stirred at reflux for 1 h. After cooling the excess of triethyl orthoformate was removed under reduced pressure. The final product was purified via FPLC using a chloroform-methanol gradient (0->10%).
- step A A mixture of the product of step A (1 eq) and 10%NaOH was refluxed overnight.
- the reaction mixture was extracted with ethyl acetate (3x30ml_) and the aqueous layer was acidified with concentrated HCI up to pH ⁇ 2.
- the aqueous layer was extracted with ethyl acetate and the aqueous layer was concentrated under vacuo and co-distilled with toluene. This crude product was taken as such for the next step.
- step C Product of step C (1 eq) was added portion wise to a suspension of sodium borohydride (3 eq) in ethanol (100ml_) at 0°C and stirred at room temperature for 5h. Excess ethanol was removed in vacuo and the residue was partitioned between water and ethyl acetate. Separated organic layer was washed with water, brine, dried over anhydrous sodium sulphate and concentrated in vacuo.
- Triethylamine (2 eq) Boc anhydride (1 .5 eq) was added successively to a stirred solution of the product of step D (1 eq) in dry dichloromethane and stirred for 4h at room temperature.
- the reaction mixture was poured into water and extracted with dichloromethane.
- the combined organic layer was washed with brine solution, dried over anhydrous sodium sulphate and concentrated in vacuo. This was purified by super fluid chromatography to obtain the R, S enantiomers.
- step F A mixture of the product of step F (1 eq), 1 ,2-diamino 4-iodo benzene (1 eq), cesium fluoride (1 .5eq) in 1 ,4-dioxane were purged with argon gas for 15min.1 , 2-diaminocyclohexane (0.1 eq) and copper iodide (0.1 eq) was added to the reaction mixture, purging continued for another 5min and stirred over night at 120°C in a sealed tube. The reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine solution, dried over anhydrous sodium sulphate and concentrated under vacuo to give crude compound. The crude product was purified by column chromatography using neutral alumina using 2% methanol in dichloromethane as eluent.
- a mixture of the product of step G (1 eq) and formic acid was heated at 70°C for 1 h.
- the reaction mixture was cooled to 0°C and basified using saturated sodium bicarbonate solution.
- the aqueous layer was extracted with ethyl acetate, washed with brine solution and dried over anhydrous sodium sulfate.
- the compound was purified by preparative TLC or H PLC 1 M ether-HCI (0.57ml_, 0.57mmol) was added to a stirred solution of the product (1 50mg, 0.47mmol) in dichloromethane (1 OmL) at 0°C and stirred for 30min at room temperature.
- the reaction mixture was filtered and washed with pentane.
- step B Product obtained from step B was dissolved in dichloromethane and di(1 H-imidazol-1 - yl)methanone (1 .2 equiv.) was added to the solution. The reaction was heated at reflux for 1 hour. The reaction was cooled down to ambient temperature and washed with water. The organic layer was dried over sodium sulphate, filtered and the solvent was removed under reduced pressure. The product was purified via FPLC using a heptane-ethyl acetate gradient (0-»100%).
- reaction was stirred at 95 °C until TLC indicated consumption of the 1 ,3- oxazinan-2-one. After cooling to 45 °C the reaction mixture was filtered through a pad of CELITE ® , the pad was washed with warm dichloromethane and the solution was concentrated u nder red uced pressu re. The prod uct was pu rified via FP LC using a chloroform-methanol gradient (0->10%).
- the product obtained from the copper(l)-catalyzed coupling was dissolved in triethyl orthoformate and the reaction was stirred at reflux for 1 h. After cooling the excess of triethyl orthoformate was removed under reduced pressure. The final product was purified via FPLC using a chloroform-methanol gradient (0->10%).
- 5(6)-Bromobenzimidazole 200 mg; 1 mmol; 1 eq.
- the respective pyrrolidine derivative 1.2 mmol; 1 .2 eq.
- 2-dicyclohexylphosphino-2'-(/V,/V-dimethylamino)biphenyl 9 mg; 0.024 mmol; 0.024 eq.; 2.4 mol%)
- Pd 2 dba 3 9 mg; 0.01 mmol; 0.01 eq.; 1 mol%) were dissolved in THF (1 ml).
- step B The product of step B (1 .0 eq) was dissolved in toluol and Lawessons Reagent (5.0 eq) was added. The mixture was kept under reflux for 6h. The solvent was removed and the remains were taken up in CHCI 3 then washed by means of a saturated solution of NaHC0 3 . The solvent was removed and the product was purified by means of preparative HPLC.
- the compound was synthesized as hydrochloride salt by the following procedure.
- Phenyl chloroformate (0.98ml_, 7.8 mmol) was dissolved in CH 2 CI 2 , cooled down to 0°C and
- 5-aminobenzimidazole (0.865g, 6.5mmol) was added slowly. The mixture was kept at 0°C for 30 min and then the mixture was allowed to adapt ambient temperature. The mixture was stirred at ambient temperature for 2h. The resulting solid was withdrawn by suction, dried and taken up in a small amount of DMF. To the solution, 1 -amino-3,3-dimethylbutan-2-one (0.986, 6.5mmol) and TEA (2.73ml_, 19.5mmol) were added. The mixture was kept at 40°C for 2h. The solvent was removed and purified by means of preparative HPLC. The remains were re-dissolved in MeOH and a small amount of HCI was added (1 -2%).
- the solution was subjected to hydrogenation (PdC, 10% on charcoal, 4 bar, 60°C) for 4h.
- the catalyst was removed by filtration through a pad of CELITE ® and the residue was washed with water.
- the organic layer was dried, filtrated and the solvent was removed to result in the final product.
- the compound was synthesized as trifluoroacetate salt starting from 5-aminobenzimidazole (0.59g , 4.4 mmol), cyclohexanecarbaldehyde (0.45 g, 0.485ml_, 4 mmol), TMSCN (0.5 ml_, 4 mmol), PdC (10%, 0.05g). di-(imidazol-1 -yl)methanone (0.64g, 3.92 mmol), as described in method 2. The product was purified via preperative HPLC using a water-acetonitrile gradient with 0.04 % trifluoroacetic acid.
- the compound was synthesized starting from 5-aminobenzimidazole (1 .46g, l Ommol), benzaldehyde (1 .06g, 10mmol), TMSCN (1 .25 mL, 10mmol), PdC (10%, 0.05g). di-(imidazol- 1 -yl)methanone (1 .73, 12mmol), as described in method 2.
- the compound was synthesized as hydrochloride salt by the following procedure.
- the compound was synthesized as hydrochloride salt starting from 5-aminobenzimidazole (0.266g, 2mmol), di(1 H-imidazol-1 -yl)methanone (0.052g, 2mmol), TEA (0.799ml_, 6mmol), aminomethyl-(4-methoxy)phenyl ketone hydrochloride (0.403g, 2mmol), TEA (0.558ml_, 4mmol), PdC (10%, 0.02 g ) as described in method 1 .
- Example 12 Separation of example 12 by chiral HPLC, column: Nucleocel Alpha RP-S, 250 * 21 ⁇ " ⁇ " ⁇ (5 ⁇ " ⁇ ), eluent: 50/50 acetonitrile/water 30/70, flow 10mL/min, second eluting enantiomer rt: 20.2min (99.35)%.
- Example 7 1 -(1 H-benzo[dlimidazol-5-yl)-5-(4-methoxyphenyl)imidazolidin-2-one
- Example 12 Separation of example 12 by chiral HPLC, column: Nucleocel Alpha RP-S, 250 * 21 ⁇ " ⁇ " ⁇ (5 ⁇ " ⁇ ), eluent: 50/50 acetonitrile/water 30/70, flow 10mL/min, first eluting enantiomer rt: 16.5min (99.75)%
- Example 8 (4R,5S)-1 -( 1 H-benzo[dlimidazol-6-yl)-5-(4-methoxyphenyl)-4-
- the combined organic layers were washed with brine, dried over sodium sulfate, filtrated and the solvent was removed under reduced pressure.
- the final product was purified by FPLC using a chloroform-methanol gradient (0->10%). The product elutes at about 5 % methanol.
- the compound was synthesized as hydrochloride salt starting from 5-aminobenzimidazole (0.532g, 4mmol), di(1 H-imidazol-1 -yl)methanone (0.713g, 4.4mmol), TEA (1 .67mL, 12mmol), aminomethyl-(3-methoxyphenyl)ketone hydrochloride (0.807g, 4mmol), TEA (1 .12mL, 8mmol), PdC (10%, 0.02 g ) as described in method 1 .
- the compound was synthesized starting from 5-aminobenzimidazole (0.585g, 4.4mmol), 2- methoxybenzaldehyde (0.484ml_, 4mmol), TMSCN (0.5ml_, 4mmol), PdC (10%, 0.02g), TEA (1 .05ml_, 7.55 mmol), di-(imidazol-1 -yl)methanone (0.667, 4.12mmol) as described in method 2.
- Example 1 1 -(1 H-benzo[dlimidazol-5-yl)-5-(4-ethoxyphenyl)imidazolidin-2-one
- the compound was synthesized starting from 5-aminobenzimidazole (0.585g, 4.4mmol), 4- ethoxybenzaldehyde (0.601 g, 4mmol), TMSCN (0.5mL, 4mmol), PdC (10%, 0.02g), TEA (0.98mL, 7.0 mmol), di-(imidazol-1 -yl)methanone (0.622, 3.84mmol) as described in method 2.
- Example 12 1 -(1 H-benzo[dlimidazol-5-yl)-5-(4-propoxyphenyl)imidazolidin-2-one
- the compound was synthesized starting from 5-aminobenzimidazole (0.585g, 4.4mmol), 4- propoxybenzaldehyde (0.632mL, 4mmol), TMSCN (0.5mL, 4mmol), PdC (10%, 0.02g), TEA 0.558mL, 4mmol), di-(imidazol-1 -yl)methanone (0.648, 4mmol) as described in method 2.
- example 12 Separation of example 12 by chiral HPLC, column: Nucleocel Alpha RP-S, 250 * 21 ⁇ " ⁇ " ⁇ (5 ⁇ " ⁇ ), eluent: 50/50 acetonitrile/water 50/50, flow 1 0mL/min , second eluting enenatiomer rt: 12.8min (98.35)%.
- ie/f-butyl carbamate (9.08g, 77.5mmol), 0.38 M aqueous NaOH (200mL, 76mmol), 1 ,3- dichloro-5,5-dimethylimidazolidine-2,4-d ione (7.56g, 38.4mmol), (DHQ) 2 PHAL (1 .17g, 1 .5mmol), 1 -propoxy-4-vinylbenzene (4.055g, 25mmol), potassium osmate dihydrate (0.368g, 1 mmol)
- Step D Product obtained from step C (2.59g, 5.76mmol), sodium azide (0.562g, 8.64mmol)
- Phenol (1 Og, 106.1 mmol) was added to a solution of powdered aluminium chloride (28.3g, 212.2mmol) over a period of 15min in dichloromethane (100ml_) at 0°C, stirred for 30min and ethyl oxalyl chloride (14.2ml_, 127.5mmol) was added to the above reaction mass drop wise over a period of 30min keeping the temperature at 0°C. Warmed to room temperature and stirred for 15h. The reaction mass was quenched into cold water and the organic layer separated. The aqueous layer was extracted with dichloromethane.
- Raney nickel 500mg was added to a solution of the product of step C (3.6g, 14.34mmol) in ethanol (60ml_), containing catalytic methanolic ammonia and hydrogenated at 85psi for 20h in Parr apparatus.
- the reaction mass was filtered though celite and washed with ethanol.
- the filtrate was concentrated under reduced pressure to afford 2.7g (79.5%) of the product as pale brown solid.
- Triethyl amine (1 .42ml_, 10.2mmol) and di-t-butyldicarbonate (1 .4ml_, 6.12mmol) were added successively to a solution of the product of step F (1 .0g, 5.10mmol) in dichloromethane at room temperature and stirred for 3h.
- the reaction mass was poured into water and extracted with dichloromethane (2x30ml_).
- the combined organic layer was washed successively with water, brine, dried over anhydrous sodium sulfate and concentrated in vacuum to afford crude compound. Purification by triturating with petroleum ether afforded 750 mg (50%) of the product as yellow solid.
- step F Og of the product of step F was purified by chiral preparative HPLC using the following conditions: Column: Chiralpak IA (19x250mm) 10 ⁇ ; Mobile Phase: Hexane: Ethyl acetate; 92:8; Flow rate: 16mL/min; UV: 227nm.
- the resulting ML's from Chiral preparative HPLC was concentrated in vacuum to afford 3.1 g (31 %) of the enantiomer as off white solid.
- example 12 Separation of example 12 by chiral HPLC, column: Nucleocel Alpha RP-S, 250 * 21 ⁇ - ⁇ - ⁇ (5 ⁇ - ⁇ ), eluent: 50/50 acetonitrile/water 50/50, flow 10mL/min, first eluting enenatiomer rt: 1 1 .6min (99.15)%.
- the compound was synthesized as trifluoroacetate salt starting from 5-aminobenzimidazole (0.585g, 4.4mmol), 4-butoxybenzaldehyde (0.691 mL, 4mmol), TMSCN (0.5mL, 4mmol), PdC (10%, 0.02g), TEA (1.03mL, 7.4 mmol), di-(imidazol-1 -yl)methanone (0.658, 4.06mmol) as described in method 2.
- the product was purified by means of preparative HPLC.
- Example 16 1 -(1 H-benzo[dlimidazol-5-yl)-5-(4-(pentyloxy)phenyl)imidazolidin-2-one
- the compound was synthesized as trifluoroacetate salt starting from 5-aminobenzimidazole (0.585g, 4.4mmol), 4-pentoxybenzaldehyde (0.755mL, 4mmol), TMSCN (0.5mL, 4mmol), PdC (10%, 0.02 g), TEA (1 .05mL, 7.4mmol), di-(imidazol-1 -yl)methanone (0.667g, 4.12mmol) as described in method 2.
- the product was purified by means of preparative HPLC.
- Example 17 1 -(1 H-benzo[dlimidazol-5-yl)-5-(4-isopropoxyphenyl)imidazolidin-2-one
- the compound was synthesized as trifluoroacetate salt starting from 5-aminobenzimidazole (0.585g, 4.4mmol), 4-isopropoxybenzaldehyde (0.657g, 4mmol), TMSCN (0.5ml_, 4mmol), PdC (10%, 0.02g), TEA (0.889mL, 6.38mmol), di-(imidazol-1 -yl)methanone (0.564, 3.48mmol) as described in method 2.
- the product was purified by means of preparative HPLC.
- Example 18 1 -(1 H-benzo[dlimidazol-5-yl)-5-(4-methoxybenzo[dl[1 ,31dioxol-6- yl)imidazolidin-2-one
- the compound was synthesized as trifluoroacetate salt starting from 5-aminobenzimidazole (0.585g, 4.4mmol), 7-methoxybenzo[d][1 ,3]dioxole-5-carbaldehyde (0.721 g, 4mmol), TMSCN (0.5mL, 4mmol), PdC (10%, 0.02g), TEA (0.521 mL, 3.74 mmol), di-(imidazol-1 -yl)methanone (0.331 g, 2.04mmol) as described in method 2.
- the product was purified by means of preparative HPLC.
- the compound was synthesized as hydrochloride salt starting from 5-aminobenzimidazole (0.37g, 2.78mmol), di(1 H-imidazol-1 -yl)methanone (0.496g, 3.06mmol), TEA (1 .16mL, 8.34mmol), aminomethyl-(2,3-dihydrobenzo[b][1 ,4]dioxin-6-yl)ketone hydrobromide (0.761 g, 2.78mmol), TEA (0.775mL, 5.56mmol), PdC (10%, 0.02 g ) as described in method 1.
- the compound was synthesized starting from 5-aminobenzimidazole (0.585g, 4.4mmol), 4- (1 ,1 ,2,2-tetrafluoroethoxy)benzaldehyde (0.888g, 4mmol), TMSCN (0.5mL, 4mmol), PdC (10%, 0.02g), TEA (0.978ml_, 7.0 mmol), di-(imidazol-1 -yl)methanone (0.621 g, 3.83mmol) as described in method 2.
- the product was purified by means of FPLC.
- Example 21 1 -(1 H-benzo[dlimidazol-5-yl)-5-(2,2-difluorobenzo[dl[1 ,31dioxol-5- yl)imidazolidin-2-one
- the compound was synthesized starting from 5-aminobenzimidazole (0.585g, 4.4mmol), 2,2- difluorobenzo[d][1 ,3]dioxole-5-carbaldehyde (0.744g, 4mmol), TMSCN (0.5ml_, 4mmol), PdC (10%, 0.02g), TEA (0.81 ml_, 5.81 mmol), di-(imidazol-1 -yl)methanone (0.514g, 3.17mmol) as described in method 2.
- the product was purified by means of FPLC.
- Example 22 1 -(1 H-benzo[dlimidazol-5-yl)-5-(3-fluoro-4-methoxyphenyl)imidazolidin-2-one
- the compound was synthesized starting from 5-aminobenzimidazole (0.585g, 4.4mmol), 3- fluoro-4-methoxybenzaldehyde (0.617g, 4mmol), TMSCN (0.5mL, 4mmol), PdC (10%, 0.02g), TEA (0.524mL, 3.76 mmol), di-(imidazol-1 -yl)methanone (0.333g, 2.05mmol) as described in method 2.
- the product was purified by means of FPLC.
- Example 23 1 -(1 H-benzo[dlimidazol-5-yl)-5-(2,6-difluoro-4-methoxyphenyl)imidazolidin-2- one
- the compound was synthesized starting from 5-aminobenzimidazole (0.585g, 4.4mmol), 2,6- difluoro-4-methoxybenzaldehyde (0.688ml_, 4mmol), TMSCN (0.5ml_, 4mmol), PdC (10%, 0.02g), TEA (1.2mL, 8.6mmol), di-(imidazol-1 -yl)methanone (0.761 g, 4.69mmol) as described in method 2.
- the product was purified by means of FPLC.
- the compound was synthesized as ditrifluoroacetate salt starting from 5- aminobenzimidazole (0.585g, 4.4mmol), 4-(2-morpholinoethoxy)benzaldehyde (0.941 g, 4mmol), TMSCN (0.5mL, 4mmol), PdC (10%, 0.02g), TEA (1 .34mL, 9.6 mmol), di-(imidazol- 1 -yl)methanone (0.582g, 3.6mmol) as described in method 2.
- the product was purified by means of preparative HPLC.
- the compound was synthesized starting from 5-aminobenzimidazole (1 .9g, 14.45mmol), 4- (3-morpholinopropoxy)phenyl carbaldehyde (3g, 12.05mmol), TMSCN (1 .25g, 12.05mmol), PdC (10%, 0.40g), TEA (2.8mL, 20.25mmol), di-(imidazol-1 -yl)methanone (1 .6g, 10.13mmol) as described in method 2.
- the product was purified by means of preparative HPLC.
- the compound was synthesized starting from 5-aminobenzimidazole (679mg, 5.1 1 mmol), 2- (2-morpholinoethoxy)phenyl carbaldehyde (1 g, 4.26mmol), TMSCN (0.6ml_, 4.26mmol), PdC (10%, 250mg), TEA (1 .3ml_, 7.80mmol), di-(imidazol-1 -yl)methanone (220mg,1 .31 mmol) as described in method 2.
- the compound was synthesized as hydrochloride salt starting from 5-aminobenzimidazole (0.665g, 5mmol), di(1 H-imidazol-1 -yl)methanone (0.891 g, 5.5mmol), TEA (2.09mL, 15mmol), aminomethyl-(4-fluorophenyl)ketone hydrochloride (0.948g, 5mmol), TEA (1 .39mL, 10mmol), PdC (10%, 0.02 g ) as described in method 1 .
- Example 28 1 -(1 H-benzo[dlimidazol-5-yl)-5-(2-fluorophenyl)imidazolidin-2-one
- the compound was synthesized starting from 5-aminobenzimidazole (0.585g, 4.4mmol), 2- fluorobenzaldehyde (0.496g, 4mmol), TMSCN (0.5mL, 4mmol), PdC (10%, 0.02g), TEA (1 .04mL, 7.5mmol), di-(imidazol-1 -yl)methanone (0.662, 4.08mmol) as described in method 2.
- the compound was synthesized as tnfluoroacetate salt starting from 5-aminobenzimidazole (0.585g, 4.4mmol), 3-fluorobenzaldehyde (0.496g, 4mmol), TMSCN (0.5ml_, 4mmol), PdC (10%, 0.02g), TEA (0.979ml_, 7.02mmol), di-(imidazol-1 -yl)methanone (0.621 , 3.83mmol) as described in method 2.
- the compound was synthesized as tnfluoroacetate salt starting from 5-aminobenzimidazole (0.585g, 4.4mmol), 2,6-difluorobenzaldehyde (0.431 mL, 4mmol), TMSCN (0.5mL, 4mmol), PdC (10%, 0.02g), TEA (1 .15mL, 8.22mmol), di-(imidazol-1 -yl)methanone (0.730, 4.5mmol) as described in method 2.
- the compound was synthesized as hydrochloride salt starting from 5-aminobenzimidazole (0.585g, 4.4mmol), di(1 H-imidazol-1 -yl)methanone (0.713g, 4.4mmol), TEA (1 .84mL, 13.2mmol), aminomethyl-(3,4-difluorophenyl)ketone hydrochloride (0.91 1 g, 4.4mmol), TEA (1 .23mL, 8.8mmol), PdC (10%, 0.02 g ) as described in method 1 .
- Example 32 1 -(1 H-benzo[dlimidazol-5-yl)-5-(2-fluoro-5-(trifluoromethyl)phenyl)imidazolidin- 2-one
- the compound was synthesized from 2-fluoro-5-(trifluoromethyl)benzaldehyde (0.565ml_, 4mmol), 5-aminobenzimidazole (0.585g, 4.4mmol), TMSCN (0.5g, 4mmol), TEA (0.669mL, 4.8mmol), PdC (10%, 0.02 g ), di(1 H-imidazol-1 -yl)methanone (0.778g, 4.8 mmol) as described in method 2.
- Example 33 1 -(1 H-benzo[dlimidazol-5-yl)-5-(3-fluoro-5-(trifluoromethyl)phenyl)imidazolidin- 2-one
- the compound was synthesized starting from 5-aminobenzimidazole (0.585g, 4.4mmol), 3- fluoro-5-(trifluoromethyl)benzaldehyde (0.768g, 4mmol), TMSCN (0.5m L, 4mmol), PdC (10%, 0.02g), TEA (0.558mL, 4mmol), di-(imidazol-1 -yl)methanone (0.648, 4mmol) as described in method 2.
- Example 34 1 -(1 H-benzo[dlimidazol-5-yl)-5-(2-fluoro-4-(trifluoromethyl)phenyl)imidazolidin- 2-one
- the compound was synthesized starting from 5-aminobenzimidazole (0.457g, 3.44mmol), 2- fluoro-4-(trifluoromethyl)benzaldehyde (0.600g, 3.13mmol), TMSCN (0.39mL, 3.13mmol), PdC (10%, 0.02g), TEA (0.455mL, 3.26mmol), di-(imidazol-1 -yl)methanone (0.529, 3.26mmol) as described in method 2.
- Example 35 1 -(1 H-benzo[dlimidazol-5-yl)-5-(3-fluoro-4-(trifluoromethyl)phenyl)imidazolidin 2-one
- the compound was synthesized starting from 5-aminobenzimidazole (0.585g, 4.4mmol), 3- fluoro-4-(trifluoromethyl)benzaldehyde (0.768g, 4mmol), TMSCN (0.5mL, 4mmol), PdC (10%, 0.02g), TEA (0.585ml_, 4.2mmol), di-(imidazol-1 -yl)methanone (0.681 , 4.2mmol) as described in method 2.
- the compound was synthesized starting from 5-aminobenzimidazole (0.585g, 4.4mmol), 2- chloro benzaldehyde (0.448ml_, 4mmol), TMSCN (0.5ml_, 4mmol), PdC (10%, 0.02g), TEA (1 .15ml_, 8.25mmol), di-(imidazol-1 -yl)methanone (0.700g, 4.32mmol) as described in method 2.
- the compound was synthesized as trifluoroacetate salt starting from 5-aminobenzimidazole
- the compound was synthesized as trifluoroacetate salt starting from 5-aminobenzimidazole (0.585g, 4.4mmol), 2,6-dichloro-benzaldehyde (0.7g, 4mmol), TMSCN (0.5mL, 4mmol), PdC (10%, 0.02g), TEA (0.4ml_, 2.8mmol), di-(imidazol-1 -yl)methanone (0.253g, 1 .56mmol) as described in method 2.
- the product was purified by means of preparative HPLC.
- Example 39 1 -(1 H-benzo[dlimidazol-5-yl)-5-(2,3-dichlorophenyl)imidazolidin-2-one
- the compound was synthesized starting from 5-aminobenzimidazole (0.585g, 4.4mmol), 2,3- dichloro-benzaldehyde (0.700g, 4mmol), TMSCN (0.5ml_, 4mmol), PdC (10%, 0.02g), TEA (0.5ml_, 3.6mmol), di-(imidazol-1 -yl)methanone (0.308, 1 .9mmol) as described in method 2.
- Example 40 1 -(1 H-benzo[dlimidazol-5-yl)-5-(3,4-dichlorophenyl)imidazolidin-2-one
- the compound was synthesized as hydrochloride salt starting from 5-aminobenzimidazole
- the compound was synthesized from according to method 3.
- step D Product of step D (2.2g, 6.65mmol), zinc dust (1 .3g, 19.96mmol) yield 3.3g (89%), para- anisaldehyde (0.78mL, 6.49mmol), sodium borohydride (870mg, 23.6mmol), yield: 1 .88g (75%)
- step F Product of step F (400mg, 1 .14mmol), 1 ,2-diamino 4-bromo benzene (213mg, 1 .14mmol), cesium fluoride (347mg, 2.28mmol), copper iodide (21 mg, 0.1 1 mmol), 1 ,2- diaminocyclohexane(13mg, 0.1 1 mmol), yield: 400mg (76%).
- Trifluoroacetic acid (10ml_) was added stirred for 15h at room temperature. Excess Trifluoroacetic acid was removed in vacuum and the crude compound was extracted with ethyl acetate. The combined organic layer was washed with 10% sodium carbonate, water, brine solution and dried over anhydrous sodium sulphate. The solvent was evaporated under vacuum. Purification by column chromatography over silica gel (100-200mesh) using gradient 5% methanol in chloroform as eluent afforded 200mg (76%) product.
- Example 42 1 -(1 H-1 ,3-benzodiazol-5-yl)-5-(4-biphenyl)imidazolidin-2-one
- the compound was synthesized as hydrochloride salt starting from 5-aminobenzimidazole (0.522g, 3.92mmol), di(1 H-imidazol-1 -yl)methanone (0.699g, 4.31 mmol), TEA (1 .64ml_, 1 1 .76mmol), aminomethyl-(4-biphenyl)ketone hydrobromide (1.14g, 3.92mmol), TEA (1 .09mL, 7.8mmol), PdC (10%, 0.02 g ) as described in method 1 .
- the compound was synthesized according to method 3.
- step D (4.0g, 1 1.83mmol) 10% PdC (400mg), yield 3.3g (89%) Para-Anisaldehyde (1 .3g, 9.61 mmol), sodium borohydride (71 1 mg, 19.23mmol), yield: 3.1 g
- step F Product of step F (1 .0g,2.79mmol), 1 ,2-diamino 4-bromo benzene (522mg2.79mmol), cesium fluoride (849mg,5.58mmol), copper iodide (53mg), 1 ,2- diaminocyclohexane(32mg,0.28mmol), yield: 400mg (30.8%)
- Trifluoroacetic acid (10ml_) was added stirred for 15h at room temperature. Excess trifluoroacetic acid was removed in vacuum and the crude compound was extracted with ethyl acetate. The combined organic layer was washed with 10% sodium carbonate, water, brine solution and dried over anhydrous sodium sulphate. The solvent was evaporated under vacuum. Purification by column chromatography over silica gel (100-200mesh) using gradient 5% methanol in chloroform as eluent afforded 200mg (76%) product.
- Example 44 (R)-1 -(1 H-1 ,3-benzodiazol-5-yl)-5-(4-biphenyl)imidazolidin-2-one
- Example 45 1 -(1 H-1 ,3-benzodiazol-5-yl)-5-(3-fluoro-4-biphenyl)imidazolidin-2-one
- the compound was synthesized starting from 5-aminobenzimidazole (0.585g, 4.4mmol), 3- fluoro-4-biphenyl carbaldehyde (0.801 g, 4mmol), TMSCN (0.5mL, 4mmol), PdC (10%, 0.02g), TEA (0.754ml_, 5.4mmol), di-(imidazol-1 -yl)methanone (0.479g, 2.95mmol) as described in method 2.
- Example 46 1 -(1 H-benzo[dlimidazol-5-yl)-5-[4-(3-chlorophenyl)phenyllimidazolidin-2-one
- the compound was synthesized starting from 5-aminobenzimidazole (0.614mg, 4.62mmol), 4-(3-chlorophenyl)phenyl] carbaldehyde (1 .0g, 4.68mmol), TMSCN (0.93ml_, 6.93mmol), 10% PdC (200mg), TEA (1 .31 ml_, 8.76mmol), di-(imidazol-1 -yl)methanone (460mg, 2.84mmol ) as described in method 2.
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2010294214A AU2010294214B2 (en) | 2009-09-11 | 2010-09-13 | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
MX2012002993A MX2012002993A (en) | 2009-09-11 | 2010-09-13 | Heterocylcic derivatives as inhibitors of glutaminyl cyclase. |
NZ598685A NZ598685A (en) | 2009-09-11 | 2010-09-13 | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
EA201200474A EA022007B1 (en) | 2009-09-11 | 2010-09-13 | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
EP10751952.2A EP2475428B1 (en) | 2009-09-11 | 2010-09-13 | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
ES10751952.2T ES2548913T3 (en) | 2009-09-11 | 2010-09-13 | Heterocyclic derivatives such as glutaminyl cyclase inhibitors |
SG2012014817A SG178953A1 (en) | 2009-09-11 | 2010-09-13 | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
DK10751952.2T DK2475428T3 (en) | 2009-09-11 | 2010-09-13 | Heterocyclic derivatives as glutaminylcyklaseinhibitorer |
BR112012008346-5A BR112012008346B1 (en) | 2009-09-11 | 2010-09-13 | HETEROCYCLIC DERIVATIVES, THEIR PREPARATION PROCESS, AND PHARMACEUTICAL COMPOSITION |
CA2772488A CA2772488C (en) | 2009-09-11 | 2010-09-13 | Heterocyclic derivatives as inhibitors of glutaminyl cyclase |
KR1020127008546A KR101755737B1 (en) | 2009-09-11 | 2010-09-13 | Heterocyclic derivatives as inhibitors of glutaminyl cyclase |
CN201080050870.XA CN102695546B (en) | 2009-09-11 | 2010-09-13 | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
PL10751952T PL2475428T3 (en) | 2009-09-11 | 2010-09-13 | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
JP2012528379A JP5934645B2 (en) | 2009-09-11 | 2010-09-13 | Heterocyclic derivatives as glutaminyl cyclase inhibitors |
IL218259A IL218259A (en) | 2009-09-11 | 2012-02-22 | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
ZA2012/01366A ZA201201366B (en) | 2009-09-11 | 2012-02-23 | Heterocycic derivatives as inhibitors of glutaminyl cyclase |
HK13102485.3A HK1175135A1 (en) | 2009-09-11 | 2013-02-27 | Heterocylcic derivatives as inhibiyors of glutaminyl cyclase |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24143209P | 2009-09-11 | 2009-09-11 | |
US61/241,432 | 2009-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011029920A1 true WO2011029920A1 (en) | 2011-03-17 |
Family
ID=43732030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2010/063341 WO2011029920A1 (en) | 2009-09-11 | 2010-09-13 | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
Country Status (18)
Country | Link |
---|---|
US (3) | US8486940B2 (en) |
EP (1) | EP2475428B1 (en) |
JP (1) | JP5934645B2 (en) |
KR (1) | KR101755737B1 (en) |
CN (1) | CN102695546B (en) |
AU (1) | AU2010294214B2 (en) |
CA (1) | CA2772488C (en) |
DK (1) | DK2475428T3 (en) |
EA (1) | EA022007B1 (en) |
ES (1) | ES2548913T3 (en) |
HK (1) | HK1175135A1 (en) |
IL (1) | IL218259A (en) |
MX (1) | MX2012002993A (en) |
NZ (1) | NZ598685A (en) |
PL (1) | PL2475428T3 (en) |
SG (1) | SG178953A1 (en) |
WO (1) | WO2011029920A1 (en) |
ZA (1) | ZA201201366B (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012123563A1 (en) * | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
JP2014515364A (en) * | 2011-05-27 | 2014-06-30 | プロビオドルグ エージー | Radiolabeled glutaminyl cyclase inhibitor |
WO2014140279A1 (en) * | 2013-03-15 | 2014-09-18 | Probiodrug Ag | Novel inhibitors |
DE102015011780A1 (en) | 2015-09-16 | 2017-03-16 | Hochschule Anhalt | New glutaminyl cyclase inhibitors |
WO2018178384A1 (en) * | 2017-03-31 | 2018-10-04 | Probiodrug Ag | Novel inhibitors |
WO2019022600A1 (en) | 2017-07-24 | 2019-01-31 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Treating pathological conditions by direct and indirect targeting of sirpa - cd47 interaction |
EP3461819A1 (en) | 2017-09-29 | 2019-04-03 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
EP3521308A1 (en) | 2018-01-31 | 2019-08-07 | Probiodrug AG | Humanized and de-immunized antibodies |
WO2022268179A1 (en) * | 2021-06-24 | 2022-12-29 | Insilico Medicine Ip Limited | Beta-lactam derivatives for the treatment of diseases |
EP4151207A1 (en) * | 2021-09-17 | 2023-03-22 | National Health Research Institutes | Benzimidazoles for use in the treatment of conditions involving cd47 upregulation or for increasing phagocytosis of a cell |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2968346B1 (en) * | 2013-03-15 | 2024-02-07 | Cancer Research Technology, LLC | Methods and compositions for gamma-glutamyl cycle modulation |
TWI477479B (en) * | 2013-07-18 | 2015-03-21 | Daxin Materials Corp | Benzene diamine, polymer, composition for alignment film, alignment film, and liquid crystal display device |
CA3090439A1 (en) * | 2018-02-06 | 2019-08-15 | Shanghai Haihe Pharmaceutical Co., Ltd. | Compound having bet inhibitory activity and preparation method and use therefor |
JP7301862B2 (en) | 2018-02-23 | 2023-07-03 | フラウンホーファー-ゲゼルシャフト ツル フェルデルング デル アンゲヴァンテン フォルシュング エー ファウ | Novel inhibitors of bacterial glutaminyl cyclase for the treatment of periodontal disease and related diseases |
TWI715156B (en) * | 2018-08-31 | 2021-01-01 | 財團法人國家衛生研究院 | Benzimidazole compounds and use thereof for treating alzheimer's disease or huntington's disease |
CA3109623C (en) * | 2018-08-31 | 2023-01-24 | National Health Research Institutes | Benzimidazole compounds and use thereof for treating alzheimer's disease or huntington's disease |
CN115448892B (en) * | 2022-09-19 | 2023-07-07 | 郑州铁路职业技术学院 | Synthesis method of benzothiadiazole heterocyclic compound |
Citations (587)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6137764A (en) | 1984-07-31 | 1986-02-22 | Suntory Ltd | Novel physiologically active compound having anti-prolyl-endopeptidase activity |
EP0201743A2 (en) | 1985-04-16 | 1986-11-20 | Suntory Limited | Dipeptide derivatives of fatty acids, process for preparing them, pharmaceutical composition and use |
EP0201742A2 (en) | 1985-04-16 | 1986-11-20 | Suntory Limited | N-Acylpyrrolidine derivatives, processes for preparing them, pharmaceutical composition and use |
EP0201741A2 (en) | 1985-04-16 | 1986-11-20 | Suntory Limited | Dipeptide derivatives, processes for preparing them, pharmaceutical composition and use |
JPS62114978A (en) | 1985-11-14 | 1987-05-26 | Suntory Ltd | Novel pyrrolidinylimide having prolyl-endopeptidase inhibiting activity and production and use thereof |
JPS62114957A (en) | 1985-11-13 | 1987-05-26 | Suntory Ltd | Novel pyrrolidine derivative having prolylendopeptidase inhibiting action its production and use thereof |
EP0224272A1 (en) | 1985-11-29 | 1987-06-03 | Suntory Limited | Pyrrolidinylamide ester derivative having anti-prolyl endopeptidase activity, its synthesis and use and a pharmaceutical composition containing it |
EP0232849A2 (en) | 1986-02-04 | 1987-08-19 | Suntory Limited | Pyrrolidineamide derivative of acylamino acid, pharmaceutical composition and use |
EP0253310A2 (en) | 1986-07-11 | 1988-01-20 | E.I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
EP0268281A2 (en) | 1986-11-18 | 1988-05-25 | Suntory Limited | Pyrrolidineamide derivative having anti-prolyl endopeptidase activity, compositions comprising the same, processes for the preparation of the same, and the use of the same for the preparation of a medicament of therapeutic value |
EP0268190A1 (en) | 1986-11-20 | 1988-05-25 | Ono Pharmaceutical Co., Ltd. | Prolinal derivatives |
JPS63162672A (en) | 1986-12-25 | 1988-07-06 | Ono Pharmaceut Co Ltd | Novel prolinal derivative, its production and antiamnestic agent containing said derivative |
EP0275482A2 (en) | 1986-12-29 | 1988-07-27 | Ono Pharmaceutical Co., Ltd. | Proline derivatives |
EP0277588A1 (en) | 1987-02-04 | 1988-08-10 | Ono Pharmaceutical Co., Ltd. | Prolinal derivatives |
EP0280956A1 (en) | 1987-02-23 | 1988-09-07 | Ono Pharmaceutical Co., Ltd. | Thiazolidine derivatives |
JPS63264454A (en) | 1986-12-29 | 1988-11-01 | Ono Pharmaceut Co Ltd | Novel prolinal derivative, production thereof and antiamnesic agent containing said derivative |
JPS6469A (en) | 1987-02-04 | 1989-01-05 | Ono Pharmaceut Co Ltd | Novel prolinal derivative, production thereof and drug for alleviating amnesia containing said derivative |
JPS6442465A (en) | 1987-08-07 | 1989-02-14 | Wakunaga Pharma Co Ltd | N-acylprolylpyrrolidine derivative, production and use thereof |
EP0303434A1 (en) | 1987-08-08 | 1989-02-15 | Kissei Pharmaceutical Co. Ltd. | Thiazolidine compounds |
JPS6468396A (en) | 1987-09-10 | 1989-03-14 | Yakult Honsha Kk | Novel peptide and amnesia alleviating drug comprising said peptide as active ingredient |
JPH01143897A (en) | 1987-11-30 | 1989-06-06 | Kissei Pharmaceut Co Ltd | Thiazolidine derivative |
WO1989006242A1 (en) | 1987-10-08 | 1989-07-13 | The Mclean Hospital Corporation | Antibodies to a4 amyloid peptide |
JPH01226880A (en) | 1988-03-07 | 1989-09-11 | Kissei Pharmaceut Co Ltd | Thiazolidine derivative |
JPH01250370A (en) | 1987-12-23 | 1989-10-05 | Zeria Pharmaceut Co Ltd | Novel amino acid imide derivative, its production and use thereof |
EP0345428A1 (en) | 1988-04-08 | 1989-12-13 | Ono Pharmaceutical Co., Ltd. | Anti-amnesic pyrrolidine derivatives |
EP0355794A2 (en) | 1988-08-26 | 1990-02-28 | Merrell Dow Pharmaceuticals Inc. | Neuropeptide Y antagonists |
EP0355793A2 (en) | 1988-08-26 | 1990-02-28 | Merrell Pharmaceuticals Inc. | Neuropeptide Y agonists and partial agonists |
EP0372484A2 (en) | 1988-12-08 | 1990-06-13 | Zeria Pharmaceutical Co., Ltd. | Condensed benzene derivative |
JPH02207070A (en) | 1989-02-07 | 1990-08-16 | Zeria Pharmaceut Co Ltd | Amide acid imide derivative, drug containing same and intermediate for producing the compound |
WO1990012870A1 (en) | 1989-04-14 | 1990-11-01 | Research Foundation For Mental Hygiene, Inc. | Monoclonal antibody to amyloid peptide |
WO1990012871A1 (en) | 1989-04-14 | 1990-11-01 | Research Foundation For Mental Hygiene, Inc. | Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10 |
JPH02275858A (en) | 1988-09-14 | 1990-11-09 | Yoshitomi Pharmaceut Ind Ltd | Pyridine compound |
WO1990014840A1 (en) | 1989-06-06 | 1990-12-13 | California Biotechnology Inc. | Recombinant alzheimer's amyloid protein |
EP0403159A2 (en) | 1989-06-14 | 1990-12-19 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids |
JPH0356486A (en) | 1989-07-24 | 1991-03-12 | Kissei Pharmaceut Co Ltd | Thiazolidine derivative |
US4999349A (en) | 1990-03-22 | 1991-03-12 | Bristol-Myers Squibb Co. | BU-4164E - A and B, prolyl endopeptidase inhibitors |
JPH0331298B2 (en) | 1984-09-18 | 1991-05-02 | Sanyo Electric Co | |
DE3939797A1 (en) | 1989-12-01 | 1991-06-06 | Basf Ag | NEW PEPTIDES DERIVED FROM NEUROPEPTIDE Y |
WO1991010664A1 (en) | 1990-01-12 | 1991-07-25 | American Home Products Corporation | PYRIDAZINO[4,5-b]INDOLIZINES |
EP0443983A1 (en) | 1990-02-19 | 1991-08-28 | Ciba-Geigy Ag | Acyl compounds |
EP0454511A1 (en) | 1990-03-20 | 1991-10-30 | Sanofi | N-substituted heterocycle derivatives, their preparation, compositions containing them |
JPH03255080A (en) | 1990-03-05 | 1991-11-13 | Yoshitomi Pharmaceut Ind Ltd | Benzene compound |
EP0459136A1 (en) | 1990-04-27 | 1991-12-04 | Takeda Chemical Industries, Ltd. | Benzimidazole derivatives, their production and use |
WO1991018877A1 (en) | 1990-06-07 | 1991-12-12 | Zeria Pharmaceutical Co., Ltd. | Novel arylalkanoylamine derivative and drug containing the same |
US5073549A (en) | 1990-03-22 | 1991-12-17 | Bristol-Myers Squibb Company | BU-4164E - A and B, prolyl endopeptidase inhibitors and their methods of use |
JPH049367A (en) | 1990-04-26 | 1992-01-14 | Zeria Pharmaceut Co Ltd | Arylalkanoyl derivative, production intermediate for the compound and drug containing the same |
EP0468339A2 (en) | 1990-07-27 | 1992-01-29 | Nippon Kayaku Kabushiki Kaisha | Alpha-keto-amide derivatives having protease inhibiting activity |
EP0468469A2 (en) | 1990-07-27 | 1992-01-29 | Japan Tobacco Inc. | Proline derivatives |
US5118811A (en) | 1989-04-13 | 1992-06-02 | Japan Tobacco Inc. | Amino acid derivatives possessing prolyl endopeptidase-inhibitory activities |
JPH04208299A (en) | 1990-11-30 | 1992-07-29 | Ajinomoto Co Inc | Prolyl endopeptidase-inhibiting peptide |
JPH04235162A (en) | 1990-08-09 | 1992-08-24 | Zeria Pharmaceut Co Ltd | Novel succinamide derivative and drug containing the same |
EP0503785A1 (en) | 1991-02-21 | 1992-09-16 | Sankyo Company Limited | 1-Biphenylimidazole derivatives, their preparation and their therapeutic use |
WO1992019238A1 (en) | 1991-05-01 | 1992-11-12 | Mayo Foundation For Medical Education And Research | Huperzine a analogs |
WO1992021333A2 (en) | 1991-05-24 | 1992-12-10 | Pharmavene, Inc. | Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors |
WO1993000361A1 (en) | 1991-06-20 | 1993-01-07 | Snow Brand Milk Products Co., Ltd. | Novel prolyl endopeptidase inhibitors sna-115 and sna-115t, production thereof, and strain which produces said inhibitors |
EP0522314A1 (en) | 1991-07-03 | 1993-01-13 | BASF Aktiengesellschaft | Thermoplastic moulding composition based on polycarbonates, styrene/acrylanitrile-polymerisates and polyolefins |
JPH0515314A (en) | 1991-07-04 | 1993-01-26 | Fuji Oil Co Ltd | Method for removing bitterness of peptide |
JPH0525125A (en) | 1990-07-27 | 1993-02-02 | Japan Tobacco Inc | New proline derivative |
WO1993003034A1 (en) | 1991-07-29 | 1993-02-18 | Warner-Lambert Company | Quinazoline derivatives as acetylcholinesterase inhibitors |
US5198458A (en) | 1986-02-04 | 1993-03-30 | Suntory Limited | Pyrrolidineamide derivatives of acylamino acid and pharmaceutical composition containing the same |
EP0539086A2 (en) | 1991-10-24 | 1993-04-28 | American Home Products Corporation | Condensed pyrimidine derivatives and their use as angiotensine II antagonists |
WO1993012139A1 (en) | 1991-12-19 | 1993-06-24 | Garvan Institute Of Medical Research | A novel molecule which inhibits neuropeptide tyrosine biological function |
WO1993013065A1 (en) | 1991-12-27 | 1993-07-08 | Japan Tobacco Inc. | Proline derivative |
JPH05201970A (en) | 1992-01-24 | 1993-08-10 | Japan Tobacco Inc | New proline derivative |
EP0556482A2 (en) | 1991-12-24 | 1993-08-25 | Snow Brand Milk Products Co., Ltd. | Propyl endopeptidase inhibitor |
US5254550A (en) | 1986-11-20 | 1993-10-19 | Ono Pharmaceutical Co., Ltd. | Prolinal derivatives and pharmaceutical compositions thereof |
US5262431A (en) | 1986-12-29 | 1993-11-16 | Ono Pharmaceutical Co., Ltd. | Prolinal derivatives and pharmaceutical compositions thereof |
JPH05331072A (en) | 1992-05-27 | 1993-12-14 | Agency Of Ind Science & Technol | Prolyl endopeptidase inhibitor |
WO1993025534A1 (en) | 1992-06-10 | 1993-12-23 | Zeneca Limited | 2,5-DIOXO-2,5-DIHYDRO-1H-BENZ[b]AZEPINES AS NMDA RECEPTOR ANTAGONISTS |
WO1994000486A1 (en) | 1992-06-20 | 1994-01-06 | The Wellcome Foundation Limited | Neuropeptide y antagonists |
WO1994007890A1 (en) | 1992-10-05 | 1994-04-14 | Ube Industries, Ltd. | Pyrimidine compound |
JPH06116284A (en) | 1992-10-02 | 1994-04-26 | Yamanouchi Pharmaceut Co Ltd | New peptide |
WO1994009016A1 (en) | 1992-10-16 | 1994-04-28 | Sri International | 2-piperidinecarboxylic acid derivatives useful as nmda receptor antagonists |
WO1994012474A1 (en) | 1992-11-20 | 1994-06-09 | Japan Tobacco Inc. | Compound with prolyl endopeptidase inhibitor activity and pharmaceutical use thereof |
WO1994013641A1 (en) | 1992-12-16 | 1994-06-23 | Japan Tobacco Inc. | Benzomorphan useful as nmda receptor antagonist |
JPH06192298A (en) | 1992-12-24 | 1994-07-12 | Mitsui Toatsu Chem Inc | Novel function peptide |
US5328899A (en) | 1988-07-15 | 1994-07-12 | The Salk Institute For Biological Studies | NPY peptide analogs |
WO1994017035A1 (en) | 1993-01-20 | 1994-08-04 | Dr. Karl Thomae Gmbh | Aminoacid derivates, medicaments containing these compounds and process for preparing the same |
WO1994017197A1 (en) | 1993-01-25 | 1994-08-04 | Takeda Chemical Industries, Ltd. | ANTIBODY AGAINST β-AMYLOID OR DERIVATIVE THEREOF AND USE THEREOF |
JPH06234693A (en) | 1993-02-09 | 1994-08-23 | Snow Brand Milk Prod Co Ltd | New isotetracenone-based substance and its production |
WO1994019356A1 (en) | 1993-02-16 | 1994-09-01 | Merrell Dow Pharmaceuticals Inc. | Silylated acetylcholinesterase inhibitors |
EP0614911A1 (en) | 1993-02-15 | 1994-09-14 | Sanofi | Compounds having a sulfonamide and an amidinegroup, process for preparation and pharmaceutical compositions comprising them |
WO1994020109A1 (en) | 1993-03-03 | 1994-09-15 | Rhone-Poulenc Rorer S.A. | Use of 2h-1,2,4-benzothiadiazine 3(4h)-one 1,1 dioxide derivatives as non-competitive nmda receptor antagonists |
WO1994020476A1 (en) | 1993-03-02 | 1994-09-15 | Fujisawa Pharmaceutical Co., Ltd. | Novel heterocyclic compound |
EP0618193A1 (en) | 1993-03-24 | 1994-10-05 | Adir Et Compagnie | Nitrogen containing bicyclic derivatives as prolyl-endopeptidase inhibitors |
WO1994029255A1 (en) | 1993-06-04 | 1994-12-22 | Merrell Pharmaceuticals Inc. | Aromatic acetylcholinesterase inhibitors |
WO1995000161A1 (en) | 1993-06-18 | 1995-01-05 | University Of Cincinnati | Neuropeptide y antagonists and agonists |
WO1995001352A1 (en) | 1993-06-30 | 1995-01-12 | Zeria Pharmaceutical Co., Ltd. | Thiazolidine derivative and medicine containing the same |
WO1995002601A1 (en) | 1993-07-16 | 1995-01-26 | Rhone-Poulenc Rorer S.A. | IMIDAZO[1,2-a]PYRAZINE-4-ONE, PREPARATION THEREOF AND DRUGS CONTAINING SAME |
WO1995002602A1 (en) | 1993-07-16 | 1995-01-26 | Rhone-Poulenc Rorer S.A. | Imidazo(1,2-a)pyrazin-4-one derivatives for use as ampa and nmda receptor antagonists |
WO1995012594A1 (en) | 1993-11-05 | 1995-05-11 | Rhone-Poulenc Rorer S.A. | 7H-IMIDAZO(1,2-a)PYRAZINE-8-ONE NMDA RECEPTOR ANTAGONISTS |
WO1995015310A1 (en) | 1993-12-02 | 1995-06-08 | Merrell Pharmaceuticals Inc. | Prolyl endopeptidase inhibitors |
WO1995015309A1 (en) | 1993-12-03 | 1995-06-08 | Ferring B.V. | Dp-iv-serine protease inhibitors |
WO1995026342A1 (en) | 1994-03-28 | 1995-10-05 | Rhone-Poulenc Rorer S.A. | 5H-INDENO[1,2-b]PYRAZINE-2,3-DIONE DERIVATIVES, PREPARATION THEREOF AND DRUGS CONTAINING SAME |
WO1995026352A1 (en) | 1994-03-28 | 1995-10-05 | Rhone-Poulenc Rorer S.A. | IMIDAZO[1,2-a]PYRAZINE-4-ONE DERIVATIVES, PREPARATION THEREOF AND DRUGS CONTAINING SAME |
WO1995026349A1 (en) | 1994-03-28 | 1995-10-05 | Rhone-Poulenc Rorer S.A. | INDENO[1,2-e]PYRAZINE-4-ONES, PREPARATION THEREOF AND DRUGS CONTAINING SAME |
WO1995026350A1 (en) | 1994-03-28 | 1995-10-05 | Rhone-Poulenc Rorer S.A. | Imidazo(1,2-a)indeno(1,2-e)pyrazine-4-one derivatives and pharmaceutical compositions containing same |
JPH07267988A (en) | 1994-03-31 | 1995-10-17 | Yamanouchi Pharmaceut Co Ltd | New peptide |
WO1995031986A1 (en) | 1994-05-24 | 1995-11-30 | Astra Aktiebolag | Combination product of dichloroacetic acid and an nmda antagonist |
WO1996008485A1 (en) | 1994-09-13 | 1996-03-21 | Pfizer Limited | Quinoxalinedione nmda receptor antagonists |
US5506256A (en) | 1990-07-27 | 1996-04-09 | Yoshitomi Pharmaceutical Industries, Ltd. | Proline derivatives possessing prolyl endopeptidase-inhibitory activity |
EP0709373A1 (en) | 1993-07-23 | 1996-05-01 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Novel pyrrolidine derivative |
WO1996012489A1 (en) | 1994-10-20 | 1996-05-02 | Eli Lilly And Company | Bicyclic neuropeptide y receptor antagonists |
WO1996012490A1 (en) | 1994-10-20 | 1996-05-02 | Eli Lilly And Company | Methods of inhibiting conditions associated with neuropeptide y |
WO1996014318A1 (en) | 1994-11-02 | 1996-05-17 | Rhone-Poulenc Rorer S.A. | SPIRO[HETEROCYCLE-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZINE]-4'-ONES, PREPARATION THEREOF AND DRUGS CONTAINING SAME |
WO1996020946A1 (en) | 1994-12-29 | 1996-07-11 | Research Development Foundation | Flavin adenine dinucleotide analogues, their pharmaceutical compositions, and their activity as monoamine oxidase inhibitors |
WO1996021655A2 (en) | 1995-01-11 | 1996-07-18 | Hoechst Marion Roussel, Inc. | Substituted oxazolidine calpain and/or cathepsin b inhibitors |
WO1996022305A2 (en) | 1995-01-12 | 1996-07-25 | The Wellcome Foundation Limited | Modified peptides |
WO1996025435A1 (en) | 1995-02-14 | 1996-08-22 | Bayer Corporation | MONOCLONAL ANTIBODY SPECIFIC FOR βA4 PEPTIDE |
US5552411A (en) | 1995-05-26 | 1996-09-03 | Warner-Lambert Company | Sulfonylquinolines as central nervous system and cardiovascular agents |
EP0747357A2 (en) | 1995-06-07 | 1996-12-11 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: piperidine derivatives |
EP0747356A1 (en) | 1995-06-07 | 1996-12-11 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: piperazine derivatives |
EP0747378A1 (en) | 1995-06-07 | 1996-12-11 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists |
WO1996040660A1 (en) | 1995-06-07 | 1996-12-19 | Pfizer Inc. | Certain substituted benzylamine derivatives: a new class of neuropeptide y1 specific ligands |
JPH0940693A (en) | 1995-07-31 | 1997-02-10 | Gekkeikan Sake Co Ltd | Inhibitor of prolyl endopeptidase |
WO1997009308A1 (en) | 1995-09-01 | 1997-03-13 | Eli Lilly And Company | Indolyl neuropeptide y receptor antagonists |
WO1997012615A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Benzimidazole derivatives as 15-lo inhibitors |
WO1997013754A1 (en) | 1995-10-11 | 1997-04-17 | Pelayo Camps Garcia | Novel polycyclic aminopyridine compounds as acetylcholinesterase inhibitors, preparation process and use thereof |
WO1997019682A1 (en) | 1995-12-01 | 1997-06-05 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
WO1997019911A1 (en) | 1995-11-30 | 1997-06-05 | Dr. Karl Thomae Gmbh | Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them |
WO1997019913A1 (en) | 1995-11-30 | 1997-06-05 | Dr. Karl Thomae Gmbh | Amino acid derivatives, medicaments containing said compounds and methods of producing them |
WO1997019914A1 (en) | 1995-11-30 | 1997-06-05 | Dr. Karl Thomae Gmbh | Amino acid derivatives, medicaments containing said compounds and methods of producing said compounds |
WO1997020822A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Quinazolin-2,4-diazirines as npy receptor antagonist |
WO1997020823A2 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | 2-amino quinazoline derivatives as npy receptor antagonists |
WO1997020820A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl compounds |
WO1997020821A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl derivatives |
JPH09157253A (en) | 1995-12-12 | 1997-06-17 | Yamanouchi Pharmaceut Co Ltd | New amino acid derivative |
WO1997023215A1 (en) | 1995-12-22 | 1997-07-03 | Warner-Lambert Company | 2-substituted piperidine analogs and their use as subtype-selective nmda receptor antagonists |
WO1997023216A1 (en) | 1995-12-22 | 1997-07-03 | Warner-Lambert Company | 4-substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
WO1997023214A1 (en) | 1995-12-22 | 1997-07-03 | Warner-Lambert Company | 4-substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
WO1997025041A1 (en) | 1996-01-09 | 1997-07-17 | Eli Lilly And Company | Benzimidzolyl neuropeptide y receptor antagonists |
US5663192A (en) | 1994-10-20 | 1997-09-02 | Eli Lilly And Company | Heterocyclic neuropeptide Y receptor antagonists |
WO1997032873A1 (en) | 1996-03-09 | 1997-09-12 | Pfizer Research And Development Company, N.V./S.A. | Quinoxalinediones |
WO1997034843A1 (en) | 1996-03-22 | 1997-09-25 | Libbey Glass Inc. | Apparatus and method for forming a decorative pattern on glassware having an edge |
WO1997038993A1 (en) | 1996-04-12 | 1997-10-23 | Hoechst Marion Roussel, Inc. | Isatin derivatives as acetylcholinesterase inhibitors and analgesics |
WO1997040832A1 (en) | 1996-04-25 | 1997-11-06 | Probiodrug Gesellschaft für Arzneimittelforschung mbH | Use of dipeptidyl peptidase iv effectors for lowering the blood glucose level in mammals |
WO1997046250A1 (en) | 1996-06-04 | 1997-12-11 | Synaptic Pharmaceutical Corporation | Methods of modifying feeding behavior, compounds useful in such methods, and dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5) |
WO1998001157A1 (en) | 1996-07-05 | 1998-01-15 | The Wwk Trust | Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter |
WO1998003492A1 (en) | 1996-07-23 | 1998-01-29 | Neurogen Corporation | Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands |
WO1998003494A1 (en) | 1996-07-23 | 1998-01-29 | Neurogen Corporation | Certain amido- and amino-substituted benzylamine derivatives; a new class of neuropeptite y1 specific ligands |
WO1998003493A1 (en) | 1996-07-23 | 1998-01-29 | Neurogen Corporation | Certain substituted benzylamine derivatives; a new class of neuropeptide-y1 specific ligands |
WO1998005337A1 (en) | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
WO1998006703A1 (en) | 1996-08-14 | 1998-02-19 | Warner-Lambert Company | 2-phenyl benzimidazole derivatives as mcp-1 antagonists |
WO1998007420A1 (en) | 1996-08-23 | 1998-02-26 | Agouron Acquisition Corp. | Neuropeptide-y ligands |
WO1998010757A2 (en) | 1996-09-11 | 1998-03-19 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | The use of functional n-methyl-d-aspartate antagonists to ameliorate or prevent aminoglycoside-induced ototoxicity |
JPH1077300A (en) | 1996-09-04 | 1998-03-24 | Gekkeikan Sake Co Ltd | Prolyl endopeptidase-inhibiting peptide |
WO1998015647A1 (en) | 1996-10-08 | 1998-04-16 | Novartis Ag | Modulation of apoptosis |
WO1998019998A2 (en) | 1996-11-07 | 1998-05-14 | Novartis Ag | N-substituted 2-cyanopyrrolidines |
WO1998030243A1 (en) | 1997-01-08 | 1998-07-16 | Warner-Lambert Company | Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease |
WO1998040102A1 (en) | 1997-03-13 | 1998-09-17 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Cytoprotective agents comprising monoamine oxidase inhibitors |
WO1998044955A1 (en) | 1997-04-09 | 1998-10-15 | Mindset Ltd. | Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof |
WO1998046559A1 (en) | 1997-04-16 | 1998-10-22 | Arqule, Inc. | SYNTHESIS AND USE OF α-KETOAMIDE DERIVATIVES AND ARRAYS |
WO1998050075A1 (en) | 1997-05-07 | 1998-11-12 | Algos Pharmaceutical Corporation | Cox-2 inhibitors in combination with nmda-blockers for treating pain |
WO1998050044A1 (en) | 1997-05-07 | 1998-11-12 | Algos Pharmaceutical Corporation | Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain |
US5847155A (en) | 1990-06-04 | 1998-12-08 | Pfizer Inc | Aromatic pyrrolidine amide prolyl endopeptidase inhibitors |
WO1999001416A2 (en) | 1997-06-30 | 1999-01-14 | Merz + Co. Gmbh & Co. | 1-amino-alkylcyclohexane nmda receptor antagonists |
WO1999007351A2 (en) | 1997-08-07 | 1999-02-18 | Zeneca Limited | Indole derivatives and their use as mcp-1 antagonists |
WO1999007359A1 (en) | 1997-08-08 | 1999-02-18 | Shire International Licensing B.V. | Use of cholinesterase inhibitors for treating attention deficit disorders |
WO1999007413A1 (en) | 1997-08-11 | 1999-02-18 | Algos Pharmaceutical Corporation | Substance p inhibitors in combination with nmda-blockers for treating pain |
WO1999013878A1 (en) | 1997-09-18 | 1999-03-25 | Astrazeneca Ab | A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST |
WO1999015498A1 (en) | 1997-09-23 | 1999-04-01 | Astrazeneca Ab | New npy antagonists |
WO1999027944A1 (en) | 1997-12-02 | 1999-06-10 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
WO1999038501A2 (en) | 1998-02-02 | 1999-08-05 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
WO1999046272A1 (en) | 1998-03-09 | 1999-09-16 | Fondatech Benelux N.V. | Serine peptidase modulators |
WO1999045963A1 (en) | 1998-03-13 | 1999-09-16 | Algos Pharmaceutical Corporation | Analgesic combination comprising nmda receptor antagonists and narcotic analgesics |
WO1999046991A1 (en) | 1998-03-17 | 1999-09-23 | University Of Maryland Biotechnology Institute | Methods for treating hiv-associated dementia |
WO1999047131A2 (en) | 1998-03-16 | 1999-09-23 | Merck Sharp & Dohme Limited | Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor |
WO1999048891A1 (en) | 1998-03-20 | 1999-09-30 | Merck Patent Gmbh | 1-(3-heteroarylpropyl- or -prop-2-enyl)-4-benzylpiperidines used as nmda receptor antagonists |
WO1999053922A1 (en) | 1998-04-21 | 1999-10-28 | Algos Pharmaceutical Corporation | Analgesic compositions comprising nmda-antagonists and abt-594 |
WO1999057120A1 (en) | 1998-05-04 | 1999-11-11 | Neotherapeutics, Inc. | Novel serotonin-like 9-substituted hypoxanthine and methods of use |
WO1999057119A1 (en) | 1998-05-04 | 1999-11-11 | Neotherapeutics, Inc. | Novel dopamine-like 9-substituted hypoxanthine and methods of use |
WO1999060024A1 (en) | 1998-05-21 | 1999-11-25 | The University Of Tennessee Research Corporation | Methods for amyloid removal using anti-amyloid antibodies |
WO1999061431A1 (en) | 1998-05-28 | 1999-12-02 | Probiodrug Gesellschaft für Arzneimittelforschung mbH | New dipeptidyl peptidase iv effectors |
WO1999067278A1 (en) | 1998-06-24 | 1999-12-29 | Probiodrug Gesellschaft für Arzneimittelforschung mbH | Prodrugs of dipeptidyl peptidase iv inhibitors |
WO1999067279A1 (en) | 1998-06-24 | 1999-12-29 | Probiodrug Gesellschaft für Arzneimittelforschung mbH | Compounds of unstable dipeptidyl peptidase iv inhibitors |
US6011155A (en) | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
WO2000000197A1 (en) | 1998-06-26 | 2000-01-06 | Warner-Lambert Company | 4-benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective nmda receptor antagonists |
DE19834591A1 (en) | 1998-07-31 | 2000-02-03 | Probiodrug Ges Fuer Arzneim | Use of substances that decrease the activity of dipeptidyl peptidase IV to increase blood sugar levels, e.g. for treating hypoglycemia |
WO2000015205A2 (en) | 1998-09-11 | 2000-03-23 | Eisai Co., Ltd. | Use of acetylcholinesterase inhibitors for the preparation of pharmaceutical compositions for the treatment of functional and/or organic pain syndromes |
WO2000029023A1 (en) | 1998-11-12 | 2000-05-25 | Algos Pharmaceutical Corporation | Cox-2 inhibitors in combination with nmda-blockers for treating pain |
WO2000030674A1 (en) | 1998-11-26 | 2000-06-02 | Ferring Bv | Neuropeptide y y4 agents in the treatment of reproductive disorders |
WO2000046195A1 (en) | 1999-02-05 | 2000-08-10 | Astrazeneca Ab | Anti-inflammatory indole derivatives |
WO2000046197A1 (en) | 1999-02-05 | 2000-08-10 | Astrazeneca Ab | Indole derivatives and their use as mcp-1 receptor antagonists |
WO2000046196A1 (en) | 1999-02-05 | 2000-08-10 | Astrazeneca Ab | Indole derivatives and their use as mcp-1 antagonists |
WO2000046198A1 (en) | 1999-02-05 | 2000-08-10 | Astrazeneca Ab | Anti-inflammatory indole derivatives |
WO2000046199A2 (en) | 1999-02-05 | 2000-08-10 | Astrazeneca Ab | Indole derivatives as anti-inflammation agents |
US6107317A (en) | 1999-06-24 | 2000-08-22 | Novartis Ag | N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
US6110949A (en) | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
US6114336A (en) | 1996-10-23 | 2000-09-05 | Sanofi | Cosmetic composition containing a neuropeptide Y receptor antagonist |
US6121311A (en) | 1999-04-28 | 2000-09-19 | Japan Tobacco Inc. | Method for treating cocainism |
WO2000056711A1 (en) | 1999-03-23 | 2000-09-28 | Sumitomo Pharmaceuticals Co., Ltd. | Tricyclic indole-2-carboxylic acid compound used as nmda receptor antagonist |
WO2000063250A1 (en) | 1999-04-15 | 2000-10-26 | Merck Frosst Canada & Co. | Antibodies that recognize app cleaved by caspases and methods of use |
WO2000068197A1 (en) | 1999-05-05 | 2000-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | 3a,4,5,9b-TETRAHYDRO-1H-BENZ[e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS |
WO2000071144A1 (en) | 1999-05-19 | 2000-11-30 | Domer, Inc. | Prolyl endopeptidase inhibitor |
WO2000072880A2 (en) | 1999-05-28 | 2000-12-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
WO2000077178A1 (en) | 1999-06-16 | 2000-12-21 | Boston Biomedical Research Institute | IMMUNOLOGICAL CONTROL OF β-AMYLOID LEVELS IN VIVO |
WO2001000215A1 (en) | 1999-06-25 | 2001-01-04 | Wake Forest University | Compositions for treating or preventing neurodegeneration and cognitive decline |
US6172081B1 (en) | 1999-06-24 | 2001-01-09 | Novartis Ag | Tetrahydroisoquinoline 3-carboxamide derivatives |
WO2001010831A1 (en) | 1999-08-06 | 2001-02-15 | Grünenthal GmbH | Substituted pyrrolidin-2,3,4-trion-3-oxime derivatives useful as nmda-receptor antagonists |
WO2001010833A1 (en) | 1999-08-06 | 2001-02-15 | Grünenthal GmbH | Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain |
WO2001012598A2 (en) | 1999-08-13 | 2001-02-22 | The Trustees Of Columbia University In The City Of New York | METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
WO2001012176A2 (en) | 1999-08-16 | 2001-02-22 | Sanofi-Synthelabo | Use of monoamine oxidase inhibitors for the manufacture of drugs intended for the treatment of obesity |
WO2001014318A2 (en) | 1999-08-24 | 2001-03-01 | Probiodrug Ag | New effectors of dipeptidyl peptidase iv for topical use |
WO2001026656A2 (en) | 1999-10-11 | 2001-04-19 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | 5-membered heterocycle derivatives and use thereof as monoamine oxidase inhibitors |
WO2001032640A1 (en) | 1999-11-01 | 2001-05-10 | Merz Pharmaceuticals Gmbh | 1-cyclic amino-alkylcyclohexane compounds, pharmaceutical compositions thereof, and their use as anticonvulsants |
WO2001034594A1 (en) | 1999-11-12 | 2001-05-17 | Guilford Pharmaceuticals, Inc. | Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors |
WO2001040180A2 (en) | 1999-11-30 | 2001-06-07 | Ferring Bv | N-substituted 2-cyanopyrrolidines and their use as antidiabetic agents |
WO2001053255A1 (en) | 2000-01-24 | 2001-07-26 | Merck Sharp & Dohme Limited | Gamma-secretase inhibitors |
WO2001055105A1 (en) | 2000-01-24 | 2001-08-02 | Novo Nordisk A/S | N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv |
WO2001057226A1 (en) | 2000-02-03 | 2001-08-09 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use therefor |
WO2001062801A2 (en) | 2000-02-24 | 2001-08-30 | Washington University | Humanized antibodies that sequester amyloid beta peptide |
WO2001066564A2 (en) | 2000-03-03 | 2001-09-13 | Merck Sharp & Dohme Limited | Gamma-secretase inhibitors |
WO2001066096A2 (en) | 2000-03-06 | 2001-09-13 | Immune Network Ltd. | Compositions for prevention and treatment of dementia |
WO2001068603A2 (en) | 2000-03-10 | 2001-09-20 | Bristol-Myers Squibb Co. | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use |
WO2001077144A1 (en) | 2000-04-07 | 2001-10-18 | Merck Sharp & Dohme Limited | Gamma-secretase inhibitors |
WO2001078728A1 (en) | 2000-04-13 | 2001-10-25 | Eisai Co., Ltd. | Acetylcholinesterase inhibitors containing 1-benzyl- pyridinium salts |
WO2001081295A1 (en) | 2000-04-26 | 2001-11-01 | Warner-Lambert Company | Cyclohexylamine derivative as subtype selective nmda receptor antagonists |
WO2001081304A1 (en) | 2000-04-26 | 2001-11-01 | Ferring Bv | Inhibitors of dipeptidyl peptidase iv |
WO2001081337A1 (en) | 2000-04-26 | 2001-11-01 | Ferring B.V. | Inhibitors of dipeptidyl peptidase iv |
US6316449B1 (en) | 1999-07-08 | 2001-11-13 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists |
WO2001085145A2 (en) | 2000-05-09 | 2001-11-15 | Pfizer Products Inc. | A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal |
WO2001092204A1 (en) | 2000-06-01 | 2001-12-06 | Warner-Lambert Company | Cyclohexylamine derivatives as subtype selective nmda receptor antagonists |
WO2001094321A1 (en) | 2000-06-06 | 2001-12-13 | Warner-Lambert Company | Bicyclic cyclohexylamines and their use as nmda receptor antagonists |
WO2001098289A1 (en) | 2000-06-22 | 2001-12-27 | Pharmos Corporation | Novel non-psychotropic cannabinoids |
WO2001098262A1 (en) | 2000-06-23 | 2001-12-27 | Merck Sharp & Dohme Limited | Amidine derivatives as selective antagonists of nmda receptors |
WO2002002560A2 (en) | 2000-07-04 | 2002-01-10 | Novo Nordisk A/S | Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv) |
WO2002021509A1 (en) | 2000-09-01 | 2002-03-14 | Snap-On Technologies, Inc. | Computer-implemented speech recognition system training |
WO2002027418A2 (en) | 2000-09-25 | 2002-04-04 | Motorwiz, Inc. | Model-based machine diagnostics and prognostics using theory of noise and communications |
WO2002032412A2 (en) | 2000-10-17 | 2002-04-25 | Pfizer Products Inc. | Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders |
WO2002034718A1 (en) | 2000-10-24 | 2002-05-02 | Richter Gedeon Vegyeszeti Gyar Rt. | Amide derivatives as nmda receptor antagonists |
WO2002036555A1 (en) | 2000-11-02 | 2002-05-10 | Merck Sharp & Dohme Limited | Sulfamides as gamma-secretase inhibitors |
WO2002038541A1 (en) | 2000-11-10 | 2002-05-16 | Taisho Pharmaceutical Co., Ltd. | Cyanopyrrolidine derivatives |
WO2002041842A2 (en) | 2000-11-03 | 2002-05-30 | Proteotech. Inc. | Antibody pti-hs7 for treatment of alzheimer's disease and other amyloidoses and parkinson's disease |
WO2002046237A2 (en) | 2000-12-06 | 2002-06-13 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
WO2002046222A2 (en) | 2000-12-07 | 2002-06-13 | Mario Chojkier | Compositions and methods for diagnosing alzheimer's disease |
US6426365B1 (en) | 1997-02-12 | 2002-07-30 | Japan Tobacco Inc. | CETP activity inhibitors |
WO2002060900A2 (en) | 2001-01-31 | 2002-08-08 | Telik, Inc. | Antagonists of mcp-1 function and methods of use thereof |
US6448229B2 (en) | 2000-07-06 | 2002-09-10 | Merck Sharp & Dohme Ltd. | Gamma secretase inhibitors |
WO2002070509A2 (en) | 2001-03-01 | 2002-09-12 | Telik, Inc. | Antagonists of mcp-1 function and methods of use thereof |
WO2002072542A2 (en) | 2001-03-08 | 2002-09-19 | Emory University | Ph-dependent nmda receptor antagonists |
WO2002074240A2 (en) | 2001-03-16 | 2002-09-26 | Cornell Research Foundation, Inc. | Anti-amyloid antibody based diagnosis and treatment of a neurological disease or disorder |
WO2002081463A1 (en) | 2001-04-03 | 2002-10-17 | Telik, Inc. | Antagonists of mcp-1 function and methods of use thereof |
WO2002083128A1 (en) | 2001-04-12 | 2002-10-24 | Bristol-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and method |
WO2002088307A2 (en) | 2001-04-30 | 2002-11-07 | Eli Lilly And Company | Humanized antibodies |
WO2002088306A2 (en) | 2001-04-30 | 2002-11-07 | Eli Lilly And Company | Humanized antibodies |
EP1258476A1 (en) | 2001-05-15 | 2002-11-20 | Les Laboratoires Servier | Alpha-amino acid derivatives, method for their preparation and their use as dipeptidyl-peptidase IV inhibitors (DPP IV) |
WO2002094881A2 (en) | 2001-05-18 | 2002-11-28 | Krka Tovarna Zdravil, D.D., Novo Mesto | Monoclonal antibody neutralising cathepsin b activity and uses thereof |
WO2002096897A1 (en) | 2001-05-30 | 2002-12-05 | Neurologic, Inc. | PHOSPHINYLMETHYL AND PHOSPHORYLMETHYL SUCCINIC AND GLUTARIC ACID ANALOGS AS β-SECRETASE INHIBITORS |
WO2002096937A2 (en) | 2001-05-29 | 2002-12-05 | Neurochem, Inc. | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
WO2002098849A2 (en) | 2001-06-01 | 2002-12-12 | Elan Pharmaceuticals, Inc. | Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer’s disease and similar diseases |
WO2003000250A1 (en) | 2001-06-25 | 2003-01-03 | Ferring Bv | 3-fluoro-pyrrolidines as antidiabetic agents |
WO2003000180A2 (en) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
WO2003000181A2 (en) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
WO2003002530A2 (en) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Pyrrolidines as dipeptidyl peptidase inhibitors |
WO2003002553A2 (en) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
WO2003002531A2 (en) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
WO2003002593A2 (en) | 2001-06-27 | 2003-01-09 | Probiodrug Ag | Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis |
WO2003004498A1 (en) | 2001-07-06 | 2003-01-16 | Merck & Co., Inc. | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2003004496A1 (en) | 2001-07-03 | 2003-01-16 | Novo Nordisk A/S | Dpp-iv-inhibiting purine derivatives for the treatment of diabetes |
WO2003010159A1 (en) | 2001-07-24 | 2003-02-06 | Richter Gedeon Vegyészeti Gyár Rt. | Piperidine derivatives as nmda receptor antagonists |
WO2003012141A1 (en) | 2001-07-31 | 2003-02-13 | Takeda Chemical Industries, Ltd. | Method of screening alzheimer’s disease-associated gene |
WO2003014162A1 (en) | 2001-08-03 | 2003-02-20 | Medical & Biological Laboratories Co., Ltd. | ANTIBODY RECOGNIZING GM1 GANGLIOSIDE-BOUND AMYLOID β-PROTEIN AND DNA ENCODING THE ANTIBODY |
WO2003013527A1 (en) | 2001-08-03 | 2003-02-20 | Schering Corporation | Sulfonamide derivatives as gamma secretase inhibitors |
WO2003014075A2 (en) | 2001-08-03 | 2003-02-20 | Schering Corporation | Novel gamma secretase inhibitors |
WO2003016466A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | ANTI-Aβ ANTIBODIES |
WO2003015691A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | RAPID IMPROVEMENT OF COGNITION IN CONDITIONS RELATED TO A$g(b) |
WO2003020289A1 (en) | 2001-08-30 | 2003-03-13 | Ortho-Mcneil Pharmaceutical, Inc. | Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors |
WO2003024942A1 (en) | 2001-09-14 | 2003-03-27 | Mitsubishi Pharma Corporation | Thiazolidine derivative and medicinal use thereof |
WO2003024965A2 (en) | 2001-09-19 | 2003-03-27 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme dpp-iv |
WO2003033524A2 (en) | 2001-10-12 | 2003-04-24 | Probiodrug Ag | Peptidyl ketones as inhibitors of dpiv |
WO2003035057A1 (en) | 2001-10-23 | 2003-05-01 | Ferring B.V. | Inhibitors of dipeptidyl peptidase iv |
WO2003035067A1 (en) | 2001-10-23 | 2003-05-01 | Ferring B.V. | Novel dipeptidyl peptidase iv (dp-iv) inhibitors as anti-diabetic agents |
WO2003037327A1 (en) | 2001-10-26 | 2003-05-08 | F. Hoffmann-La-Roche Ag | N-substituted pyrrolidin derivatives as dipeptidyl peptidase iv inhibitors |
WO2003037376A1 (en) | 2001-11-02 | 2003-05-08 | Kensuke Egashira | Preventives and/or remedies for post-transplant arteriosclerosis as rejection of organ transplant |
WO2003039454A2 (en) | 2001-10-23 | 2003-05-15 | Oklahoma Medical Research Foundation | Beta-secretase inhibitors and methods of use |
WO2003040183A2 (en) | 2001-11-09 | 2003-05-15 | The Genetics Company, Inc | Compounds for the diagnosis/prevention/treatment of alzheimer's disease |
WO2003039467A2 (en) | 2001-11-02 | 2003-05-15 | Diagenics International Corporation | Monoclonal antibodies specific for beta-amyloid. |
WO2003040174A2 (en) | 2001-11-09 | 2003-05-15 | Probiodrug Ag | Substituted amino ketone compounds |
WO2003043987A2 (en) | 2001-11-19 | 2003-05-30 | Elan Pharmaceuticals, Inc. | (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2003045977A2 (en) | 2001-11-26 | 2003-06-05 | Trustees Of Tufts College | Peptidomimetic Inhibitors of Post-Proline Cleaving Enzymes |
WO2003045128A2 (en) | 2001-11-21 | 2003-06-05 | New York University | SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID β, PRION PROTEIN, AMYLIN, α-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO |
WO2003048204A1 (en) | 2001-12-06 | 2003-06-12 | Takeda Chemical Industries, Ltd. | Alzheimer’s disease-associated gene and protein and use thereof |
WO2003051374A2 (en) | 2001-12-17 | 2003-06-26 | New York State Office Of Mental Health | SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES |
WO2003053368A2 (en) | 2001-12-19 | 2003-07-03 | Atherogenics, Inc. | Chalcone derivatives and their use to treat diseases |
WO2003055881A1 (en) | 2001-12-27 | 2003-07-10 | F. Hoffmann-La Roche Ag | Pyrido(2,1-a)isoquinoline derivatives as dpp-iv inhibitors |
WO2003055514A1 (en) | 2001-12-21 | 2003-07-10 | Antigenics Inc. | Compositions comprising immunoreactive reagents and saponins, and methods of use thereof |
WO2003057144A2 (en) | 2001-12-26 | 2003-07-17 | Guilford Pharmaceuticals | Change inhibitors of dipeptidyl peptidase iv |
WO2003057204A2 (en) | 2002-01-08 | 2003-07-17 | Nordic Bioscience A/S | Modulation of iamt (pimt or pcmt) in immune system |
WO2003059346A1 (en) | 2002-01-18 | 2003-07-24 | The Genetics Company Inc. | Beta-secretase inhibitors |
WO2003063760A2 (en) | 2002-01-31 | 2003-08-07 | Tel Aviv University Future Technology Development L.P. | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases |
WO2003066592A1 (en) | 2002-02-06 | 2003-08-14 | Schering Corporation | Gamma secretase inhibitors |
WO2003068748A1 (en) | 2002-02-13 | 2003-08-21 | F. Hoffmann-La Roche Ag | Novel pyridine- and quinoline-derivatives |
WO2003068757A1 (en) | 2002-02-13 | 2003-08-21 | F. Hoffmann-La Roche Ag | Novel pyridin- and pyrimidin-derivatives |
WO2003070760A2 (en) | 2002-02-20 | 2003-08-28 | F. Hoffmann-La Roche Ag | Anti-amyloid beta antibodies and their use |
WO2003072556A1 (en) | 2001-06-27 | 2003-09-04 | Prosidion Ltd. | Glutaminyl based dpiv inhibitors |
WO2003074500A2 (en) | 2002-03-06 | 2003-09-12 | Sanofi-Aventis | N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors |
WO2003074081A1 (en) | 2002-02-28 | 2003-09-12 | Mindset Biopharmaceuticals Usa Inc. | SPECIFIC ANTIBODIES TO AMYLOID β PEPTIDE, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF |
WO2003077858A2 (en) | 2002-03-12 | 2003-09-25 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
WO2003082817A2 (en) | 2002-03-25 | 2003-10-09 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2003082820A1 (en) | 2002-03-29 | 2003-10-09 | Eisai Co., Ltd. | (1-indanone)-(1,2,3,6-tetrahydropyridine) derivative |
WO2003086310A2 (en) | 2002-04-12 | 2003-10-23 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
WO2003089460A1 (en) | 2002-04-19 | 2003-10-30 | The Governing Council Of The University Of Toronto | Immunological methods and compositions for the treatment of alzheimer's disease |
WO2003091278A1 (en) | 2002-04-24 | 2003-11-06 | Hiroshi Mori | Gamma-secretase inhibitors |
WO2003091220A1 (en) | 2002-04-26 | 2003-11-06 | Schering Corporation | Muscarinic antagonists |
US6649196B2 (en) | 2001-03-12 | 2003-11-18 | Mayo Foundation For Medical Education And Research | Methods of reducing β-amyloid polypeptides |
WO2003099202A2 (en) | 2002-05-17 | 2003-12-04 | Merck & Co., Inc. | Beta-secretase inhibitors |
WO2003101449A2 (en) | 2002-06-04 | 2003-12-11 | Pfizer Products Inc. | Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof |
WO2003101958A2 (en) | 2002-06-04 | 2003-12-11 | Pfizer Products Inc. | Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors |
WO2003101458A1 (en) | 2002-05-31 | 2003-12-11 | H. Lundbeck A/S | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
WO2003104437A2 (en) | 2002-06-11 | 2003-12-18 | Northwestern University | Anti-addl antibodies and uses thereof |
WO2003104229A1 (en) | 2002-06-06 | 2003-12-18 | エーザイ株式会社 | Novel fused imidazole derivative |
WO2004000958A1 (en) | 2002-06-19 | 2003-12-31 | Surface Specialties, S.A. | Semi-gloss powder coating compositions |
WO2004007446A1 (en) | 2002-07-10 | 2004-01-22 | Yamanouchi Pharmaceutical Co., Ltd. | Novel azetidine derivative or salt thereof |
WO2004007468A1 (en) | 2002-07-15 | 2004-01-22 | Merck & Co., Inc. | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
WO2004009062A2 (en) | 2002-07-19 | 2004-01-29 | Khalid Iqbal | NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau |
US6686449B2 (en) | 2000-06-30 | 2004-02-03 | Pharmacia & Upjohn Company | Mutant presenilin 1 polypeptides |
WO2004013098A1 (en) | 2002-08-05 | 2004-02-12 | Bristol-Myers Squibb Company | Novel gamma-lactams as beta-secretase inhibitors |
WO2004018469A1 (en) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel purine derivatives, production and use thereof as medicaments |
WO2004018468A2 (en) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments |
WO2004018467A2 (en) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Phenacyl xanthine derivatives as dpp-iv inhibitor |
WO2004024921A1 (en) | 2002-09-12 | 2004-03-25 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Human antihuman mcp-1 antibody and antibody fragment thereof |
WO2004024770A1 (en) | 2002-09-12 | 2004-03-25 | Universidad De Zaragoza | Polyclonal antibodies, preparation method thereof and use of same |
WO2004024090A2 (en) | 2002-09-12 | 2004-03-25 | The Regents Of The University Of California | Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence |
US6713276B2 (en) | 2000-06-28 | 2004-03-30 | Scios, Inc. | Modulation of Aβ levels by β-secretase BACE2 |
WO2004026851A1 (en) | 2002-09-20 | 2004-04-01 | Axys Pharmaceuticals, Inc. | 3-(3,5-disubstituted-4-hydroxyphenyl)propionamide derivatives as cathepsin b inhibitors |
WO2004026822A2 (en) | 2002-09-19 | 2004-04-01 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv) |
WO2004029630A1 (en) | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses |
WO2004028522A1 (en) | 2002-09-25 | 2004-04-08 | Innovative Drug Delivery Systems, Inc. | Analgesic compositions comprising nmda receptor antagonists and benzalkonium chloride |
WO2004031400A2 (en) | 2002-10-01 | 2004-04-15 | Northwestern University | Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof |
WO2004031137A1 (en) | 2002-10-04 | 2004-04-15 | Merck Sharp & Dohme Limited | Cyclohexyl sulphone derivatives as gamma-secretase inhibitors |
WO2004031139A1 (en) | 2002-10-04 | 2004-04-15 | Merck Sharp & Dohme Limited | Cyclohexyl sulphones as gamma-secretase inhibitors |
WO2004033455A2 (en) | 2002-10-08 | 2004-04-22 | Novo Nordisk A/S | Hemisuccinate salts of heterocyclic dpp-iv inhibitors |
WO2004032836A2 (en) | 2002-10-07 | 2004-04-22 | Merck & Co., Inc. | Antidiabetic beta-amino heterocylcic dipeptidyl peptidase inhibitors |
WO2004032868A2 (en) | 2002-10-09 | 2004-04-22 | Rinat Neuroscience Corp. | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
WO2004032929A2 (en) | 2002-10-09 | 2004-04-22 | Neuropharma, S.A. | Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer’s disease |
WO2004037169A2 (en) | 2002-10-18 | 2004-05-06 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2004037234A2 (en) | 2002-10-24 | 2004-05-06 | Merz Pharma Gmbh & Co. Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
WO2004039371A2 (en) | 2002-10-29 | 2004-05-13 | Pharmacia Corporation | Compositions of cyclooxygenase-2 selective inhibitors and nmda receptor antagonists for the treatment or prevention of neuropathic pain |
WO2004039773A2 (en) | 2002-10-30 | 2004-05-13 | Nordic Bioscience A/S | Coumpounds modulating the activity of gapdh and/or iamt |
WO2004039370A1 (en) | 2002-11-01 | 2004-05-13 | Merck Sharp & Dohme Limited | Sulfonamides, sulfamates and sulfamides as gamma-secretase inhibitors |
WO2004041795A1 (en) | 2002-10-30 | 2004-05-21 | Guilford Pharmaceuticals Inc. | Novel inhibitors of dipeptidyl peptidase iv |
WO2004043916A1 (en) | 2002-11-12 | 2004-05-27 | Merck & Co., Inc. | Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2004043940A1 (en) | 2002-11-07 | 2004-05-27 | Merck & Co., Inc. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2004044204A2 (en) | 2002-11-06 | 2004-05-27 | Institut Pasteur | Variable fragments of single-chain camelide antibodies and uses thereof for diagnosing and treating various pathologies |
WO2004048352A2 (en) | 2002-11-27 | 2004-06-10 | Fujisawa Pharmaceutical Co., Ltd. | 2-cyanopyrrolidines and their analogues as dpp-iv inhibitors |
WO2004050022A2 (en) | 2002-12-04 | 2004-06-17 | Merck & Co., Inc. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2004052850A2 (en) | 2002-12-09 | 2004-06-24 | Bristol-Myers Squibb Company | Methods and compounds producing dipeptidyl peptidase iv inhibitors and intermediates thereof |
WO2004056727A2 (en) | 2002-12-19 | 2004-07-08 | Atherogenics, Inc. | Process of making chalcone derivatives |
WO2004058266A1 (en) | 2002-12-20 | 2004-07-15 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2004062625A2 (en) | 2003-01-07 | 2004-07-29 | Merck & Co., Inc. | Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease |
WO2004064778A2 (en) | 2003-01-17 | 2004-08-05 | Merck & Co. Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2004067561A1 (en) | 2003-01-31 | 2004-08-12 | Abbott Gmbh & Co. Kg | Amyloid-$g(b)(1-42) oligomers, derivatives thereof, antibodies for the same, method for production and use therof |
WO2004069826A1 (en) | 2003-02-04 | 2004-08-19 | F. Hoffmann-La Roche Ag | Malonamide derivatives as gamma-secretase inhibitors |
WO2004069162A2 (en) | 2003-01-31 | 2004-08-19 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2004069182A2 (en) | 2003-02-01 | 2004-08-19 | Neuralab Limited | Active immunization to generate antibodies to soluble a-beta |
WO2004071454A2 (en) | 2003-02-13 | 2004-08-26 | Guilford Pharmaceuticals Inc. | Substituted azetidine compounds as inhibitors of dipeptidyl peptidase iv |
WO2004071408A2 (en) | 2003-02-10 | 2004-08-26 | Applied Molecular Evolution, Inc. | Aβ BINDING MOLECULES |
WO2004073630A2 (en) | 2003-02-18 | 2004-09-02 | Roskamp Research Llc | Anti-angiogenic and anti-tumoral properties of beta and gamma secretase inhibitors |
WO2004076433A1 (en) | 2003-02-28 | 2004-09-10 | Aic | Dipeptidyl peptidase inhibitors |
WO2004076434A1 (en) | 2003-02-28 | 2004-09-10 | Aic | Dipeptidyl peptidase inhibitors |
WO2004078908A2 (en) | 2003-03-06 | 2004-09-16 | Santhera Pharmaceuticals (Schweiz) Gmbh | Alpha-keto carbonyl calpain inhibitors |
WO2004080419A2 (en) | 2003-03-12 | 2004-09-23 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
WO2004084830A2 (en) | 2003-03-21 | 2004-10-07 | Buck Institute | Method for treating alzheimer’s dementia |
WO2004084884A1 (en) | 2003-03-24 | 2004-10-07 | The Chinese University Of Hong Kong | Use of tanshinone derivates as cholinesterase inhibitors in treating related diseases |
WO2004087158A2 (en) | 2003-03-28 | 2004-10-14 | Acadia Pharmaceuticals Inc. | Muscarinic m1 receptor agonists for pain management |
WO2004087053A2 (en) | 2003-03-25 | 2004-10-14 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
WO2004089362A1 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | 2-cyanopyrroles and their analogues as ddp-iv inhibitors |
WO2004089351A2 (en) | 2003-04-10 | 2004-10-21 | Cambridge University Technical Services Ltd | Treatment of progressive neurological disorders comprising a mao inhibitor (miclobemid) and an acetylcholinesterase inhibitor (tacrin) |
WO2004089911A1 (en) | 2003-04-10 | 2004-10-21 | Merck Sharp & Dohme Limited | Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of alzheimer’s disease |
WO2004092189A1 (en) | 2003-04-09 | 2004-10-28 | Wyeth | Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists |
WO2004098631A1 (en) | 2003-05-08 | 2004-11-18 | Universidad De Zaragoza | Alzheimer's disease treatment method |
WO2004098591A2 (en) | 2003-05-05 | 2004-11-18 | Probiodrug Ag | Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases |
WO2004099185A1 (en) | 2003-05-09 | 2004-11-18 | Fujisawa Pharmaceutical Co. Ltd. | 2-cyanopyrrolidine derivatives and their use as dpp-iv inhibitors |
WO2004099134A2 (en) | 2003-05-05 | 2004-11-18 | Prosidion Ltd. | Glutaminyl based dp iv-inhibitors |
WO2004098625A2 (en) | 2003-05-05 | 2004-11-18 | Probiodrug Ag | Medical use of inhibitors of glutaminyl and glutamate cyclases |
WO2004101562A2 (en) | 2003-05-13 | 2004-11-25 | Schering Corporation | Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors |
WO2004101538A1 (en) | 2003-05-16 | 2004-11-25 | Merck Sharp & Dohme Limited | Cyclohexyl sulphones as gamma-secretase inhibitors |
WO2004103276A2 (en) | 2003-05-14 | 2004-12-02 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2004103993A1 (en) | 2003-05-14 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
WO2004108895A2 (en) | 2003-05-30 | 2004-12-16 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
WO2004108730A1 (en) | 2003-06-05 | 2004-12-16 | Fujisawa Pharmaceutical Co., Ltd. | 1h-imidazo`4,5-d!pyridazines as dpp-iv inhibitors for the treatment of niddm |
WO2004111041A1 (en) | 2003-06-12 | 2004-12-23 | Fujisawa Pharmaceutical Co., Ltd. | Pyrrolidine, thiazolidine and oxazolidine compounds which inhibit dipeptidyl peptidase-iv (dpp) |
WO2004110436A1 (en) | 2003-06-06 | 2004-12-23 | Merck & Co., Inc. | Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2004112701A2 (en) | 2003-06-17 | 2004-12-29 | Merck & Co., Inc. | Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2005000848A1 (en) | 2003-06-20 | 2005-01-06 | F. Hoffmann-La Roche Ag | Pyrido` 2, 1-a - isoquinoline derivatives as dpp-iv inhibitors |
WO2005000193A2 (en) | 2003-06-30 | 2005-01-06 | Tel Aviv University Future Technology Development L.P. | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases |
WO2005000846A1 (en) | 2003-06-20 | 2005-01-06 | F.Hoffmann-La Roche Ag | Hexahydropyridoisoqinolines as dpp-iv inhibitors |
WO2005000216A2 (en) | 2003-05-27 | 2005-01-06 | Forest Laboratories, Inc. | Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders |
WO2005004803A2 (en) | 2003-07-01 | 2005-01-20 | Merck & Co., Inc. | Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2005004802A2 (en) | 2003-06-30 | 2005-01-20 | Merck & Co., Inc. | N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2005007614A1 (en) | 2003-07-03 | 2005-01-27 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services 6011 | Monoamine oxidase inhibitors |
WO2005007199A1 (en) | 2003-07-16 | 2005-01-27 | Rvx Therapeutics, Inc. | COMPOUNDS AND METHODS FOR DOWNREGULATING THE EFFECTS OF TGF-β |
WO2005008250A1 (en) | 2003-07-21 | 2005-01-27 | Angiogenetics Sweden Ab | Compounds and methods for promoting angiogenesis by using a gamma-secretase inhibitor or inhibiting the gamma-secretase pathway |
WO2005009421A2 (en) | 2003-07-28 | 2005-02-03 | Merz Pharma Gmbh & Co. Kgaa | The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity |
WO2005011599A2 (en) | 2003-08-01 | 2005-02-10 | Northwestern University | Antibodies specific for toxic amyloid beta protein oligomers |
WO2005011581A2 (en) | 2003-07-31 | 2005-02-10 | Merck & Co., Inc. | Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
WO2005014553A1 (en) | 2003-08-05 | 2005-02-17 | Merck Sharp & Dohme Limited | Novel gamma-secretase inhibitors |
WO2005014041A2 (en) | 2003-07-24 | 2005-02-17 | Novartis Ag | Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases |
WO2005016911A1 (en) | 2003-08-13 | 2005-02-24 | Takeda Pharmaceutical Company Limited | 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors |
WO2005018424A2 (en) | 2003-08-18 | 2005-03-03 | Research Foundation For Mental Hygiene, Inc. | Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits |
WO2005018545A2 (en) | 2003-08-14 | 2005-03-03 | Merck & Co., Inc. | Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2005023762A1 (en) | 2003-09-04 | 2005-03-17 | Abbott Laboratories | Pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv) |
WO2005023858A1 (en) | 2003-09-05 | 2005-03-17 | Cellzome Ag | Protein complexes associated with app-processing |
WO2005026148A1 (en) | 2003-09-08 | 2005-03-24 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
WO2005025554A2 (en) | 2003-09-09 | 2005-03-24 | Japan Tobacco Inc. | Dipeptidyl peptidase iv inhibitor |
WO2005025616A1 (en) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | Use of antibody |
WO2005025516A2 (en) | 2003-09-12 | 2005-03-24 | The Regents Of The University Of California | Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates |
WO2005028511A2 (en) | 2003-03-28 | 2005-03-31 | Centocor, Inc. | Anti-amyloid antibodies, compositions, methods and uses |
WO2005027975A1 (en) | 2003-09-22 | 2005-03-31 | Pfizer Limited | Combinations of alpha-2-delta ligands and acetylcholinesterase inhibitors |
WO2005028440A1 (en) | 2003-09-16 | 2005-03-31 | Schering Corporation | Novel gamma secretase inhibitors |
WO2005030751A2 (en) | 2003-09-08 | 2005-04-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2005030731A1 (en) | 2003-09-24 | 2005-04-07 | Merck Sharp & Dohme Limited | Gamma-secretase inhibitors |
WO2005032471A2 (en) | 2003-10-03 | 2005-04-14 | Merck & Co., Inc. | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2005033106A1 (en) | 2003-10-06 | 2005-04-14 | Alangudi Sankaranarayanan | Azolidinecarbonitriles and their use as dpp-iv inhibitors |
WO2005035522A1 (en) | 2003-10-08 | 2005-04-21 | Pfizer Japan, Inc. | 1-‘2-(4-hydroxyphenyl)-2-hydroxyethyl!-piperidin-4-ol compounds as nmda receptor antagonists |
WO2005037828A1 (en) | 2003-10-20 | 2005-04-28 | Lg Life Sciences Ltd. | Novel inhibitors of dpp-iv, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent |
WO2005040095A1 (en) | 2003-10-16 | 2005-05-06 | Astrazeneca Ab | Inhibitors of dipeptidyl peptidase iv |
WO2005039580A1 (en) | 2003-10-16 | 2005-05-06 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor |
WO2005039548A2 (en) | 2003-10-15 | 2005-05-06 | Probiodrug Ag | Use of effectors of glutaminyl and glutamate cyclases |
WO2005040126A1 (en) | 2003-10-06 | 2005-05-06 | F. Hoffman-La Roche Ag | Substituted dibenzo-azepine and benzo-diazepine derivatives useful as gamma-secretase inhibitors |
WO2005044830A1 (en) | 2003-11-11 | 2005-05-19 | F. Hoffmann-La Roche Ag | Phosphinic acids derivatives, beta-secretase inhibitors for the treatment of alzheimer’s disease |
WO2005044195A2 (en) | 2003-11-04 | 2005-05-19 | Merck & Co., Inc. | Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
WO2005047297A1 (en) | 2003-11-12 | 2005-05-26 | Phenomix Corporation | Heterocyclic boronic acid compounds |
WO2005051914A1 (en) | 2003-11-24 | 2005-06-09 | Merck & Co., Inc. | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2005051950A1 (en) | 2003-11-27 | 2005-06-09 | Boehringer Ingelheim International Gmbh | Novel 8-(piperazine-1-yl)- and 8-([1,4]diazepan-1-yl)-xanthine, the production and use thereof in the from of a drug |
WO2005056013A1 (en) | 2003-12-09 | 2005-06-23 | Santhera Pharmaceuticals (Schweiz) Gmbh | Dpp-iv inhibitors |
WO2005056003A1 (en) | 2003-12-09 | 2005-06-23 | Santhera Pharmaceuticals (Schweiz) Gmbh | Dpp-iv inhibitors |
WO2005055996A1 (en) | 2003-12-05 | 2005-06-23 | Forest Laboratories, Inc. | Memantine for the prevention or reduction of suicidality and for treatment of major depression associated with suicidality |
WO2005058849A1 (en) | 2003-12-15 | 2005-06-30 | Glenmark Pharmaceuticals Ltd. | New dipeptidyl peptidase in inhibitors; process for their preparation and compositions containing them |
WO2005065195A2 (en) | 2003-12-19 | 2005-07-21 | Merck & Co., Inc. | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2005070429A1 (en) | 2004-01-22 | 2005-08-04 | Neurosearch A/S | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist |
WO2005072705A1 (en) | 2004-01-29 | 2005-08-11 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions |
WO2005075436A2 (en) | 2004-02-05 | 2005-08-18 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
WO2005075426A1 (en) | 2004-02-03 | 2005-08-18 | Glenmark Pharmaceuticals Ltd. | Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof |
WO2005079789A1 (en) | 2004-02-17 | 2005-09-01 | Axonyx, Inc. | Combinatorial therapy with an acetylcholinesterase inhibitor and (3ar)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate |
WO2005079779A1 (en) | 2003-10-22 | 2005-09-01 | Merz Pharma Gmbh & Co. Kgaa | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES |
WO2005080435A1 (en) | 2004-02-20 | 2005-09-01 | Immuno-Biological Laboratories Co., Ltd. | Monoclonal antibody and use thereof |
WO2005079756A2 (en) | 2004-02-13 | 2005-09-01 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions |
WO2005082348A2 (en) | 2004-02-23 | 2005-09-09 | Trustees Of Tufts College | Inhibitors of dipeptidylpeptidase iv for regulating glucose metabolism |
WO2005081872A2 (en) | 2004-02-20 | 2005-09-09 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
WO2005085246A1 (en) | 2004-02-18 | 2005-09-15 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthine, the production thereof and the use in the form of a dpp inhibitor |
WO2005087235A1 (en) | 2004-03-09 | 2005-09-22 | National Health Research Institutes | Pyrrolidine compounds |
WO2005092009A2 (en) | 2004-03-19 | 2005-10-06 | Axonyx, Inc. | Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders |
WO2005095339A1 (en) | 2004-03-31 | 2005-10-13 | Pfizer Products Inc. | Dicyanopyrrolidines as dipeptidyl peptidase iv inhibitors |
WO2005095343A1 (en) | 2004-03-05 | 2005-10-13 | Santhera Pharmaceuticals (Schweiz) Gmbh | Dpp-iv inhibitors |
WO2005095381A1 (en) | 2004-03-15 | 2005-10-13 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2005097768A2 (en) | 2004-04-05 | 2005-10-20 | Schering Corporation | Novel gamma secretase inhibitors |
WO2005097103A2 (en) | 2004-04-01 | 2005-10-20 | Axys Pharmaceuticals, Inc. | Diabetes and metabolic syndrome therapy utilizing cathepsin b inhibitors |
WO2005102390A2 (en) | 2004-04-22 | 2005-11-03 | Pfizer Japan, Inc. | Combinations comprising alpha-2-delta ligands and nmda receptor antagonists |
WO2005103020A1 (en) | 2004-04-20 | 2005-11-03 | Merck & Co., Inc. | 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2005103043A1 (en) | 2004-04-20 | 2005-11-03 | Merck & Co., Inc. | 2, 4, 6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer’s disease |
WO2005105133A2 (en) | 2004-04-23 | 2005-11-10 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving the viability of photoreceptor cells |
WO2005105998A1 (en) | 2004-04-27 | 2005-11-10 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | HUMAN ANTIAMYLOID β PEPTIDE ANTIBODY AND ANTIBODY FRAGMENT THEREOF |
WO2005108382A1 (en) | 2004-05-04 | 2005-11-17 | Merck & Co., Inc. | 1,2,4-oxadiazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
WO2005113484A1 (en) | 2004-05-13 | 2005-12-01 | Merck & Co., Inc. | Phenyl carboxamide compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2005113510A1 (en) | 2004-05-21 | 2005-12-01 | Santhera Pharmaceuticals (Schweiz) Ag | Dpp-iv inhibitors |
WO2005116029A1 (en) | 2004-05-18 | 2005-12-08 | Merck & Co., Inc. | Cyclohexylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
WO2005116014A1 (en) | 2004-05-12 | 2005-12-08 | Pfizer Products Inc. | Proline derivatives and their use as dipeptidyl peptidase iv inhibitors |
WO2005118555A1 (en) | 2004-06-04 | 2005-12-15 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2005120571A2 (en) | 2004-06-07 | 2005-12-22 | Ramot At Tel Aviv University Ltd. | Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation |
WO2005121089A1 (en) | 2004-06-08 | 2005-12-22 | Santhera Pharmaceuticals (Schweiz) Ag | Dpp-iv inhibitors |
WO2005121131A1 (en) | 2004-06-08 | 2005-12-22 | Santhera Pharmaceuticals (Schweiz) Ag | Dpp-iv inhibitors |
WO2005120494A1 (en) | 2004-06-08 | 2005-12-22 | Santhera Pharmaceuticals (Schweiz) Ag | 1-`(3r)-amino-4-(2-fluoro-phenyl)-butyl !-pyrrolidine-(2r)-carboxilic acid-benzyl amine derivatives and related compounds as dipeptidyl-peptidase iv (dpp-iv) inhibitors for the treatment of type 2 diabetes mellitus |
WO2005123775A1 (en) | 2004-06-21 | 2005-12-29 | Bioarctic Neuroscience Ab | Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof |
WO2005123685A1 (en) | 2004-06-16 | 2005-12-29 | Astrazeneca Ab | Tetrahydroquinolones and aza-analogues thereof for use as dpp-iv inhibitors in the treatement of diabetes |
US6982264B2 (en) | 2001-06-27 | 2006-01-03 | Elan Pharmaceuticals, Inc. | Substituted alcohols useful in treatment of Alzheimer's disease |
WO2006002004A1 (en) | 2004-06-15 | 2006-01-05 | Merck & Co., Inc. | Pyrrolidin-3-yl compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2006004880A2 (en) | 2004-06-30 | 2006-01-12 | Schering Corporation | Substituted n-arylsulfonylheterocyclic amines as gamma-secretase inhibitors |
WO2006008661A2 (en) | 2004-07-19 | 2006-01-26 | Neurochem (International) Limited | Diagnostic methods of multiple organ amyloidosis |
WO2006009886A1 (en) | 2004-06-21 | 2006-01-26 | Merck & Co., Inc. | Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
US6992081B2 (en) | 2000-03-23 | 2006-01-31 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
WO2006010965A1 (en) | 2004-07-29 | 2006-02-02 | Richter Gedeon Vegyészeti Gyár Rt. | Indole-2 -carboxamidine derivatives as nmda receptor antagonists |
WO2006014944A1 (en) | 2004-07-28 | 2006-02-09 | Schering Corporation | Macrocyclic beta-secretase inhibitors |
WO2006014478A1 (en) | 2004-07-02 | 2006-02-09 | Northwestern University | MONOLOCAL ANTIBODIES THAT TARGET PATHOLOGICAL ASSEMBLIES OF AMYLOID β (ABETA) |
WO2006014638A2 (en) | 2004-07-19 | 2006-02-09 | The General Hospital Corporation | ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS |
WO2006013104A1 (en) | 2004-08-05 | 2006-02-09 | Santhera Pharmaceuticals (Schweiz) Ag | Heterocyclic compounds useful as dpp- iv inhibitors |
WO2006014762A1 (en) | 2004-07-22 | 2006-02-09 | Schering Corporation | Substituted amide beta secretase inhibitors |
WO2006017292A1 (en) | 2004-07-12 | 2006-02-16 | Phenomix Corporation | Constrained cyano compounds |
WO2006016644A1 (en) | 2004-08-11 | 2006-02-16 | Mitsubishi Chemical Corporation | Antibody and utilization of the same |
WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
WO2006021413A1 (en) | 2004-08-25 | 2006-03-02 | Santhera Pharmaceuticals (Schweiz) Ag | Alpha-keto carbonyl calpain inhibitors |
WO2006023750A2 (en) | 2004-08-23 | 2006-03-02 | Merck & Co., Inc. | Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
WO2006021409A1 (en) | 2004-08-25 | 2006-03-02 | Santhera Pharmaceuticals (Schweiz) Ag | Alpha-keto carbonyl calpain inhibitors |
WO2006026204A2 (en) | 2004-08-26 | 2006-03-09 | Bristol-Myers Squibb Company | Novel gamma-lactams as beta-secretase inhibitors |
WO2006026408A2 (en) | 2004-08-27 | 2006-03-09 | Wyeth Research Ireland Limited | Production of anti-amyloid beta antibodies |
WO2006029850A1 (en) | 2004-09-14 | 2006-03-23 | The Genetics Company, Inc. | Hydrazone derivatives and their use as beta secretase inhibitors |
WO2006034296A2 (en) | 2004-09-17 | 2006-03-30 | Comentis, Inc. | Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof |
WO2006034277A1 (en) | 2004-09-17 | 2006-03-30 | Comentis, Inc. | Bicyclic compounds which inhibit beta-secretase activity and methods of use thereof |
WO2006036291A2 (en) | 2004-07-30 | 2006-04-06 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
WO2006039325A2 (en) | 2004-10-01 | 2006-04-13 | Merck & Co., Inc. | Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
WO2006039470A2 (en) | 2004-09-29 | 2006-04-13 | Centocor, Inc. | Anti- amyloid antibodies, compositions, methods and uses |
US7030239B2 (en) | 2000-03-23 | 2006-04-18 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
WO2006039807A1 (en) | 2004-10-15 | 2006-04-20 | Biopharmacopae Design International Inc. | Methods and therapeutic compositions comprising plant extracts for the treatment of cancer |
WO2006042103A2 (en) | 2004-10-05 | 2006-04-20 | Axys Pharmaceuticals, Inc. | Reversible inhibitors of cathepsin b |
WO2006040688A2 (en) | 2004-10-12 | 2006-04-20 | Ernir Snorrason | Inhibitors of acetylcholinesterase for treating skin diseases |
WO2006041976A1 (en) | 2004-10-08 | 2006-04-20 | Novartis Ag | Combination of organic compounds |
US7034182B2 (en) | 2000-06-30 | 2006-04-25 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
WO2006044497A2 (en) | 2004-10-13 | 2006-04-27 | Merck & Co., Inc. | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease |
WO2006046644A1 (en) | 2004-10-28 | 2006-05-04 | Sanko Junyaku Co., Ltd. | Method of examining alzheimer’s disease and diagnostic reagent |
WO2006047248A1 (en) | 2004-10-25 | 2006-05-04 | Novartis Ag | Combination of dpp-iv inhibitor, ppar antidiabetic and metformin |
WO2006055434A2 (en) | 2004-11-17 | 2006-05-26 | Merck & Co., Inc. | Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2006055178A2 (en) | 2004-10-25 | 2006-05-26 | Merck & Co., Inc. | Anti-addl antibodies and uses thereof |
WO2006057945A2 (en) | 2004-11-23 | 2006-06-01 | Merck & Co., Inc. | 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2006057983A1 (en) | 2004-11-23 | 2006-06-01 | Merck & Co., Inc. | Macrocyclic aminopyridyl beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2006058059A2 (en) | 2004-11-23 | 2006-06-01 | Neuromolecular Pharmaceuticals, Inc. | Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject |
WO2006058064A2 (en) | 2004-11-29 | 2006-06-01 | Merck & Co., Inc. | Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
WO2006058236A2 (en) | 2004-11-24 | 2006-06-01 | Neuromolecular Pharmaceuticals, Inc. | Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease |
WO2006058720A2 (en) | 2003-11-03 | 2006-06-08 | Probiodrug Ag | Novel compounds for the treatment of neurological disorders |
WO2006058628A2 (en) | 2004-11-30 | 2006-06-08 | F.Hoffmann-La Roche Ag | Substituted benzoquinolizines as dpp-iv inhibitors for the treatment of diabetes |
WO2006060473A2 (en) | 2004-12-03 | 2006-06-08 | Mucosal Therapeutics Llc | Methods of treatment of injured or diseased joints with lubricin compositions |
WO2006060109A1 (en) | 2004-10-29 | 2006-06-08 | Merck & Co., Inc. | 2-aminopyridine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2006066089A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
WO2006066171A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Amyloid βετα antibodies for use in improving cognition |
WO2006066049A2 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
WO2006066233A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | An immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies |
WO2006068978A2 (en) | 2004-12-21 | 2006-06-29 | Takeda Pharmaceutial Company Limited | Dipeptidyl peptidase inhibitors |
WO2006066747A1 (en) | 2004-12-20 | 2006-06-29 | F. Hoffmann-La Roche Ag | 4-aminopiperidine derivatives |
WO2006066770A1 (en) | 2004-12-20 | 2006-06-29 | F.Hoffmann-La Roche Ag | Cycloalkylamine derivatives |
WO2006071274A2 (en) | 2004-12-23 | 2006-07-06 | Voyager Pharmaceutical Corporation | Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer’s disease |
WO2006070394A1 (en) | 2004-12-28 | 2006-07-06 | Council Of Scientific And Industrial Research | Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors |
WO2006074265A2 (en) | 2005-01-06 | 2006-07-13 | Merck & Co., Inc. | Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders |
WO2006078576A2 (en) | 2005-01-19 | 2006-07-27 | Merck & Co., Inc. | Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2006081171A1 (en) | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
WO2006085961A2 (en) | 2004-06-30 | 2006-08-17 | Centocor, Inc. | Anti-mcp-1 antibodies, compositions, methods and uses |
WO2006091988A1 (en) | 2005-02-28 | 2006-08-31 | Thomas Christian Lines | Composition for treating mental health disorders |
WO2006095041A1 (en) | 2005-03-09 | 2006-09-14 | Consejo Superior De Investigaciones Científicas | Method for the in vitro diagnosis of alzheimer's disease using a monoclonal antibody |
WO2006094674A1 (en) | 2005-03-07 | 2006-09-14 | Michael Hermanussen | Nmda receptor antagonists in the medical intervention of metabolic disorders |
WO2006099352A1 (en) | 2005-03-10 | 2006-09-21 | Bristol-Myers Squibb Company | Novel isophthalates as beta-secretase inhibitors |
WO2006097624A1 (en) | 2005-03-17 | 2006-09-21 | Sanofi-Aventis | 7-(2-(4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydro-pyrid-1-yl)ethyl) isoquinoline besylate salt, preparation and therapeutic use thereof |
WO2006103116A1 (en) | 2005-04-01 | 2006-10-05 | Biotherapix Molecular Medicines S.L.U. | Human antibodies with beta-amyloid peptide-binding capacity and their applications |
WO2006116435A2 (en) | 2005-04-27 | 2006-11-02 | Novartis Ag | Methods of treating atherosclerosis |
WO2006118959A2 (en) | 2005-04-29 | 2006-11-09 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
WO2006125202A2 (en) | 2005-05-19 | 2006-11-23 | Centocor, Inc. | Anti- mcp-1 antibodies, compositions, methods and uses |
WO2006137354A1 (en) | 2005-06-21 | 2006-12-28 | Medical & Biological Laboratories Co., Ltd. | Antibody having inhibitory effect on amyloid fibril formation |
WO2007011810A1 (en) | 2005-07-18 | 2007-01-25 | Merck & Co., Inc. | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2007019078A2 (en) | 2005-08-03 | 2007-02-15 | Merck & Co., Inc. | Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2007019080A2 (en) | 2005-08-03 | 2007-02-15 | Merck & Co., Inc. | Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2007021793A1 (en) | 2005-08-12 | 2007-02-22 | Bristol-Myers Squibb Company | Macrocyclic diaminopropanes as beta-secretase inhibitors |
WO2007022416A2 (en) | 2005-08-18 | 2007-02-22 | Ramot At Tel Aviv University Ltd. | Single chain antibodies against beta-amyloid peptide |
WO2007038772A1 (en) | 2005-09-28 | 2007-04-05 | American Life Science Pharmaceuticals | Novel drugs for dementia |
WO2007051333A1 (en) | 2005-11-02 | 2007-05-10 | Oncalis Ag | Triazine beta-secretase inhibitors |
WO2007068411A2 (en) | 2005-12-12 | 2007-06-21 | Ac Immune S.A. | Therapeutic vaccine |
WO2007068412A2 (en) | 2005-12-12 | 2007-06-21 | Ac Immune Sa | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
WO2007084595A2 (en) | 2006-01-20 | 2007-07-26 | Schering Corporation | Carbocyclic and heterocyclic arylsulfones as gamma secretase inhibitors |
WO2007097251A1 (en) | 2006-02-22 | 2007-08-30 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | PEPTIDE VACCINE FOR INDUCING PRODUCTION OF ANTI-AMYLOID-β-PEPTIDE ANTIBODY |
WO2007113172A2 (en) | 2006-03-30 | 2007-10-11 | Glaxo Group Limited | Antibodies against amyloid-beta peptide |
WO2008011348A2 (en) | 2006-07-14 | 2008-01-24 | Ac Immune S.A. | Humanized antibody against amyloid beta |
WO2008054698A2 (en) | 2006-10-30 | 2008-05-08 | Merck & Co., Inc. | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2008055950A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
WO2008055947A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
WO2008060364A2 (en) | 2006-10-02 | 2008-05-22 | Ac Immune S.A | Humani zed antibody against amyloid beta |
WO2008065141A1 (en) | 2006-11-30 | 2008-06-05 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
WO2008077109A1 (en) | 2006-12-20 | 2008-06-26 | Gregory Hook | Methods of treating alzheimer's disease |
WO2008110523A1 (en) | 2007-03-09 | 2008-09-18 | Probiodrug Ag | Imidazo [1,5-a] pyridine derivatives as inhibitors of glutaminyl cyclase |
WO2008128983A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Cyano-guanidine derivatives as glutaminyl cyclase inhibitors |
WO2008128984A1 (en) | 2007-04-20 | 2008-10-30 | Probiodrug Ag | Aminopyrimidine derivatives as glutaminyl cyclase inhibitors |
WO2008128982A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thioxoquinazolinone derivatives as glutaminyl cyclase inhibitors |
WO2008128987A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Novel inhibitors |
WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
WO2008128986A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Urea derivatives as glutaminyl cyclase inhibitors |
WO2008128981A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Nitrovinyl-diamine derivatives as glutaminyl cyclase inhibitors |
WO2008147800A1 (en) | 2007-05-25 | 2008-12-04 | Elan Pharmaceuticals, Inc. | Pyrazolopyrrolidines as inhibitors of gamma secretase |
WO2008156621A1 (en) | 2007-06-12 | 2008-12-24 | Ac Immune S.A. | Monoclonal anti beta amyloid antibody |
EP2011349A2 (en) | 2006-03-17 | 2009-01-07 | Vodafone Group PLC | Improvements in an ehspa architecture |
WO2009008980A2 (en) | 2007-07-05 | 2009-01-15 | Schering Corporation | Tetrahydropyranochromene gamma secretase inhibitors |
WO2009011851A1 (en) | 2007-07-17 | 2009-01-22 | Schering Corporation | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors |
WO2009029272A2 (en) | 2007-08-27 | 2009-03-05 | Agadjanyan Michael G | Epitope vaccine for prevention and reversion of ad pathology |
WO2009033743A1 (en) | 2007-09-13 | 2009-03-19 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
WO2009042694A1 (en) | 2007-09-24 | 2009-04-02 | Comentis, Inc. | (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating |
WO2009053696A1 (en) | 2007-10-25 | 2009-04-30 | University College Cardiff Consultants Limited | Monoclonal antibody for app |
WO2009054537A1 (en) | 2007-10-25 | 2009-04-30 | Kagoshima University | PEPTIDE VACCINE USING MIMIC MOLECULE OF AMYLOID β-PEPTIDE |
WO2009056490A1 (en) | 2007-10-29 | 2009-05-07 | Innogenetics Nv | NEW ANTIBODIES SPECIFIC OF THE β-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS |
WO2009065054A2 (en) | 2007-11-16 | 2009-05-22 | The Rockefeller University | Antibodies specific for the protofibril form of beta-amyloid protein |
WO2009090650A2 (en) | 2008-01-16 | 2009-07-23 | Ben-Gurion University Of The Negev Research And Development Authority | Vaccine for alzheimer's disease |
WO2009095857A1 (en) | 2008-01-28 | 2009-08-06 | Consiglio Nazionale Delle Ricerche | Multimeric proteins able to induce an antibody response against the beta-amyloid and use thereof |
WO2009108550A1 (en) | 2008-02-28 | 2009-09-03 | Merck & Co., Inc. | 2-aminoimidazole beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2010012004A2 (en) | 2008-07-25 | 2010-01-28 | The Regents Of The University Of California | Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence |
WO2010011999A2 (en) | 2008-07-25 | 2010-01-28 | The Regents Of The University Of California | Methods and compositions for eliciting an amyloid-selective immune response |
WO2010011947A2 (en) | 2008-07-25 | 2010-01-28 | Abbott Laboratories | AMYLOID ß PEPTIDE ANALOGUES, OLIGOMERS THEREOF, PROCESSES FOR PREPARING AND COMPOSITIONS COMPRISING SAID ANALOGUES OR OLIGOMERS, AND THEIR USES |
WO2010016912A2 (en) | 2008-08-07 | 2010-02-11 | Mercia Pharma, Llc | Immunotherapeutic compositions for the treatment of alzheimer's disease |
WO2010021680A2 (en) | 2008-08-19 | 2010-02-25 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
WO2010026212A1 (en) | 2008-09-04 | 2010-03-11 | Probiodrug Ag | Novel inhibitors |
WO2010044464A1 (en) | 2008-10-16 | 2010-04-22 | 財団法人化学及血清療法研究所 | Modified amyloid beta peptide |
WO2010058333A1 (en) | 2008-11-23 | 2010-05-27 | Pfizer Inc. | Lactams as beta secretase inhibitors |
WO2010090954A1 (en) | 2009-02-06 | 2010-08-12 | Merck Sharp & Dohme Corp. | Novel trifluoromethylsulfonamide gamma secretase inhibitor |
WO2010094242A1 (en) | 2009-02-20 | 2010-08-26 | Merck Sharp & Dohme Corp. | Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1351946A2 (en) * | 2000-09-01 | 2003-10-15 | Icos Corporation | Materials and methods to potentiate cancer treatment |
US7452911B2 (en) * | 2002-10-31 | 2008-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
JP2008542322A (en) | 2005-06-01 | 2008-11-27 | ユセベ ファルマ ソシエテ アノニム | 2-Oxo-1-pyrrolidine derivatives |
CA2672213C (en) * | 2006-12-22 | 2016-02-16 | Astex Therapeutics Limited | Bicyclic amine derivatives as protein tyrosine kinase inhibitors |
ES2434693T3 (en) * | 2007-04-20 | 2013-12-17 | The Research Foundation For The State University Of New York | Benzimidazoles and pharmaceutical compositions thereof |
WO2008151927A2 (en) | 2007-06-15 | 2008-12-18 | Nycomed Gmbh | 6-n-substituted benz imidazole derivatives as acid pump antagonists |
AU2008304231A1 (en) | 2007-09-27 | 2009-04-02 | Albany Molecular Research, Inc. | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
PT2294066E (en) | 2008-04-28 | 2014-11-21 | Janssen Pharmaceutica Nv | Benzoimidazoles as prolyl hydroxylase inhibitors |
AU2009271019A1 (en) * | 2008-07-14 | 2010-01-21 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
-
2010
- 2010-09-13 EA EA201200474A patent/EA022007B1/en unknown
- 2010-09-13 MX MX2012002993A patent/MX2012002993A/en active IP Right Grant
- 2010-09-13 CN CN201080050870.XA patent/CN102695546B/en active Active
- 2010-09-13 ES ES10751952.2T patent/ES2548913T3/en active Active
- 2010-09-13 EP EP10751952.2A patent/EP2475428B1/en active Active
- 2010-09-13 SG SG2012014817A patent/SG178953A1/en unknown
- 2010-09-13 JP JP2012528379A patent/JP5934645B2/en active Active
- 2010-09-13 WO PCT/EP2010/063341 patent/WO2011029920A1/en active Application Filing
- 2010-09-13 KR KR1020127008546A patent/KR101755737B1/en active IP Right Grant
- 2010-09-13 PL PL10751952T patent/PL2475428T3/en unknown
- 2010-09-13 NZ NZ598685A patent/NZ598685A/en unknown
- 2010-09-13 DK DK10751952.2T patent/DK2475428T3/en active
- 2010-09-13 AU AU2010294214A patent/AU2010294214B2/en active Active
- 2010-09-13 CA CA2772488A patent/CA2772488C/en active Active
- 2010-09-13 US US12/880,369 patent/US8486940B2/en active Active
-
2012
- 2012-02-22 IL IL218259A patent/IL218259A/en active IP Right Grant
- 2012-02-23 ZA ZA2012/01366A patent/ZA201201366B/en unknown
-
2013
- 2013-02-27 HK HK13102485.3A patent/HK1175135A1/en unknown
- 2013-06-05 US US13/910,702 patent/US9173885B2/en active Active
-
2015
- 2015-09-23 US US14/862,245 patent/US9650362B2/en active Active
Patent Citations (630)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4743616A (en) | 1984-07-31 | 1988-05-10 | Suntory Limited | Novel biologically active compound having anti-prolyl endopeptidase activity |
EP0172458A2 (en) | 1984-07-31 | 1986-02-26 | Suntory Limited | Novel biologically active compound having anti-prolyl endopeptidase activity |
JPS6137764A (en) | 1984-07-31 | 1986-02-22 | Suntory Ltd | Novel physiologically active compound having anti-prolyl-endopeptidase activity |
JPH0331298B2 (en) | 1984-09-18 | 1991-05-02 | Sanyo Electric Co | |
EP0201743A2 (en) | 1985-04-16 | 1986-11-20 | Suntory Limited | Dipeptide derivatives of fatty acids, process for preparing them, pharmaceutical composition and use |
EP0201742A2 (en) | 1985-04-16 | 1986-11-20 | Suntory Limited | N-Acylpyrrolidine derivatives, processes for preparing them, pharmaceutical composition and use |
EP0201741A2 (en) | 1985-04-16 | 1986-11-20 | Suntory Limited | Dipeptide derivatives, processes for preparing them, pharmaceutical composition and use |
US4873342A (en) | 1985-04-16 | 1989-10-10 | Suntory Limited | Dipeptide derivative and synthesis and use thereof |
US4772587A (en) | 1985-04-16 | 1988-09-20 | Suntory Limited | Dipeptide derivative of fatty acid |
JPS62114957A (en) | 1985-11-13 | 1987-05-26 | Suntory Ltd | Novel pyrrolidine derivative having prolylendopeptidase inhibiting action its production and use thereof |
JPS62114978A (en) | 1985-11-14 | 1987-05-26 | Suntory Ltd | Novel pyrrolidinylimide having prolyl-endopeptidase inhibiting activity and production and use thereof |
US4757083A (en) | 1985-11-29 | 1988-07-12 | Suntory Limited | Novel pyrrolidinylamide ester derivatives having anti-prolyl endopeptidase activity and synthesis and use thereof |
EP0224272A1 (en) | 1985-11-29 | 1987-06-03 | Suntory Limited | Pyrrolidinylamide ester derivative having anti-prolyl endopeptidase activity, its synthesis and use and a pharmaceutical composition containing it |
US5198458A (en) | 1986-02-04 | 1993-03-30 | Suntory Limited | Pyrrolidineamide derivatives of acylamino acid and pharmaceutical composition containing the same |
US4826870A (en) | 1986-02-04 | 1989-05-02 | Suntory Limited | Pyrrolidineamide derivative of acylamino acid and pharmaceutical containing the same |
EP0232849A2 (en) | 1986-02-04 | 1987-08-19 | Suntory Limited | Pyrrolidineamide derivative of acylamino acid, pharmaceutical composition and use |
EP0253310A2 (en) | 1986-07-11 | 1988-01-20 | E.I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
EP0268281A2 (en) | 1986-11-18 | 1988-05-25 | Suntory Limited | Pyrrolidineamide derivative having anti-prolyl endopeptidase activity, compositions comprising the same, processes for the preparation of the same, and the use of the same for the preparation of a medicament of therapeutic value |
US4810721A (en) | 1986-11-18 | 1989-03-07 | Suntory Limited | Pyrrolidineamide derivative having anti-prolyl endopeptidase |
US5254550A (en) | 1986-11-20 | 1993-10-19 | Ono Pharmaceutical Co., Ltd. | Prolinal derivatives and pharmaceutical compositions thereof |
US4956380A (en) | 1986-11-20 | 1990-09-11 | Ono Pharmaceutical Co., Ltd. | Prolinal compounds useful in treating amnesia |
US5340832A (en) | 1986-11-20 | 1994-08-23 | Ono Pharmaceutical Co., Ltd. | Prolinal derivatives useful for treating amnesia |
EP0268190A1 (en) | 1986-11-20 | 1988-05-25 | Ono Pharmaceutical Co., Ltd. | Prolinal derivatives |
US5100904A (en) | 1986-11-20 | 1992-03-31 | Ono Pharmaceutical Co., Ltd. | Prolinal compounds which are useful in treating amnesia |
JPS63162672A (en) | 1986-12-25 | 1988-07-06 | Ono Pharmaceut Co Ltd | Novel prolinal derivative, its production and antiamnestic agent containing said derivative |
US5112847A (en) | 1986-12-29 | 1992-05-12 | Ono Pharmaceutical Co., Ltd. | Prolinal derivatives having inhibitory activity on prolyl endopeptidase |
US4983624A (en) | 1986-12-29 | 1991-01-08 | Ono Pharmaceutical Co., Ltd | Novel prolinal derivatives |
EP0275482A2 (en) | 1986-12-29 | 1988-07-27 | Ono Pharmaceutical Co., Ltd. | Proline derivatives |
JPS63264454A (en) | 1986-12-29 | 1988-11-01 | Ono Pharmaceut Co Ltd | Novel prolinal derivative, production thereof and antiamnesic agent containing said derivative |
US5262431A (en) | 1986-12-29 | 1993-11-16 | Ono Pharmaceutical Co., Ltd. | Prolinal derivatives and pharmaceutical compositions thereof |
EP0277588A1 (en) | 1987-02-04 | 1988-08-10 | Ono Pharmaceutical Co., Ltd. | Prolinal derivatives |
US4977180A (en) | 1987-02-04 | 1990-12-11 | Ono Pharmaceutical Co., Ltd. | Novel prolinal derivatives |
US5091406A (en) | 1987-02-04 | 1992-02-25 | Ono Pharmaceutical Co., Ltd. | Prolinal derivatives |
JPS6469A (en) | 1987-02-04 | 1989-01-05 | Ono Pharmaceut Co Ltd | Novel prolinal derivative, production thereof and drug for alleviating amnesia containing said derivative |
EP0461677A1 (en) | 1987-02-23 | 1991-12-18 | Ono Pharmaceutical Co., Ltd. | Novel thiazolidine derivatives |
US4857537A (en) | 1987-02-23 | 1989-08-15 | Ono Pharmaceutical Co., Ltd. | Novel thiazolidine derivatives |
EP0280956A1 (en) | 1987-02-23 | 1988-09-07 | Ono Pharmaceutical Co., Ltd. | Thiazolidine derivatives |
JPS6442465A (en) | 1987-08-07 | 1989-02-14 | Wakunaga Pharma Co Ltd | N-acylprolylpyrrolidine derivative, production and use thereof |
EP0303434A1 (en) | 1987-08-08 | 1989-02-15 | Kissei Pharmaceutical Co. Ltd. | Thiazolidine compounds |
JPS6468396A (en) | 1987-09-10 | 1989-03-14 | Yakult Honsha Kk | Novel peptide and amnesia alleviating drug comprising said peptide as active ingredient |
WO1989006242A1 (en) | 1987-10-08 | 1989-07-13 | The Mclean Hospital Corporation | Antibodies to a4 amyloid peptide |
JPH01143897A (en) | 1987-11-30 | 1989-06-06 | Kissei Pharmaceut Co Ltd | Thiazolidine derivative |
JPH01250370A (en) | 1987-12-23 | 1989-10-05 | Zeria Pharmaceut Co Ltd | Novel amino acid imide derivative, its production and use thereof |
JPH01226880A (en) | 1988-03-07 | 1989-09-11 | Kissei Pharmaceut Co Ltd | Thiazolidine derivative |
EP0345428A1 (en) | 1988-04-08 | 1989-12-13 | Ono Pharmaceutical Co., Ltd. | Anti-amnesic pyrrolidine derivatives |
US5328899A (en) | 1988-07-15 | 1994-07-12 | The Salk Institute For Biological Studies | NPY peptide analogs |
EP0355794A2 (en) | 1988-08-26 | 1990-02-28 | Merrell Dow Pharmaceuticals Inc. | Neuropeptide Y antagonists |
EP0355793A2 (en) | 1988-08-26 | 1990-02-28 | Merrell Pharmaceuticals Inc. | Neuropeptide Y agonists and partial agonists |
JPH02275858A (en) | 1988-09-14 | 1990-11-09 | Yoshitomi Pharmaceut Ind Ltd | Pyridine compound |
EP0372484A2 (en) | 1988-12-08 | 1990-06-13 | Zeria Pharmaceutical Co., Ltd. | Condensed benzene derivative |
US5028604A (en) | 1988-12-08 | 1991-07-02 | Zeria Pharmaceutical Co., Ltd. | Condensed benzene derivative |
JPH02207070A (en) | 1989-02-07 | 1990-08-16 | Zeria Pharmaceut Co Ltd | Amide acid imide derivative, drug containing same and intermediate for producing the compound |
US5118811A (en) | 1989-04-13 | 1992-06-02 | Japan Tobacco Inc. | Amino acid derivatives possessing prolyl endopeptidase-inhibitory activities |
WO1990012870A1 (en) | 1989-04-14 | 1990-11-01 | Research Foundation For Mental Hygiene, Inc. | Monoclonal antibody to amyloid peptide |
WO1990012871A1 (en) | 1989-04-14 | 1990-11-01 | Research Foundation For Mental Hygiene, Inc. | Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10 |
WO1990014840A1 (en) | 1989-06-06 | 1990-12-13 | California Biotechnology Inc. | Recombinant alzheimer's amyloid protein |
EP0403159A2 (en) | 1989-06-14 | 1990-12-19 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids |
JPH0356486A (en) | 1989-07-24 | 1991-03-12 | Kissei Pharmaceut Co Ltd | Thiazolidine derivative |
DE3939797A1 (en) | 1989-12-01 | 1991-06-06 | Basf Ag | NEW PEPTIDES DERIVED FROM NEUROPEPTIDE Y |
WO1991010664A1 (en) | 1990-01-12 | 1991-07-25 | American Home Products Corporation | PYRIDAZINO[4,5-b]INDOLIZINES |
EP0443983A1 (en) | 1990-02-19 | 1991-08-28 | Ciba-Geigy Ag | Acyl compounds |
JPH03255080A (en) | 1990-03-05 | 1991-11-13 | Yoshitomi Pharmaceut Ind Ltd | Benzene compound |
EP0454511A1 (en) | 1990-03-20 | 1991-10-30 | Sanofi | N-substituted heterocycle derivatives, their preparation, compositions containing them |
JPH06339390A (en) | 1990-03-22 | 1994-12-13 | Bristol Myers Squibb Co | Bu-4164e-a and b and prolyl endopeptidase inhibitor |
US4999349A (en) | 1990-03-22 | 1991-03-12 | Bristol-Myers Squibb Co. | BU-4164E - A and B, prolyl endopeptidase inhibitors |
EP0451547A1 (en) | 1990-03-22 | 1991-10-16 | Bristol-Myers Squibb Company | 1,4,8-Triazacyclotridecane derivatives having prolyl endopeptidase inhibiting activity |
US5073549A (en) | 1990-03-22 | 1991-12-17 | Bristol-Myers Squibb Company | BU-4164E - A and B, prolyl endopeptidase inhibitors and their methods of use |
JPH049367A (en) | 1990-04-26 | 1992-01-14 | Zeria Pharmaceut Co Ltd | Arylalkanoyl derivative, production intermediate for the compound and drug containing the same |
EP0459136A1 (en) | 1990-04-27 | 1991-12-04 | Takeda Chemical Industries, Ltd. | Benzimidazole derivatives, their production and use |
US5847155A (en) | 1990-06-04 | 1998-12-08 | Pfizer Inc | Aromatic pyrrolidine amide prolyl endopeptidase inhibitors |
US5407950A (en) | 1990-06-07 | 1995-04-18 | Zeria Pharmaceutical Co., Ltd. | Arylalkanoylamine derivative and drug containing the same |
WO1991018877A1 (en) | 1990-06-07 | 1991-12-12 | Zeria Pharmaceutical Co., Ltd. | Novel arylalkanoylamine derivative and drug containing the same |
EP0468469A2 (en) | 1990-07-27 | 1992-01-29 | Japan Tobacco Inc. | Proline derivatives |
EP0468339A2 (en) | 1990-07-27 | 1992-01-29 | Nippon Kayaku Kabushiki Kaisha | Alpha-keto-amide derivatives having protease inhibiting activity |
JPH0525125A (en) | 1990-07-27 | 1993-02-02 | Japan Tobacco Inc | New proline derivative |
US5506256A (en) | 1990-07-27 | 1996-04-09 | Yoshitomi Pharmaceutical Industries, Ltd. | Proline derivatives possessing prolyl endopeptidase-inhibitory activity |
JPH04211648A (en) | 1990-07-27 | 1992-08-03 | Nippon Kayaku Co Ltd | Keto-acid amide derivative |
US5221752A (en) | 1990-07-27 | 1993-06-22 | Nippon Kayaku Kabushiki Kaisha | α-keto amide derivatives |
JPH04235162A (en) | 1990-08-09 | 1992-08-24 | Zeria Pharmaceut Co Ltd | Novel succinamide derivative and drug containing the same |
JPH04208299A (en) | 1990-11-30 | 1992-07-29 | Ajinomoto Co Inc | Prolyl endopeptidase-inhibiting peptide |
EP0503785A1 (en) | 1991-02-21 | 1992-09-16 | Sankyo Company Limited | 1-Biphenylimidazole derivatives, their preparation and their therapeutic use |
WO1992019238A1 (en) | 1991-05-01 | 1992-11-12 | Mayo Foundation For Medical Education And Research | Huperzine a analogs |
WO1992021333A2 (en) | 1991-05-24 | 1992-12-10 | Pharmavene, Inc. | Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors |
WO1993000361A1 (en) | 1991-06-20 | 1993-01-07 | Snow Brand Milk Products Co., Ltd. | Novel prolyl endopeptidase inhibitors sna-115 and sna-115t, production thereof, and strain which produces said inhibitors |
EP0522314A1 (en) | 1991-07-03 | 1993-01-13 | BASF Aktiengesellschaft | Thermoplastic moulding composition based on polycarbonates, styrene/acrylanitrile-polymerisates and polyolefins |
JPH0515314A (en) | 1991-07-04 | 1993-01-26 | Fuji Oil Co Ltd | Method for removing bitterness of peptide |
WO1993003034A1 (en) | 1991-07-29 | 1993-02-18 | Warner-Lambert Company | Quinazoline derivatives as acetylcholinesterase inhibitors |
EP0539086A2 (en) | 1991-10-24 | 1993-04-28 | American Home Products Corporation | Condensed pyrimidine derivatives and their use as angiotensine II antagonists |
WO1993012139A1 (en) | 1991-12-19 | 1993-06-24 | Garvan Institute Of Medical Research | A novel molecule which inhibits neuropeptide tyrosine biological function |
EP0556482A2 (en) | 1991-12-24 | 1993-08-25 | Snow Brand Milk Products Co., Ltd. | Propyl endopeptidase inhibitor |
WO1993013065A1 (en) | 1991-12-27 | 1993-07-08 | Japan Tobacco Inc. | Proline derivative |
JPH05201970A (en) | 1992-01-24 | 1993-08-10 | Japan Tobacco Inc | New proline derivative |
JPH05331072A (en) | 1992-05-27 | 1993-12-14 | Agency Of Ind Science & Technol | Prolyl endopeptidase inhibitor |
WO1993025534A1 (en) | 1992-06-10 | 1993-12-23 | Zeneca Limited | 2,5-DIOXO-2,5-DIHYDRO-1H-BENZ[b]AZEPINES AS NMDA RECEPTOR ANTAGONISTS |
WO1994000486A1 (en) | 1992-06-20 | 1994-01-06 | The Wellcome Foundation Limited | Neuropeptide y antagonists |
JPH06116284A (en) | 1992-10-02 | 1994-04-26 | Yamanouchi Pharmaceut Co Ltd | New peptide |
WO1994007890A1 (en) | 1992-10-05 | 1994-04-14 | Ube Industries, Ltd. | Pyrimidine compound |
WO1994009016A1 (en) | 1992-10-16 | 1994-04-28 | Sri International | 2-piperidinecarboxylic acid derivatives useful as nmda receptor antagonists |
WO1994012474A1 (en) | 1992-11-20 | 1994-06-09 | Japan Tobacco Inc. | Compound with prolyl endopeptidase inhibitor activity and pharmaceutical use thereof |
EP0670309A1 (en) | 1992-11-20 | 1995-09-06 | Japan Tobacco Inc. | Compound with prolyl endopeptidase inhibitor activity and pharmaceutical use thereof |
WO1994013641A1 (en) | 1992-12-16 | 1994-06-23 | Japan Tobacco Inc. | Benzomorphan useful as nmda receptor antagonist |
JPH06192298A (en) | 1992-12-24 | 1994-07-12 | Mitsui Toatsu Chem Inc | Novel function peptide |
WO1994017035A1 (en) | 1993-01-20 | 1994-08-04 | Dr. Karl Thomae Gmbh | Aminoacid derivates, medicaments containing these compounds and process for preparing the same |
WO1994017197A1 (en) | 1993-01-25 | 1994-08-04 | Takeda Chemical Industries, Ltd. | ANTIBODY AGAINST β-AMYLOID OR DERIVATIVE THEREOF AND USE THEREOF |
JPH06234693A (en) | 1993-02-09 | 1994-08-23 | Snow Brand Milk Prod Co Ltd | New isotetracenone-based substance and its production |
EP0614911A1 (en) | 1993-02-15 | 1994-09-14 | Sanofi | Compounds having a sulfonamide and an amidinegroup, process for preparation and pharmaceutical compositions comprising them |
WO1994019356A1 (en) | 1993-02-16 | 1994-09-01 | Merrell Dow Pharmaceuticals Inc. | Silylated acetylcholinesterase inhibitors |
WO1994020476A1 (en) | 1993-03-02 | 1994-09-15 | Fujisawa Pharmaceutical Co., Ltd. | Novel heterocyclic compound |
WO1994020109A1 (en) | 1993-03-03 | 1994-09-15 | Rhone-Poulenc Rorer S.A. | Use of 2h-1,2,4-benzothiadiazine 3(4h)-one 1,1 dioxide derivatives as non-competitive nmda receptor antagonists |
EP0618193A1 (en) | 1993-03-24 | 1994-10-05 | Adir Et Compagnie | Nitrogen containing bicyclic derivatives as prolyl-endopeptidase inhibitors |
WO1994029255A1 (en) | 1993-06-04 | 1994-12-22 | Merrell Pharmaceuticals Inc. | Aromatic acetylcholinesterase inhibitors |
WO1995000161A1 (en) | 1993-06-18 | 1995-01-05 | University Of Cincinnati | Neuropeptide y antagonists and agonists |
WO1995001352A1 (en) | 1993-06-30 | 1995-01-12 | Zeria Pharmaceutical Co., Ltd. | Thiazolidine derivative and medicine containing the same |
WO1995002601A1 (en) | 1993-07-16 | 1995-01-26 | Rhone-Poulenc Rorer S.A. | IMIDAZO[1,2-a]PYRAZINE-4-ONE, PREPARATION THEREOF AND DRUGS CONTAINING SAME |
WO1995002602A1 (en) | 1993-07-16 | 1995-01-26 | Rhone-Poulenc Rorer S.A. | Imidazo(1,2-a)pyrazin-4-one derivatives for use as ampa and nmda receptor antagonists |
US5965556A (en) | 1993-07-23 | 1999-10-12 | Zaidan Hojin Biseibutsu Kagaku Kenkyukai | Pyrrolidine derivatives |
US5756763A (en) | 1993-07-23 | 1998-05-26 | Zaidan Hojin Biseibutsu Kagaku Kenkyukai | Pyrrolidine derivatives |
EP0709373A1 (en) | 1993-07-23 | 1996-05-01 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Novel pyrrolidine derivative |
WO1995012594A1 (en) | 1993-11-05 | 1995-05-11 | Rhone-Poulenc Rorer S.A. | 7H-IMIDAZO(1,2-a)PYRAZINE-8-ONE NMDA RECEPTOR ANTAGONISTS |
WO1995015310A1 (en) | 1993-12-02 | 1995-06-08 | Merrell Pharmaceuticals Inc. | Prolyl endopeptidase inhibitors |
WO1995015309A1 (en) | 1993-12-03 | 1995-06-08 | Ferring B.V. | Dp-iv-serine protease inhibitors |
WO1995026342A1 (en) | 1994-03-28 | 1995-10-05 | Rhone-Poulenc Rorer S.A. | 5H-INDENO[1,2-b]PYRAZINE-2,3-DIONE DERIVATIVES, PREPARATION THEREOF AND DRUGS CONTAINING SAME |
WO1995026350A1 (en) | 1994-03-28 | 1995-10-05 | Rhone-Poulenc Rorer S.A. | Imidazo(1,2-a)indeno(1,2-e)pyrazine-4-one derivatives and pharmaceutical compositions containing same |
WO1995026349A1 (en) | 1994-03-28 | 1995-10-05 | Rhone-Poulenc Rorer S.A. | INDENO[1,2-e]PYRAZINE-4-ONES, PREPARATION THEREOF AND DRUGS CONTAINING SAME |
WO1995026352A1 (en) | 1994-03-28 | 1995-10-05 | Rhone-Poulenc Rorer S.A. | IMIDAZO[1,2-a]PYRAZINE-4-ONE DERIVATIVES, PREPARATION THEREOF AND DRUGS CONTAINING SAME |
JPH07267988A (en) | 1994-03-31 | 1995-10-17 | Yamanouchi Pharmaceut Co Ltd | New peptide |
WO1995031986A1 (en) | 1994-05-24 | 1995-11-30 | Astra Aktiebolag | Combination product of dichloroacetic acid and an nmda antagonist |
WO1996008485A1 (en) | 1994-09-13 | 1996-03-21 | Pfizer Limited | Quinoxalinedione nmda receptor antagonists |
WO1996012490A1 (en) | 1994-10-20 | 1996-05-02 | Eli Lilly And Company | Methods of inhibiting conditions associated with neuropeptide y |
WO1996012489A1 (en) | 1994-10-20 | 1996-05-02 | Eli Lilly And Company | Bicyclic neuropeptide y receptor antagonists |
US5567714A (en) | 1994-10-20 | 1996-10-22 | Eli Lilly And Company | Methods of treating obesity by inhibiting physiological conditions associated with an excess of neuropeptide Y |
US5663192A (en) | 1994-10-20 | 1997-09-02 | Eli Lilly And Company | Heterocyclic neuropeptide Y receptor antagonists |
WO1996014318A1 (en) | 1994-11-02 | 1996-05-17 | Rhone-Poulenc Rorer S.A. | SPIRO[HETEROCYCLE-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZINE]-4'-ONES, PREPARATION THEREOF AND DRUGS CONTAINING SAME |
WO1996020946A1 (en) | 1994-12-29 | 1996-07-11 | Research Development Foundation | Flavin adenine dinucleotide analogues, their pharmaceutical compositions, and their activity as monoamine oxidase inhibitors |
WO1996021655A2 (en) | 1995-01-11 | 1996-07-18 | Hoechst Marion Roussel, Inc. | Substituted oxazolidine calpain and/or cathepsin b inhibitors |
WO1996022305A2 (en) | 1995-01-12 | 1996-07-25 | The Wellcome Foundation Limited | Modified peptides |
WO1996025435A1 (en) | 1995-02-14 | 1996-08-22 | Bayer Corporation | MONOCLONAL ANTIBODY SPECIFIC FOR βA4 PEPTIDE |
US5552411A (en) | 1995-05-26 | 1996-09-03 | Warner-Lambert Company | Sulfonylquinolines as central nervous system and cardiovascular agents |
EP0747357A2 (en) | 1995-06-07 | 1996-12-11 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: piperidine derivatives |
EP0747356A1 (en) | 1995-06-07 | 1996-12-11 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: piperazine derivatives |
EP0747378A1 (en) | 1995-06-07 | 1996-12-11 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists |
WO1996040660A1 (en) | 1995-06-07 | 1996-12-19 | Pfizer Inc. | Certain substituted benzylamine derivatives: a new class of neuropeptide y1 specific ligands |
JPH0940693A (en) | 1995-07-31 | 1997-02-10 | Gekkeikan Sake Co Ltd | Inhibitor of prolyl endopeptidase |
WO1997009308A1 (en) | 1995-09-01 | 1997-03-13 | Eli Lilly And Company | Indolyl neuropeptide y receptor antagonists |
WO1997012615A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Benzimidazole derivatives as 15-lo inhibitors |
WO1997013754A1 (en) | 1995-10-11 | 1997-04-17 | Pelayo Camps Garcia | Novel polycyclic aminopyridine compounds as acetylcholinesterase inhibitors, preparation process and use thereof |
WO1997019914A1 (en) | 1995-11-30 | 1997-06-05 | Dr. Karl Thomae Gmbh | Amino acid derivatives, medicaments containing said compounds and methods of producing said compounds |
WO1997019913A1 (en) | 1995-11-30 | 1997-06-05 | Dr. Karl Thomae Gmbh | Amino acid derivatives, medicaments containing said compounds and methods of producing them |
WO1997019911A1 (en) | 1995-11-30 | 1997-06-05 | Dr. Karl Thomae Gmbh | Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them |
WO1997020821A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl derivatives |
WO1997020823A2 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | 2-amino quinazoline derivatives as npy receptor antagonists |
WO1997020820A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl compounds |
WO1997019682A1 (en) | 1995-12-01 | 1997-06-05 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
WO1997020822A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Quinazolin-2,4-diazirines as npy receptor antagonist |
JPH09157253A (en) | 1995-12-12 | 1997-06-17 | Yamanouchi Pharmaceut Co Ltd | New amino acid derivative |
WO1997023215A1 (en) | 1995-12-22 | 1997-07-03 | Warner-Lambert Company | 2-substituted piperidine analogs and their use as subtype-selective nmda receptor antagonists |
WO1997023216A1 (en) | 1995-12-22 | 1997-07-03 | Warner-Lambert Company | 4-substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
WO1997023214A1 (en) | 1995-12-22 | 1997-07-03 | Warner-Lambert Company | 4-substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
WO1997025041A1 (en) | 1996-01-09 | 1997-07-17 | Eli Lilly And Company | Benzimidzolyl neuropeptide y receptor antagonists |
WO1997032873A1 (en) | 1996-03-09 | 1997-09-12 | Pfizer Research And Development Company, N.V./S.A. | Quinoxalinediones |
WO1997034843A1 (en) | 1996-03-22 | 1997-09-25 | Libbey Glass Inc. | Apparatus and method for forming a decorative pattern on glassware having an edge |
WO1997038993A1 (en) | 1996-04-12 | 1997-10-23 | Hoechst Marion Roussel, Inc. | Isatin derivatives as acetylcholinesterase inhibitors and analgesics |
WO1997040832A1 (en) | 1996-04-25 | 1997-11-06 | Probiodrug Gesellschaft für Arzneimittelforschung mbH | Use of dipeptidyl peptidase iv effectors for lowering the blood glucose level in mammals |
WO1997046250A1 (en) | 1996-06-04 | 1997-12-11 | Synaptic Pharmaceutical Corporation | Methods of modifying feeding behavior, compounds useful in such methods, and dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5) |
WO1998001157A1 (en) | 1996-07-05 | 1998-01-15 | The Wwk Trust | Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter |
WO1998003493A1 (en) | 1996-07-23 | 1998-01-29 | Neurogen Corporation | Certain substituted benzylamine derivatives; a new class of neuropeptide-y1 specific ligands |
WO1998003492A1 (en) | 1996-07-23 | 1998-01-29 | Neurogen Corporation | Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands |
WO1998003494A1 (en) | 1996-07-23 | 1998-01-29 | Neurogen Corporation | Certain amido- and amino-substituted benzylamine derivatives; a new class of neuropeptite y1 specific ligands |
WO1998005337A1 (en) | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
WO1998006703A1 (en) | 1996-08-14 | 1998-02-19 | Warner-Lambert Company | 2-phenyl benzimidazole derivatives as mcp-1 antagonists |
WO1998007420A1 (en) | 1996-08-23 | 1998-02-26 | Agouron Acquisition Corp. | Neuropeptide-y ligands |
JPH1077300A (en) | 1996-09-04 | 1998-03-24 | Gekkeikan Sake Co Ltd | Prolyl endopeptidase-inhibiting peptide |
WO1998010757A2 (en) | 1996-09-11 | 1998-03-19 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | The use of functional n-methyl-d-aspartate antagonists to ameliorate or prevent aminoglycoside-induced ototoxicity |
WO1998015647A1 (en) | 1996-10-08 | 1998-04-16 | Novartis Ag | Modulation of apoptosis |
US6114336A (en) | 1996-10-23 | 2000-09-05 | Sanofi | Cosmetic composition containing a neuropeptide Y receptor antagonist |
US6011155A (en) | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
US6124305A (en) | 1996-11-07 | 2000-09-26 | Novartis Ag | Use of N-(substituted glycyl)-2-cyanopyrrolidines in inhibiting dipeptidyl peptidase-IV |
WO1998019998A2 (en) | 1996-11-07 | 1998-05-14 | Novartis Ag | N-substituted 2-cyanopyrrolidines |
WO1998030243A1 (en) | 1997-01-08 | 1998-07-16 | Warner-Lambert Company | Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease |
US6426365B1 (en) | 1997-02-12 | 2002-07-30 | Japan Tobacco Inc. | CETP activity inhibitors |
WO1998040102A1 (en) | 1997-03-13 | 1998-09-17 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Cytoprotective agents comprising monoamine oxidase inhibitors |
WO1998044955A1 (en) | 1997-04-09 | 1998-10-15 | Mindset Ltd. | Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof |
WO1998046559A1 (en) | 1997-04-16 | 1998-10-22 | Arqule, Inc. | SYNTHESIS AND USE OF α-KETOAMIDE DERIVATIVES AND ARRAYS |
WO1998050075A1 (en) | 1997-05-07 | 1998-11-12 | Algos Pharmaceutical Corporation | Cox-2 inhibitors in combination with nmda-blockers for treating pain |
WO1998050044A1 (en) | 1997-05-07 | 1998-11-12 | Algos Pharmaceutical Corporation | Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain |
WO1999001416A2 (en) | 1997-06-30 | 1999-01-14 | Merz + Co. Gmbh & Co. | 1-amino-alkylcyclohexane nmda receptor antagonists |
WO1999007351A2 (en) | 1997-08-07 | 1999-02-18 | Zeneca Limited | Indole derivatives and their use as mcp-1 antagonists |
WO1999007359A1 (en) | 1997-08-08 | 1999-02-18 | Shire International Licensing B.V. | Use of cholinesterase inhibitors for treating attention deficit disorders |
WO1999007413A1 (en) | 1997-08-11 | 1999-02-18 | Algos Pharmaceutical Corporation | Substance p inhibitors in combination with nmda-blockers for treating pain |
WO1999013878A1 (en) | 1997-09-18 | 1999-03-25 | Astrazeneca Ab | A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST |
WO1999015498A1 (en) | 1997-09-23 | 1999-04-01 | Astrazeneca Ab | New npy antagonists |
WO1999027944A1 (en) | 1997-12-02 | 1999-06-10 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
WO1999038501A2 (en) | 1998-02-02 | 1999-08-05 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
WO1999046272A1 (en) | 1998-03-09 | 1999-09-16 | Fondatech Benelux N.V. | Serine peptidase modulators |
WO1999045963A1 (en) | 1998-03-13 | 1999-09-16 | Algos Pharmaceutical Corporation | Analgesic combination comprising nmda receptor antagonists and narcotic analgesics |
WO1999047131A2 (en) | 1998-03-16 | 1999-09-23 | Merck Sharp & Dohme Limited | Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor |
WO1999046991A1 (en) | 1998-03-17 | 1999-09-23 | University Of Maryland Biotechnology Institute | Methods for treating hiv-associated dementia |
WO1999048891A1 (en) | 1998-03-20 | 1999-09-30 | Merck Patent Gmbh | 1-(3-heteroarylpropyl- or -prop-2-enyl)-4-benzylpiperidines used as nmda receptor antagonists |
WO1999053922A1 (en) | 1998-04-21 | 1999-10-28 | Algos Pharmaceutical Corporation | Analgesic compositions comprising nmda-antagonists and abt-594 |
WO1999057119A1 (en) | 1998-05-04 | 1999-11-11 | Neotherapeutics, Inc. | Novel dopamine-like 9-substituted hypoxanthine and methods of use |
WO1999057120A1 (en) | 1998-05-04 | 1999-11-11 | Neotherapeutics, Inc. | Novel serotonin-like 9-substituted hypoxanthine and methods of use |
WO1999060024A1 (en) | 1998-05-21 | 1999-11-25 | The University Of Tennessee Research Corporation | Methods for amyloid removal using anti-amyloid antibodies |
WO1999061431A1 (en) | 1998-05-28 | 1999-12-02 | Probiodrug Gesellschaft für Arzneimittelforschung mbH | New dipeptidyl peptidase iv effectors |
WO1999067278A1 (en) | 1998-06-24 | 1999-12-29 | Probiodrug Gesellschaft für Arzneimittelforschung mbH | Prodrugs of dipeptidyl peptidase iv inhibitors |
WO1999067279A1 (en) | 1998-06-24 | 1999-12-29 | Probiodrug Gesellschaft für Arzneimittelforschung mbH | Compounds of unstable dipeptidyl peptidase iv inhibitors |
WO2000000197A1 (en) | 1998-06-26 | 2000-01-06 | Warner-Lambert Company | 4-benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective nmda receptor antagonists |
DE19834591A1 (en) | 1998-07-31 | 2000-02-03 | Probiodrug Ges Fuer Arzneim | Use of substances that decrease the activity of dipeptidyl peptidase IV to increase blood sugar levels, e.g. for treating hypoglycemia |
WO2000015205A2 (en) | 1998-09-11 | 2000-03-23 | Eisai Co., Ltd. | Use of acetylcholinesterase inhibitors for the preparation of pharmaceutical compositions for the treatment of functional and/or organic pain syndromes |
WO2000029023A1 (en) | 1998-11-12 | 2000-05-25 | Algos Pharmaceutical Corporation | Cox-2 inhibitors in combination with nmda-blockers for treating pain |
WO2000030674A1 (en) | 1998-11-26 | 2000-06-02 | Ferring Bv | Neuropeptide y y4 agents in the treatment of reproductive disorders |
WO2000046199A2 (en) | 1999-02-05 | 2000-08-10 | Astrazeneca Ab | Indole derivatives as anti-inflammation agents |
WO2000046195A1 (en) | 1999-02-05 | 2000-08-10 | Astrazeneca Ab | Anti-inflammatory indole derivatives |
WO2000046197A1 (en) | 1999-02-05 | 2000-08-10 | Astrazeneca Ab | Indole derivatives and their use as mcp-1 receptor antagonists |
WO2000046198A1 (en) | 1999-02-05 | 2000-08-10 | Astrazeneca Ab | Anti-inflammatory indole derivatives |
WO2000046196A1 (en) | 1999-02-05 | 2000-08-10 | Astrazeneca Ab | Indole derivatives and their use as mcp-1 antagonists |
WO2000056711A1 (en) | 1999-03-23 | 2000-09-28 | Sumitomo Pharmaceuticals Co., Ltd. | Tricyclic indole-2-carboxylic acid compound used as nmda receptor antagonist |
WO2000063250A1 (en) | 1999-04-15 | 2000-10-26 | Merck Frosst Canada & Co. | Antibodies that recognize app cleaved by caspases and methods of use |
US6121311A (en) | 1999-04-28 | 2000-09-19 | Japan Tobacco Inc. | Method for treating cocainism |
WO2000068197A1 (en) | 1999-05-05 | 2000-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | 3a,4,5,9b-TETRAHYDRO-1H-BENZ[e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS |
WO2000071144A1 (en) | 1999-05-19 | 2000-11-30 | Domer, Inc. | Prolyl endopeptidase inhibitor |
WO2000072880A2 (en) | 1999-05-28 | 2000-12-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
WO2000077178A1 (en) | 1999-06-16 | 2000-12-21 | Boston Biomedical Research Institute | IMMUNOLOGICAL CONTROL OF β-AMYLOID LEVELS IN VIVO |
US6172081B1 (en) | 1999-06-24 | 2001-01-09 | Novartis Ag | Tetrahydroisoquinoline 3-carboxamide derivatives |
US6107317A (en) | 1999-06-24 | 2000-08-22 | Novartis Ag | N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
US6110949A (en) | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
WO2001000215A1 (en) | 1999-06-25 | 2001-01-04 | Wake Forest University | Compositions for treating or preventing neurodegeneration and cognitive decline |
US6316449B1 (en) | 1999-07-08 | 2001-11-13 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists |
WO2001010831A1 (en) | 1999-08-06 | 2001-02-15 | Grünenthal GmbH | Substituted pyrrolidin-2,3,4-trion-3-oxime derivatives useful as nmda-receptor antagonists |
WO2001010833A1 (en) | 1999-08-06 | 2001-02-15 | Grünenthal GmbH | Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain |
WO2001012598A2 (en) | 1999-08-13 | 2001-02-22 | The Trustees Of Columbia University In The City Of New York | METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
WO2001012176A2 (en) | 1999-08-16 | 2001-02-22 | Sanofi-Synthelabo | Use of monoamine oxidase inhibitors for the manufacture of drugs intended for the treatment of obesity |
WO2001014318A2 (en) | 1999-08-24 | 2001-03-01 | Probiodrug Ag | New effectors of dipeptidyl peptidase iv for topical use |
WO2001026656A2 (en) | 1999-10-11 | 2001-04-19 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | 5-membered heterocycle derivatives and use thereof as monoamine oxidase inhibitors |
WO2001032640A1 (en) | 1999-11-01 | 2001-05-10 | Merz Pharmaceuticals Gmbh | 1-cyclic amino-alkylcyclohexane compounds, pharmaceutical compositions thereof, and their use as anticonvulsants |
WO2001034594A1 (en) | 1999-11-12 | 2001-05-17 | Guilford Pharmaceuticals, Inc. | Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors |
WO2001040180A2 (en) | 1999-11-30 | 2001-06-07 | Ferring Bv | N-substituted 2-cyanopyrrolidines and their use as antidiabetic agents |
WO2001053255A1 (en) | 2000-01-24 | 2001-07-26 | Merck Sharp & Dohme Limited | Gamma-secretase inhibitors |
WO2001055105A1 (en) | 2000-01-24 | 2001-08-02 | Novo Nordisk A/S | N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv |
US6756511B2 (en) | 2000-01-24 | 2004-06-29 | Merck Sharp & Dohme Limited | Gamma-secretase inhibitors |
WO2001057226A1 (en) | 2000-02-03 | 2001-08-09 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use therefor |
WO2001062801A2 (en) | 2000-02-24 | 2001-08-30 | Washington University | Humanized antibodies that sequester amyloid beta peptide |
EP1263774A2 (en) | 2000-03-03 | 2002-12-11 | MERCK SHARP & DOHME LTD. | Gamma-secretase inhibitors |
WO2001066564A2 (en) | 2000-03-03 | 2001-09-13 | Merck Sharp & Dohme Limited | Gamma-secretase inhibitors |
US7049296B2 (en) | 2000-03-03 | 2006-05-23 | Merck Sharp & Dohme Ltd. | Gamma-secretase inhibitors |
WO2001066096A2 (en) | 2000-03-06 | 2001-09-13 | Immune Network Ltd. | Compositions for prevention and treatment of dementia |
WO2001068603A2 (en) | 2000-03-10 | 2001-09-20 | Bristol-Myers Squibb Co. | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use |
US6992081B2 (en) | 2000-03-23 | 2006-01-31 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
US7030239B2 (en) | 2000-03-23 | 2006-04-18 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
WO2001077144A1 (en) | 2000-04-07 | 2001-10-18 | Merck Sharp & Dohme Limited | Gamma-secretase inhibitors |
US6984626B2 (en) | 2000-04-07 | 2006-01-10 | Merck, Sharp & Dohme Ltd. | Gamma-secretase inhibitors |
WO2001078728A1 (en) | 2000-04-13 | 2001-10-25 | Eisai Co., Ltd. | Acetylcholinesterase inhibitors containing 1-benzyl- pyridinium salts |
WO2001081337A1 (en) | 2000-04-26 | 2001-11-01 | Ferring B.V. | Inhibitors of dipeptidyl peptidase iv |
WO2001081304A1 (en) | 2000-04-26 | 2001-11-01 | Ferring Bv | Inhibitors of dipeptidyl peptidase iv |
WO2001081295A1 (en) | 2000-04-26 | 2001-11-01 | Warner-Lambert Company | Cyclohexylamine derivative as subtype selective nmda receptor antagonists |
WO2001085145A2 (en) | 2000-05-09 | 2001-11-15 | Pfizer Products Inc. | A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal |
WO2001092204A1 (en) | 2000-06-01 | 2001-12-06 | Warner-Lambert Company | Cyclohexylamine derivatives as subtype selective nmda receptor antagonists |
WO2001094321A1 (en) | 2000-06-06 | 2001-12-13 | Warner-Lambert Company | Bicyclic cyclohexylamines and their use as nmda receptor antagonists |
WO2001098289A1 (en) | 2000-06-22 | 2001-12-27 | Pharmos Corporation | Novel non-psychotropic cannabinoids |
WO2001098262A1 (en) | 2000-06-23 | 2001-12-27 | Merck Sharp & Dohme Limited | Amidine derivatives as selective antagonists of nmda receptors |
US6713276B2 (en) | 2000-06-28 | 2004-03-30 | Scios, Inc. | Modulation of Aβ levels by β-secretase BACE2 |
US7034182B2 (en) | 2000-06-30 | 2006-04-25 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
US6686449B2 (en) | 2000-06-30 | 2004-02-03 | Pharmacia & Upjohn Company | Mutant presenilin 1 polypeptides |
WO2002002560A2 (en) | 2000-07-04 | 2002-01-10 | Novo Nordisk A/S | Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv) |
US6448229B2 (en) | 2000-07-06 | 2002-09-10 | Merck Sharp & Dohme Ltd. | Gamma secretase inhibitors |
WO2002021509A1 (en) | 2000-09-01 | 2002-03-14 | Snap-On Technologies, Inc. | Computer-implemented speech recognition system training |
WO2002027418A2 (en) | 2000-09-25 | 2002-04-04 | Motorwiz, Inc. | Model-based machine diagnostics and prognostics using theory of noise and communications |
WO2002032412A2 (en) | 2000-10-17 | 2002-04-25 | Pfizer Products Inc. | Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders |
WO2002034718A1 (en) | 2000-10-24 | 2002-05-02 | Richter Gedeon Vegyeszeti Gyar Rt. | Amide derivatives as nmda receptor antagonists |
WO2002036555A1 (en) | 2000-11-02 | 2002-05-10 | Merck Sharp & Dohme Limited | Sulfamides as gamma-secretase inhibitors |
EP1334085A1 (en) | 2000-11-02 | 2003-08-13 | Merck Sharp & Dohme Ltd. | Sulfamides as gamma-secretase inhibitors |
WO2002041842A2 (en) | 2000-11-03 | 2002-05-30 | Proteotech. Inc. | Antibody pti-hs7 for treatment of alzheimer's disease and other amyloidoses and parkinson's disease |
WO2002038541A1 (en) | 2000-11-10 | 2002-05-16 | Taisho Pharmaceutical Co., Ltd. | Cyanopyrrolidine derivatives |
WO2002046237A2 (en) | 2000-12-06 | 2002-06-13 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
WO2002046222A2 (en) | 2000-12-07 | 2002-06-13 | Mario Chojkier | Compositions and methods for diagnosing alzheimer's disease |
WO2002060900A2 (en) | 2001-01-31 | 2002-08-08 | Telik, Inc. | Antagonists of mcp-1 function and methods of use thereof |
US6670364B2 (en) | 2001-01-31 | 2003-12-30 | Telik, Inc. | Antagonists of MCP-1 function and methods of use thereof |
WO2002070509A2 (en) | 2001-03-01 | 2002-09-12 | Telik, Inc. | Antagonists of mcp-1 function and methods of use thereof |
WO2002072542A2 (en) | 2001-03-08 | 2002-09-19 | Emory University | Ph-dependent nmda receptor antagonists |
US6649196B2 (en) | 2001-03-12 | 2003-11-18 | Mayo Foundation For Medical Education And Research | Methods of reducing β-amyloid polypeptides |
WO2002074240A2 (en) | 2001-03-16 | 2002-09-26 | Cornell Research Foundation, Inc. | Anti-amyloid antibody based diagnosis and treatment of a neurological disease or disorder |
US6677365B2 (en) | 2001-04-03 | 2004-01-13 | Telik, Inc. | Antagonists of MCP-1 function and methods of use thereof |
WO2002081463A1 (en) | 2001-04-03 | 2002-10-17 | Telik, Inc. | Antagonists of mcp-1 function and methods of use thereof |
WO2002083128A1 (en) | 2001-04-12 | 2002-10-24 | Bristol-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and method |
WO2002088307A2 (en) | 2001-04-30 | 2002-11-07 | Eli Lilly And Company | Humanized antibodies |
WO2002088306A2 (en) | 2001-04-30 | 2002-11-07 | Eli Lilly And Company | Humanized antibodies |
EP1258476A1 (en) | 2001-05-15 | 2002-11-20 | Les Laboratoires Servier | Alpha-amino acid derivatives, method for their preparation and their use as dipeptidyl-peptidase IV inhibitors (DPP IV) |
WO2002094881A2 (en) | 2001-05-18 | 2002-11-28 | Krka Tovarna Zdravil, D.D., Novo Mesto | Monoclonal antibody neutralising cathepsin b activity and uses thereof |
WO2002096937A2 (en) | 2001-05-29 | 2002-12-05 | Neurochem, Inc. | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
US6562783B2 (en) | 2001-05-30 | 2003-05-13 | Neurologic, Inc. | Phosphinylmethyl and phosphorylmethyl succinic and glutauric acid analogs as β-secretase inhibitors |
WO2002096897A1 (en) | 2001-05-30 | 2002-12-05 | Neurologic, Inc. | PHOSPHINYLMETHYL AND PHOSPHORYLMETHYL SUCCINIC AND GLUTARIC ACID ANALOGS AS β-SECRETASE INHIBITORS |
WO2002098849A2 (en) | 2001-06-01 | 2002-12-12 | Elan Pharmaceuticals, Inc. | Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer’s disease and similar diseases |
WO2003000180A2 (en) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
WO2003000181A2 (en) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
WO2003000250A1 (en) | 2001-06-25 | 2003-01-03 | Ferring Bv | 3-fluoro-pyrrolidines as antidiabetic agents |
WO2003002531A2 (en) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
WO2003002530A2 (en) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Pyrrolidines as dipeptidyl peptidase inhibitors |
WO2003072556A1 (en) | 2001-06-27 | 2003-09-04 | Prosidion Ltd. | Glutaminyl based dpiv inhibitors |
WO2003002553A2 (en) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
WO2003002593A2 (en) | 2001-06-27 | 2003-01-09 | Probiodrug Ag | Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis |
US6982264B2 (en) | 2001-06-27 | 2006-01-03 | Elan Pharmaceuticals, Inc. | Substituted alcohols useful in treatment of Alzheimer's disease |
WO2003004496A1 (en) | 2001-07-03 | 2003-01-16 | Novo Nordisk A/S | Dpp-iv-inhibiting purine derivatives for the treatment of diabetes |
WO2003004498A1 (en) | 2001-07-06 | 2003-01-16 | Merck & Co., Inc. | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2003010159A1 (en) | 2001-07-24 | 2003-02-06 | Richter Gedeon Vegyészeti Gyár Rt. | Piperidine derivatives as nmda receptor antagonists |
WO2003012141A1 (en) | 2001-07-31 | 2003-02-13 | Takeda Chemical Industries, Ltd. | Method of screening alzheimer’s disease-associated gene |
US6683091B2 (en) | 2001-08-03 | 2004-01-27 | Schering Corporation | Gamma Secretase inhibitors |
WO2003014162A1 (en) | 2001-08-03 | 2003-02-20 | Medical & Biological Laboratories Co., Ltd. | ANTIBODY RECOGNIZING GM1 GANGLIOSIDE-BOUND AMYLOID β-PROTEIN AND DNA ENCODING THE ANTIBODY |
US7122675B2 (en) | 2001-08-03 | 2006-10-17 | Schering Corporation | Gamma secretase inhibitors |
WO2003013527A1 (en) | 2001-08-03 | 2003-02-20 | Schering Corporation | Sulfonamide derivatives as gamma secretase inhibitors |
WO2003014075A2 (en) | 2001-08-03 | 2003-02-20 | Schering Corporation | Novel gamma secretase inhibitors |
WO2003015691A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | RAPID IMPROVEMENT OF COGNITION IN CONDITIONS RELATED TO A$g(b) |
WO2003016466A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | ANTI-Aβ ANTIBODIES |
WO2003020289A1 (en) | 2001-08-30 | 2003-03-13 | Ortho-Mcneil Pharmaceutical, Inc. | Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors |
WO2003024942A1 (en) | 2001-09-14 | 2003-03-27 | Mitsubishi Pharma Corporation | Thiazolidine derivative and medicinal use thereof |
WO2003024965A2 (en) | 2001-09-19 | 2003-03-27 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme dpp-iv |
WO2003033524A2 (en) | 2001-10-12 | 2003-04-24 | Probiodrug Ag | Peptidyl ketones as inhibitors of dpiv |
WO2003039454A2 (en) | 2001-10-23 | 2003-05-15 | Oklahoma Medical Research Foundation | Beta-secretase inhibitors and methods of use |
WO2003035057A1 (en) | 2001-10-23 | 2003-05-01 | Ferring B.V. | Inhibitors of dipeptidyl peptidase iv |
WO2003035067A1 (en) | 2001-10-23 | 2003-05-01 | Ferring B.V. | Novel dipeptidyl peptidase iv (dp-iv) inhibitors as anti-diabetic agents |
WO2003037327A1 (en) | 2001-10-26 | 2003-05-08 | F. Hoffmann-La-Roche Ag | N-substituted pyrrolidin derivatives as dipeptidyl peptidase iv inhibitors |
WO2003037376A1 (en) | 2001-11-02 | 2003-05-08 | Kensuke Egashira | Preventives and/or remedies for post-transplant arteriosclerosis as rejection of organ transplant |
WO2003039467A2 (en) | 2001-11-02 | 2003-05-15 | Diagenics International Corporation | Monoclonal antibodies specific for beta-amyloid. |
WO2003040183A2 (en) | 2001-11-09 | 2003-05-15 | The Genetics Company, Inc | Compounds for the diagnosis/prevention/treatment of alzheimer's disease |
WO2003040174A2 (en) | 2001-11-09 | 2003-05-15 | Probiodrug Ag | Substituted amino ketone compounds |
WO2003043987A2 (en) | 2001-11-19 | 2003-05-30 | Elan Pharmaceuticals, Inc. | (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2003045128A2 (en) | 2001-11-21 | 2003-06-05 | New York University | SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID β, PRION PROTEIN, AMYLIN, α-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO |
WO2003045977A2 (en) | 2001-11-26 | 2003-06-05 | Trustees Of Tufts College | Peptidomimetic Inhibitors of Post-Proline Cleaving Enzymes |
WO2003048204A1 (en) | 2001-12-06 | 2003-06-12 | Takeda Chemical Industries, Ltd. | Alzheimer’s disease-associated gene and protein and use thereof |
WO2003051374A2 (en) | 2001-12-17 | 2003-06-26 | New York State Office Of Mental Health | SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES |
WO2003053368A2 (en) | 2001-12-19 | 2003-07-03 | Atherogenics, Inc. | Chalcone derivatives and their use to treat diseases |
WO2003055514A1 (en) | 2001-12-21 | 2003-07-10 | Antigenics Inc. | Compositions comprising immunoreactive reagents and saponins, and methods of use thereof |
WO2003057144A2 (en) | 2001-12-26 | 2003-07-17 | Guilford Pharmaceuticals | Change inhibitors of dipeptidyl peptidase iv |
WO2003057666A2 (en) | 2001-12-26 | 2003-07-17 | Guilford Pharmaceuticals | Inhibitors of dipeptidyl peptidase iv |
WO2003055881A1 (en) | 2001-12-27 | 2003-07-10 | F. Hoffmann-La Roche Ag | Pyrido(2,1-a)isoquinoline derivatives as dpp-iv inhibitors |
WO2003057204A2 (en) | 2002-01-08 | 2003-07-17 | Nordic Bioscience A/S | Modulation of iamt (pimt or pcmt) in immune system |
WO2003059346A1 (en) | 2002-01-18 | 2003-07-24 | The Genetics Company Inc. | Beta-secretase inhibitors |
WO2003063760A2 (en) | 2002-01-31 | 2003-08-07 | Tel Aviv University Future Technology Development L.P. | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases |
WO2003066592A1 (en) | 2002-02-06 | 2003-08-14 | Schering Corporation | Gamma secretase inhibitors |
WO2003068757A1 (en) | 2002-02-13 | 2003-08-21 | F. Hoffmann-La Roche Ag | Novel pyridin- and pyrimidin-derivatives |
WO2003068748A1 (en) | 2002-02-13 | 2003-08-21 | F. Hoffmann-La Roche Ag | Novel pyridine- and quinoline-derivatives |
WO2003070760A2 (en) | 2002-02-20 | 2003-08-28 | F. Hoffmann-La Roche Ag | Anti-amyloid beta antibodies and their use |
WO2003074081A1 (en) | 2002-02-28 | 2003-09-12 | Mindset Biopharmaceuticals Usa Inc. | SPECIFIC ANTIBODIES TO AMYLOID β PEPTIDE, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF |
WO2003074500A2 (en) | 2002-03-06 | 2003-09-12 | Sanofi-Aventis | N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors |
WO2003077858A2 (en) | 2002-03-12 | 2003-09-25 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
WO2003082817A2 (en) | 2002-03-25 | 2003-10-09 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2003082820A1 (en) | 2002-03-29 | 2003-10-09 | Eisai Co., Ltd. | (1-indanone)-(1,2,3,6-tetrahydropyridine) derivative |
WO2003086310A2 (en) | 2002-04-12 | 2003-10-23 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
WO2003089460A1 (en) | 2002-04-19 | 2003-10-30 | The Governing Council Of The University Of Toronto | Immunological methods and compositions for the treatment of alzheimer's disease |
WO2003091278A1 (en) | 2002-04-24 | 2003-11-06 | Hiroshi Mori | Gamma-secretase inhibitors |
WO2003091220A1 (en) | 2002-04-26 | 2003-11-06 | Schering Corporation | Muscarinic antagonists |
WO2003099202A2 (en) | 2002-05-17 | 2003-12-04 | Merck & Co., Inc. | Beta-secretase inhibitors |
WO2003101458A1 (en) | 2002-05-31 | 2003-12-11 | H. Lundbeck A/S | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
WO2003101449A2 (en) | 2002-06-04 | 2003-12-11 | Pfizer Products Inc. | Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof |
WO2003101958A2 (en) | 2002-06-04 | 2003-12-11 | Pfizer Products Inc. | Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors |
WO2003104229A1 (en) | 2002-06-06 | 2003-12-18 | エーザイ株式会社 | Novel fused imidazole derivative |
WO2003104437A2 (en) | 2002-06-11 | 2003-12-18 | Northwestern University | Anti-addl antibodies and uses thereof |
WO2004000958A1 (en) | 2002-06-19 | 2003-12-31 | Surface Specialties, S.A. | Semi-gloss powder coating compositions |
WO2004007446A1 (en) | 2002-07-10 | 2004-01-22 | Yamanouchi Pharmaceutical Co., Ltd. | Novel azetidine derivative or salt thereof |
WO2004007468A1 (en) | 2002-07-15 | 2004-01-22 | Merck & Co., Inc. | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
WO2004009062A2 (en) | 2002-07-19 | 2004-01-29 | Khalid Iqbal | NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau |
WO2004013098A1 (en) | 2002-08-05 | 2004-02-12 | Bristol-Myers Squibb Company | Novel gamma-lactams as beta-secretase inhibitors |
WO2004018468A2 (en) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments |
WO2004018467A2 (en) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Phenacyl xanthine derivatives as dpp-iv inhibitor |
WO2004018469A1 (en) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel purine derivatives, production and use thereof as medicaments |
WO2004024090A2 (en) | 2002-09-12 | 2004-03-25 | The Regents Of The University Of California | Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence |
WO2004024921A1 (en) | 2002-09-12 | 2004-03-25 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Human antihuman mcp-1 antibody and antibody fragment thereof |
WO2004024770A1 (en) | 2002-09-12 | 2004-03-25 | Universidad De Zaragoza | Polyclonal antibodies, preparation method thereof and use of same |
WO2004026822A2 (en) | 2002-09-19 | 2004-04-01 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv) |
WO2004026851A1 (en) | 2002-09-20 | 2004-04-01 | Axys Pharmaceuticals, Inc. | 3-(3,5-disubstituted-4-hydroxyphenyl)propionamide derivatives as cathepsin b inhibitors |
WO2004028522A1 (en) | 2002-09-25 | 2004-04-08 | Innovative Drug Delivery Systems, Inc. | Analgesic compositions comprising nmda receptor antagonists and benzalkonium chloride |
WO2004029630A1 (en) | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses |
WO2004029629A1 (en) | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
WO2004031400A2 (en) | 2002-10-01 | 2004-04-15 | Northwestern University | Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof |
US6890956B2 (en) | 2002-10-04 | 2005-05-10 | Merck Sharp & Dohme Limited | Cyclohexyl sulphones as gamma-secretase inhibitors |
WO2004031137A1 (en) | 2002-10-04 | 2004-04-15 | Merck Sharp & Dohme Limited | Cyclohexyl sulphone derivatives as gamma-secretase inhibitors |
US7101895B2 (en) | 2002-10-04 | 2006-09-05 | Merck Sharp & Dohme Limited | Cyclohexyl sulphone derivatives as gamma-secretase inhibitors |
WO2004031139A1 (en) | 2002-10-04 | 2004-04-15 | Merck Sharp & Dohme Limited | Cyclohexyl sulphones as gamma-secretase inhibitors |
WO2004032836A2 (en) | 2002-10-07 | 2004-04-22 | Merck & Co., Inc. | Antidiabetic beta-amino heterocylcic dipeptidyl peptidase inhibitors |
WO2004033455A2 (en) | 2002-10-08 | 2004-04-22 | Novo Nordisk A/S | Hemisuccinate salts of heterocyclic dpp-iv inhibitors |
WO2004032929A2 (en) | 2002-10-09 | 2004-04-22 | Neuropharma, S.A. | Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer’s disease |
WO2004032868A2 (en) | 2002-10-09 | 2004-04-22 | Rinat Neuroscience Corp. | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
WO2004037169A2 (en) | 2002-10-18 | 2004-05-06 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2004037234A2 (en) | 2002-10-24 | 2004-05-06 | Merz Pharma Gmbh & Co. Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
WO2004039371A2 (en) | 2002-10-29 | 2004-05-13 | Pharmacia Corporation | Compositions of cyclooxygenase-2 selective inhibitors and nmda receptor antagonists for the treatment or prevention of neuropathic pain |
WO2004039773A2 (en) | 2002-10-30 | 2004-05-13 | Nordic Bioscience A/S | Coumpounds modulating the activity of gapdh and/or iamt |
WO2004041795A1 (en) | 2002-10-30 | 2004-05-21 | Guilford Pharmaceuticals Inc. | Novel inhibitors of dipeptidyl peptidase iv |
WO2004039370A1 (en) | 2002-11-01 | 2004-05-13 | Merck Sharp & Dohme Limited | Sulfonamides, sulfamates and sulfamides as gamma-secretase inhibitors |
WO2004044204A2 (en) | 2002-11-06 | 2004-05-27 | Institut Pasteur | Variable fragments of single-chain camelide antibodies and uses thereof for diagnosing and treating various pathologies |
WO2004043940A1 (en) | 2002-11-07 | 2004-05-27 | Merck & Co., Inc. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2004043916A1 (en) | 2002-11-12 | 2004-05-27 | Merck & Co., Inc. | Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease |
US7109217B2 (en) | 2002-11-12 | 2006-09-19 | Merck & Co., Inc. | Phenylcarboxamide beta-secretase inhibitors for the treatment of Alzheimer's disease |
WO2004048352A2 (en) | 2002-11-27 | 2004-06-10 | Fujisawa Pharmaceutical Co., Ltd. | 2-cyanopyrrolidines and their analogues as dpp-iv inhibitors |
WO2004050022A2 (en) | 2002-12-04 | 2004-06-17 | Merck & Co., Inc. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2004052850A2 (en) | 2002-12-09 | 2004-06-24 | Bristol-Myers Squibb Company | Methods and compounds producing dipeptidyl peptidase iv inhibitors and intermediates thereof |
WO2004056727A2 (en) | 2002-12-19 | 2004-07-08 | Atherogenics, Inc. | Process of making chalcone derivatives |
WO2004058266A1 (en) | 2002-12-20 | 2004-07-15 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2004062625A2 (en) | 2003-01-07 | 2004-07-29 | Merck & Co., Inc. | Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease |
WO2004064778A2 (en) | 2003-01-17 | 2004-08-05 | Merck & Co. Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2004067561A1 (en) | 2003-01-31 | 2004-08-12 | Abbott Gmbh & Co. Kg | Amyloid-$g(b)(1-42) oligomers, derivatives thereof, antibodies for the same, method for production and use therof |
WO2004069162A2 (en) | 2003-01-31 | 2004-08-19 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2004069182A2 (en) | 2003-02-01 | 2004-08-19 | Neuralab Limited | Active immunization to generate antibodies to soluble a-beta |
WO2004069826A1 (en) | 2003-02-04 | 2004-08-19 | F. Hoffmann-La Roche Ag | Malonamide derivatives as gamma-secretase inhibitors |
WO2004071408A2 (en) | 2003-02-10 | 2004-08-26 | Applied Molecular Evolution, Inc. | Aβ BINDING MOLECULES |
WO2004071454A2 (en) | 2003-02-13 | 2004-08-26 | Guilford Pharmaceuticals Inc. | Substituted azetidine compounds as inhibitors of dipeptidyl peptidase iv |
WO2004073630A2 (en) | 2003-02-18 | 2004-09-02 | Roskamp Research Llc | Anti-angiogenic and anti-tumoral properties of beta and gamma secretase inhibitors |
WO2004076434A1 (en) | 2003-02-28 | 2004-09-10 | Aic | Dipeptidyl peptidase inhibitors |
WO2004076433A1 (en) | 2003-02-28 | 2004-09-10 | Aic | Dipeptidyl peptidase inhibitors |
WO2004078908A2 (en) | 2003-03-06 | 2004-09-16 | Santhera Pharmaceuticals (Schweiz) Gmbh | Alpha-keto carbonyl calpain inhibitors |
WO2004080419A2 (en) | 2003-03-12 | 2004-09-23 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
WO2004084830A2 (en) | 2003-03-21 | 2004-10-07 | Buck Institute | Method for treating alzheimer’s dementia |
WO2004084884A1 (en) | 2003-03-24 | 2004-10-07 | The Chinese University Of Hong Kong | Use of tanshinone derivates as cholinesterase inhibitors in treating related diseases |
WO2004087053A2 (en) | 2003-03-25 | 2004-10-14 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
WO2005028511A2 (en) | 2003-03-28 | 2005-03-31 | Centocor, Inc. | Anti-amyloid antibodies, compositions, methods and uses |
WO2004087158A2 (en) | 2003-03-28 | 2004-10-14 | Acadia Pharmaceuticals Inc. | Muscarinic m1 receptor agonists for pain management |
WO2004092189A1 (en) | 2003-04-09 | 2004-10-28 | Wyeth | Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists |
WO2004089911A1 (en) | 2003-04-10 | 2004-10-21 | Merck Sharp & Dohme Limited | Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of alzheimer’s disease |
WO2004089351A2 (en) | 2003-04-10 | 2004-10-21 | Cambridge University Technical Services Ltd | Treatment of progressive neurological disorders comprising a mao inhibitor (miclobemid) and an acetylcholinesterase inhibitor (tacrin) |
WO2004089362A1 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | 2-cyanopyrroles and their analogues as ddp-iv inhibitors |
WO2004098625A2 (en) | 2003-05-05 | 2004-11-18 | Probiodrug Ag | Medical use of inhibitors of glutaminyl and glutamate cyclases |
WO2004099134A2 (en) | 2003-05-05 | 2004-11-18 | Prosidion Ltd. | Glutaminyl based dp iv-inhibitors |
WO2004098591A2 (en) | 2003-05-05 | 2004-11-18 | Probiodrug Ag | Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases |
WO2004098631A1 (en) | 2003-05-08 | 2004-11-18 | Universidad De Zaragoza | Alzheimer's disease treatment method |
WO2004099185A1 (en) | 2003-05-09 | 2004-11-18 | Fujisawa Pharmaceutical Co. Ltd. | 2-cyanopyrrolidine derivatives and their use as dpp-iv inhibitors |
WO2004101562A2 (en) | 2003-05-13 | 2004-11-25 | Schering Corporation | Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors |
WO2004103993A1 (en) | 2003-05-14 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
WO2004103276A2 (en) | 2003-05-14 | 2004-12-02 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2004101538A1 (en) | 2003-05-16 | 2004-11-25 | Merck Sharp & Dohme Limited | Cyclohexyl sulphones as gamma-secretase inhibitors |
WO2005000216A2 (en) | 2003-05-27 | 2005-01-06 | Forest Laboratories, Inc. | Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders |
WO2004108895A2 (en) | 2003-05-30 | 2004-12-16 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
WO2004108730A1 (en) | 2003-06-05 | 2004-12-16 | Fujisawa Pharmaceutical Co., Ltd. | 1h-imidazo`4,5-d!pyridazines as dpp-iv inhibitors for the treatment of niddm |
WO2004110436A1 (en) | 2003-06-06 | 2004-12-23 | Merck & Co., Inc. | Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2004111041A1 (en) | 2003-06-12 | 2004-12-23 | Fujisawa Pharmaceutical Co., Ltd. | Pyrrolidine, thiazolidine and oxazolidine compounds which inhibit dipeptidyl peptidase-iv (dpp) |
WO2004112701A2 (en) | 2003-06-17 | 2004-12-29 | Merck & Co., Inc. | Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2005000846A1 (en) | 2003-06-20 | 2005-01-06 | F.Hoffmann-La Roche Ag | Hexahydropyridoisoqinolines as dpp-iv inhibitors |
WO2005000848A1 (en) | 2003-06-20 | 2005-01-06 | F. Hoffmann-La Roche Ag | Pyrido` 2, 1-a - isoquinoline derivatives as dpp-iv inhibitors |
WO2005000193A2 (en) | 2003-06-30 | 2005-01-06 | Tel Aviv University Future Technology Development L.P. | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases |
WO2005004802A2 (en) | 2003-06-30 | 2005-01-20 | Merck & Co., Inc. | N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2005004803A2 (en) | 2003-07-01 | 2005-01-20 | Merck & Co., Inc. | Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2005007614A1 (en) | 2003-07-03 | 2005-01-27 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services 6011 | Monoamine oxidase inhibitors |
WO2005007199A1 (en) | 2003-07-16 | 2005-01-27 | Rvx Therapeutics, Inc. | COMPOUNDS AND METHODS FOR DOWNREGULATING THE EFFECTS OF TGF-β |
WO2005008250A1 (en) | 2003-07-21 | 2005-01-27 | Angiogenetics Sweden Ab | Compounds and methods for promoting angiogenesis by using a gamma-secretase inhibitor or inhibiting the gamma-secretase pathway |
WO2005014041A2 (en) | 2003-07-24 | 2005-02-17 | Novartis Ag | Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases |
WO2005009421A2 (en) | 2003-07-28 | 2005-02-03 | Merz Pharma Gmbh & Co. Kgaa | The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity |
WO2005011581A2 (en) | 2003-07-31 | 2005-02-10 | Merck & Co., Inc. | Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
WO2005011599A2 (en) | 2003-08-01 | 2005-02-10 | Northwestern University | Antibodies specific for toxic amyloid beta protein oligomers |
WO2005014553A1 (en) | 2003-08-05 | 2005-02-17 | Merck Sharp & Dohme Limited | Novel gamma-secretase inhibitors |
WO2005016911A1 (en) | 2003-08-13 | 2005-02-24 | Takeda Pharmaceutical Company Limited | 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors |
WO2005018545A2 (en) | 2003-08-14 | 2005-03-03 | Merck & Co., Inc. | Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2005018424A2 (en) | 2003-08-18 | 2005-03-03 | Research Foundation For Mental Hygiene, Inc. | Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits |
WO2005023762A1 (en) | 2003-09-04 | 2005-03-17 | Abbott Laboratories | Pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv) |
WO2005023858A1 (en) | 2003-09-05 | 2005-03-17 | Cellzome Ag | Protein complexes associated with app-processing |
WO2005030751A2 (en) | 2003-09-08 | 2005-04-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2005026148A1 (en) | 2003-09-08 | 2005-03-24 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
WO2005025554A2 (en) | 2003-09-09 | 2005-03-24 | Japan Tobacco Inc. | Dipeptidyl peptidase iv inhibitor |
WO2005025616A1 (en) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | Use of antibody |
WO2005025516A2 (en) | 2003-09-12 | 2005-03-24 | The Regents Of The University Of California | Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates |
WO2005028440A1 (en) | 2003-09-16 | 2005-03-31 | Schering Corporation | Novel gamma secretase inhibitors |
WO2005027975A1 (en) | 2003-09-22 | 2005-03-31 | Pfizer Limited | Combinations of alpha-2-delta ligands and acetylcholinesterase inhibitors |
WO2005030731A1 (en) | 2003-09-24 | 2005-04-07 | Merck Sharp & Dohme Limited | Gamma-secretase inhibitors |
WO2005032471A2 (en) | 2003-10-03 | 2005-04-14 | Merck & Co., Inc. | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2005040126A1 (en) | 2003-10-06 | 2005-05-06 | F. Hoffman-La Roche Ag | Substituted dibenzo-azepine and benzo-diazepine derivatives useful as gamma-secretase inhibitors |
WO2005033106A1 (en) | 2003-10-06 | 2005-04-14 | Alangudi Sankaranarayanan | Azolidinecarbonitriles and their use as dpp-iv inhibitors |
WO2005035522A1 (en) | 2003-10-08 | 2005-04-21 | Pfizer Japan, Inc. | 1-‘2-(4-hydroxyphenyl)-2-hydroxyethyl!-piperidin-4-ol compounds as nmda receptor antagonists |
WO2005039548A2 (en) | 2003-10-15 | 2005-05-06 | Probiodrug Ag | Use of effectors of glutaminyl and glutamate cyclases |
WO2005039580A1 (en) | 2003-10-16 | 2005-05-06 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor |
WO2005040095A1 (en) | 2003-10-16 | 2005-05-06 | Astrazeneca Ab | Inhibitors of dipeptidyl peptidase iv |
WO2005037828A1 (en) | 2003-10-20 | 2005-04-28 | Lg Life Sciences Ltd. | Novel inhibitors of dpp-iv, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent |
WO2005079779A1 (en) | 2003-10-22 | 2005-09-01 | Merz Pharma Gmbh & Co. Kgaa | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES |
WO2006058720A2 (en) | 2003-11-03 | 2006-06-08 | Probiodrug Ag | Novel compounds for the treatment of neurological disorders |
WO2005044195A2 (en) | 2003-11-04 | 2005-05-19 | Merck & Co., Inc. | Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
WO2005044830A1 (en) | 2003-11-11 | 2005-05-19 | F. Hoffmann-La Roche Ag | Phosphinic acids derivatives, beta-secretase inhibitors for the treatment of alzheimer’s disease |
WO2005047297A1 (en) | 2003-11-12 | 2005-05-26 | Phenomix Corporation | Heterocyclic boronic acid compounds |
WO2005051914A1 (en) | 2003-11-24 | 2005-06-09 | Merck & Co., Inc. | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2005051950A1 (en) | 2003-11-27 | 2005-06-09 | Boehringer Ingelheim International Gmbh | Novel 8-(piperazine-1-yl)- and 8-([1,4]diazepan-1-yl)-xanthine, the production and use thereof in the from of a drug |
WO2005055996A1 (en) | 2003-12-05 | 2005-06-23 | Forest Laboratories, Inc. | Memantine for the prevention or reduction of suicidality and for treatment of major depression associated with suicidality |
WO2005056013A1 (en) | 2003-12-09 | 2005-06-23 | Santhera Pharmaceuticals (Schweiz) Gmbh | Dpp-iv inhibitors |
WO2005056003A1 (en) | 2003-12-09 | 2005-06-23 | Santhera Pharmaceuticals (Schweiz) Gmbh | Dpp-iv inhibitors |
WO2005058849A1 (en) | 2003-12-15 | 2005-06-30 | Glenmark Pharmaceuticals Ltd. | New dipeptidyl peptidase in inhibitors; process for their preparation and compositions containing them |
WO2005065195A2 (en) | 2003-12-19 | 2005-07-21 | Merck & Co., Inc. | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2005070429A1 (en) | 2004-01-22 | 2005-08-04 | Neurosearch A/S | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist |
WO2005072705A1 (en) | 2004-01-29 | 2005-08-11 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions |
WO2005075426A1 (en) | 2004-02-03 | 2005-08-18 | Glenmark Pharmaceuticals Ltd. | Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof |
WO2005075436A2 (en) | 2004-02-05 | 2005-08-18 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
WO2005079756A2 (en) | 2004-02-13 | 2005-09-01 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions |
WO2005079789A1 (en) | 2004-02-17 | 2005-09-01 | Axonyx, Inc. | Combinatorial therapy with an acetylcholinesterase inhibitor and (3ar)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate |
WO2005085246A1 (en) | 2004-02-18 | 2005-09-15 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthine, the production thereof and the use in the form of a dpp inhibitor |
WO2005081872A2 (en) | 2004-02-20 | 2005-09-09 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
WO2005080435A1 (en) | 2004-02-20 | 2005-09-01 | Immuno-Biological Laboratories Co., Ltd. | Monoclonal antibody and use thereof |
WO2005082348A2 (en) | 2004-02-23 | 2005-09-09 | Trustees Of Tufts College | Inhibitors of dipeptidylpeptidase iv for regulating glucose metabolism |
WO2005095343A1 (en) | 2004-03-05 | 2005-10-13 | Santhera Pharmaceuticals (Schweiz) Gmbh | Dpp-iv inhibitors |
WO2005087235A1 (en) | 2004-03-09 | 2005-09-22 | National Health Research Institutes | Pyrrolidine compounds |
WO2005095381A1 (en) | 2004-03-15 | 2005-10-13 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2005092009A2 (en) | 2004-03-19 | 2005-10-06 | Axonyx, Inc. | Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders |
WO2005095339A1 (en) | 2004-03-31 | 2005-10-13 | Pfizer Products Inc. | Dicyanopyrrolidines as dipeptidyl peptidase iv inhibitors |
WO2005097103A2 (en) | 2004-04-01 | 2005-10-20 | Axys Pharmaceuticals, Inc. | Diabetes and metabolic syndrome therapy utilizing cathepsin b inhibitors |
WO2005097768A2 (en) | 2004-04-05 | 2005-10-20 | Schering Corporation | Novel gamma secretase inhibitors |
WO2005103043A1 (en) | 2004-04-20 | 2005-11-03 | Merck & Co., Inc. | 2, 4, 6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer’s disease |
WO2005103020A1 (en) | 2004-04-20 | 2005-11-03 | Merck & Co., Inc. | 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2005102390A2 (en) | 2004-04-22 | 2005-11-03 | Pfizer Japan, Inc. | Combinations comprising alpha-2-delta ligands and nmda receptor antagonists |
WO2005105133A2 (en) | 2004-04-23 | 2005-11-10 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving the viability of photoreceptor cells |
WO2005105998A1 (en) | 2004-04-27 | 2005-11-10 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | HUMAN ANTIAMYLOID β PEPTIDE ANTIBODY AND ANTIBODY FRAGMENT THEREOF |
WO2005108382A1 (en) | 2004-05-04 | 2005-11-17 | Merck & Co., Inc. | 1,2,4-oxadiazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
WO2005116014A1 (en) | 2004-05-12 | 2005-12-08 | Pfizer Products Inc. | Proline derivatives and their use as dipeptidyl peptidase iv inhibitors |
WO2005113484A1 (en) | 2004-05-13 | 2005-12-01 | Merck & Co., Inc. | Phenyl carboxamide compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2005116029A1 (en) | 2004-05-18 | 2005-12-08 | Merck & Co., Inc. | Cyclohexylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
WO2005113510A1 (en) | 2004-05-21 | 2005-12-01 | Santhera Pharmaceuticals (Schweiz) Ag | Dpp-iv inhibitors |
WO2005118555A1 (en) | 2004-06-04 | 2005-12-15 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2005120571A2 (en) | 2004-06-07 | 2005-12-22 | Ramot At Tel Aviv University Ltd. | Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation |
WO2005120494A1 (en) | 2004-06-08 | 2005-12-22 | Santhera Pharmaceuticals (Schweiz) Ag | 1-`(3r)-amino-4-(2-fluoro-phenyl)-butyl !-pyrrolidine-(2r)-carboxilic acid-benzyl amine derivatives and related compounds as dipeptidyl-peptidase iv (dpp-iv) inhibitors for the treatment of type 2 diabetes mellitus |
WO2005121089A1 (en) | 2004-06-08 | 2005-12-22 | Santhera Pharmaceuticals (Schweiz) Ag | Dpp-iv inhibitors |
WO2005121131A1 (en) | 2004-06-08 | 2005-12-22 | Santhera Pharmaceuticals (Schweiz) Ag | Dpp-iv inhibitors |
WO2006002004A1 (en) | 2004-06-15 | 2006-01-05 | Merck & Co., Inc. | Pyrrolidin-3-yl compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2005123685A1 (en) | 2004-06-16 | 2005-12-29 | Astrazeneca Ab | Tetrahydroquinolones and aza-analogues thereof for use as dpp-iv inhibitors in the treatement of diabetes |
WO2005123775A1 (en) | 2004-06-21 | 2005-12-29 | Bioarctic Neuroscience Ab | Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof |
WO2006009886A1 (en) | 2004-06-21 | 2006-01-26 | Merck & Co., Inc. | Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
WO2006004880A2 (en) | 2004-06-30 | 2006-01-12 | Schering Corporation | Substituted n-arylsulfonylheterocyclic amines as gamma-secretase inhibitors |
WO2006085961A2 (en) | 2004-06-30 | 2006-08-17 | Centocor, Inc. | Anti-mcp-1 antibodies, compositions, methods and uses |
WO2006014478A1 (en) | 2004-07-02 | 2006-02-09 | Northwestern University | MONOLOCAL ANTIBODIES THAT TARGET PATHOLOGICAL ASSEMBLIES OF AMYLOID β (ABETA) |
WO2006017292A1 (en) | 2004-07-12 | 2006-02-16 | Phenomix Corporation | Constrained cyano compounds |
WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
WO2006020017A2 (en) | 2004-07-16 | 2006-02-23 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2006014638A2 (en) | 2004-07-19 | 2006-02-09 | The General Hospital Corporation | ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS |
WO2006008661A2 (en) | 2004-07-19 | 2006-01-26 | Neurochem (International) Limited | Diagnostic methods of multiple organ amyloidosis |
WO2006014762A1 (en) | 2004-07-22 | 2006-02-09 | Schering Corporation | Substituted amide beta secretase inhibitors |
WO2006014944A1 (en) | 2004-07-28 | 2006-02-09 | Schering Corporation | Macrocyclic beta-secretase inhibitors |
WO2006010965A1 (en) | 2004-07-29 | 2006-02-02 | Richter Gedeon Vegyészeti Gyár Rt. | Indole-2 -carboxamidine derivatives as nmda receptor antagonists |
WO2006036291A2 (en) | 2004-07-30 | 2006-04-06 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
WO2006013104A1 (en) | 2004-08-05 | 2006-02-09 | Santhera Pharmaceuticals (Schweiz) Ag | Heterocyclic compounds useful as dpp- iv inhibitors |
WO2006016644A1 (en) | 2004-08-11 | 2006-02-16 | Mitsubishi Chemical Corporation | Antibody and utilization of the same |
WO2006023750A2 (en) | 2004-08-23 | 2006-03-02 | Merck & Co., Inc. | Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
WO2006021409A1 (en) | 2004-08-25 | 2006-03-02 | Santhera Pharmaceuticals (Schweiz) Ag | Alpha-keto carbonyl calpain inhibitors |
WO2006021413A1 (en) | 2004-08-25 | 2006-03-02 | Santhera Pharmaceuticals (Schweiz) Ag | Alpha-keto carbonyl calpain inhibitors |
WO2006026204A2 (en) | 2004-08-26 | 2006-03-09 | Bristol-Myers Squibb Company | Novel gamma-lactams as beta-secretase inhibitors |
WO2006026408A2 (en) | 2004-08-27 | 2006-03-09 | Wyeth Research Ireland Limited | Production of anti-amyloid beta antibodies |
WO2006029850A1 (en) | 2004-09-14 | 2006-03-23 | The Genetics Company, Inc. | Hydrazone derivatives and their use as beta secretase inhibitors |
WO2006034277A1 (en) | 2004-09-17 | 2006-03-30 | Comentis, Inc. | Bicyclic compounds which inhibit beta-secretase activity and methods of use thereof |
WO2006034296A2 (en) | 2004-09-17 | 2006-03-30 | Comentis, Inc. | Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof |
WO2006039470A2 (en) | 2004-09-29 | 2006-04-13 | Centocor, Inc. | Anti- amyloid antibodies, compositions, methods and uses |
WO2006039325A2 (en) | 2004-10-01 | 2006-04-13 | Merck & Co., Inc. | Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
WO2006042103A2 (en) | 2004-10-05 | 2006-04-20 | Axys Pharmaceuticals, Inc. | Reversible inhibitors of cathepsin b |
WO2006041976A1 (en) | 2004-10-08 | 2006-04-20 | Novartis Ag | Combination of organic compounds |
WO2006040688A2 (en) | 2004-10-12 | 2006-04-20 | Ernir Snorrason | Inhibitors of acetylcholinesterase for treating skin diseases |
WO2006044497A2 (en) | 2004-10-13 | 2006-04-27 | Merck & Co., Inc. | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease |
WO2006039807A1 (en) | 2004-10-15 | 2006-04-20 | Biopharmacopae Design International Inc. | Methods and therapeutic compositions comprising plant extracts for the treatment of cancer |
WO2006047248A1 (en) | 2004-10-25 | 2006-05-04 | Novartis Ag | Combination of dpp-iv inhibitor, ppar antidiabetic and metformin |
WO2006055178A2 (en) | 2004-10-25 | 2006-05-26 | Merck & Co., Inc. | Anti-addl antibodies and uses thereof |
WO2006046644A1 (en) | 2004-10-28 | 2006-05-04 | Sanko Junyaku Co., Ltd. | Method of examining alzheimer’s disease and diagnostic reagent |
WO2006060109A1 (en) | 2004-10-29 | 2006-06-08 | Merck & Co., Inc. | 2-aminopyridine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2006055434A2 (en) | 2004-11-17 | 2006-05-26 | Merck & Co., Inc. | Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2006058059A2 (en) | 2004-11-23 | 2006-06-01 | Neuromolecular Pharmaceuticals, Inc. | Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject |
WO2006057983A1 (en) | 2004-11-23 | 2006-06-01 | Merck & Co., Inc. | Macrocyclic aminopyridyl beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2006057945A2 (en) | 2004-11-23 | 2006-06-01 | Merck & Co., Inc. | 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2006058236A2 (en) | 2004-11-24 | 2006-06-01 | Neuromolecular Pharmaceuticals, Inc. | Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease |
WO2006058064A2 (en) | 2004-11-29 | 2006-06-01 | Merck & Co., Inc. | Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
WO2006058628A2 (en) | 2004-11-30 | 2006-06-08 | F.Hoffmann-La Roche Ag | Substituted benzoquinolizines as dpp-iv inhibitors for the treatment of diabetes |
WO2006060473A2 (en) | 2004-12-03 | 2006-06-08 | Mucosal Therapeutics Llc | Methods of treatment of injured or diseased joints with lubricin compositions |
WO2006066233A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | An immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies |
WO2006066049A2 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
WO2006066171A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Amyloid βετα antibodies for use in improving cognition |
WO2006066089A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
WO2006066747A1 (en) | 2004-12-20 | 2006-06-29 | F. Hoffmann-La Roche Ag | 4-aminopiperidine derivatives |
WO2006066770A1 (en) | 2004-12-20 | 2006-06-29 | F.Hoffmann-La Roche Ag | Cycloalkylamine derivatives |
WO2006068978A2 (en) | 2004-12-21 | 2006-06-29 | Takeda Pharmaceutial Company Limited | Dipeptidyl peptidase inhibitors |
WO2006071274A2 (en) | 2004-12-23 | 2006-07-06 | Voyager Pharmaceutical Corporation | Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer’s disease |
WO2006070394A1 (en) | 2004-12-28 | 2006-07-06 | Council Of Scientific And Industrial Research | Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors |
WO2006074265A2 (en) | 2005-01-06 | 2006-07-13 | Merck & Co., Inc. | Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders |
WO2006078576A2 (en) | 2005-01-19 | 2006-07-27 | Merck & Co., Inc. | Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2006081171A1 (en) | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
WO2006091988A1 (en) | 2005-02-28 | 2006-08-31 | Thomas Christian Lines | Composition for treating mental health disorders |
WO2006094674A1 (en) | 2005-03-07 | 2006-09-14 | Michael Hermanussen | Nmda receptor antagonists in the medical intervention of metabolic disorders |
WO2006095041A1 (en) | 2005-03-09 | 2006-09-14 | Consejo Superior De Investigaciones Científicas | Method for the in vitro diagnosis of alzheimer's disease using a monoclonal antibody |
WO2006099352A1 (en) | 2005-03-10 | 2006-09-21 | Bristol-Myers Squibb Company | Novel isophthalates as beta-secretase inhibitors |
WO2006097624A1 (en) | 2005-03-17 | 2006-09-21 | Sanofi-Aventis | 7-(2-(4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydro-pyrid-1-yl)ethyl) isoquinoline besylate salt, preparation and therapeutic use thereof |
WO2006103116A1 (en) | 2005-04-01 | 2006-10-05 | Biotherapix Molecular Medicines S.L.U. | Human antibodies with beta-amyloid peptide-binding capacity and their applications |
WO2006116435A2 (en) | 2005-04-27 | 2006-11-02 | Novartis Ag | Methods of treating atherosclerosis |
WO2006118959A2 (en) | 2005-04-29 | 2006-11-09 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
WO2006125202A2 (en) | 2005-05-19 | 2006-11-23 | Centocor, Inc. | Anti- mcp-1 antibodies, compositions, methods and uses |
WO2006137354A1 (en) | 2005-06-21 | 2006-12-28 | Medical & Biological Laboratories Co., Ltd. | Antibody having inhibitory effect on amyloid fibril formation |
WO2007011810A1 (en) | 2005-07-18 | 2007-01-25 | Merck & Co., Inc. | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2007019078A2 (en) | 2005-08-03 | 2007-02-15 | Merck & Co., Inc. | Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2007019080A2 (en) | 2005-08-03 | 2007-02-15 | Merck & Co., Inc. | Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2007021793A1 (en) | 2005-08-12 | 2007-02-22 | Bristol-Myers Squibb Company | Macrocyclic diaminopropanes as beta-secretase inhibitors |
WO2007022416A2 (en) | 2005-08-18 | 2007-02-22 | Ramot At Tel Aviv University Ltd. | Single chain antibodies against beta-amyloid peptide |
WO2007038772A1 (en) | 2005-09-28 | 2007-04-05 | American Life Science Pharmaceuticals | Novel drugs for dementia |
WO2007051333A1 (en) | 2005-11-02 | 2007-05-10 | Oncalis Ag | Triazine beta-secretase inhibitors |
WO2007068411A2 (en) | 2005-12-12 | 2007-06-21 | Ac Immune S.A. | Therapeutic vaccine |
WO2007068412A2 (en) | 2005-12-12 | 2007-06-21 | Ac Immune Sa | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
WO2007084595A2 (en) | 2006-01-20 | 2007-07-26 | Schering Corporation | Carbocyclic and heterocyclic arylsulfones as gamma secretase inhibitors |
WO2007097251A1 (en) | 2006-02-22 | 2007-08-30 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | PEPTIDE VACCINE FOR INDUCING PRODUCTION OF ANTI-AMYLOID-β-PEPTIDE ANTIBODY |
EP2011349A2 (en) | 2006-03-17 | 2009-01-07 | Vodafone Group PLC | Improvements in an ehspa architecture |
WO2007113172A2 (en) | 2006-03-30 | 2007-10-11 | Glaxo Group Limited | Antibodies against amyloid-beta peptide |
WO2008011348A2 (en) | 2006-07-14 | 2008-01-24 | Ac Immune S.A. | Humanized antibody against amyloid beta |
WO2008060364A2 (en) | 2006-10-02 | 2008-05-22 | Ac Immune S.A | Humani zed antibody against amyloid beta |
WO2008054698A2 (en) | 2006-10-30 | 2008-05-08 | Merck & Co., Inc. | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2008055950A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
WO2008055947A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
WO2008065141A1 (en) | 2006-11-30 | 2008-06-05 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
WO2008077109A1 (en) | 2006-12-20 | 2008-06-26 | Gregory Hook | Methods of treating alzheimer's disease |
WO2008110523A1 (en) | 2007-03-09 | 2008-09-18 | Probiodrug Ag | Imidazo [1,5-a] pyridine derivatives as inhibitors of glutaminyl cyclase |
WO2008128983A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Cyano-guanidine derivatives as glutaminyl cyclase inhibitors |
WO2008128987A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Novel inhibitors |
WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
WO2008128986A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Urea derivatives as glutaminyl cyclase inhibitors |
WO2008128981A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Nitrovinyl-diamine derivatives as glutaminyl cyclase inhibitors |
WO2008128982A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thioxoquinazolinone derivatives as glutaminyl cyclase inhibitors |
WO2008128984A1 (en) | 2007-04-20 | 2008-10-30 | Probiodrug Ag | Aminopyrimidine derivatives as glutaminyl cyclase inhibitors |
WO2008147800A1 (en) | 2007-05-25 | 2008-12-04 | Elan Pharmaceuticals, Inc. | Pyrazolopyrrolidines as inhibitors of gamma secretase |
WO2008156621A1 (en) | 2007-06-12 | 2008-12-24 | Ac Immune S.A. | Monoclonal anti beta amyloid antibody |
WO2009008980A2 (en) | 2007-07-05 | 2009-01-15 | Schering Corporation | Tetrahydropyranochromene gamma secretase inhibitors |
WO2009011851A1 (en) | 2007-07-17 | 2009-01-22 | Schering Corporation | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors |
WO2009029272A2 (en) | 2007-08-27 | 2009-03-05 | Agadjanyan Michael G | Epitope vaccine for prevention and reversion of ad pathology |
WO2009033743A1 (en) | 2007-09-13 | 2009-03-19 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
WO2009042694A1 (en) | 2007-09-24 | 2009-04-02 | Comentis, Inc. | (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating |
WO2009053696A1 (en) | 2007-10-25 | 2009-04-30 | University College Cardiff Consultants Limited | Monoclonal antibody for app |
WO2009054537A1 (en) | 2007-10-25 | 2009-04-30 | Kagoshima University | PEPTIDE VACCINE USING MIMIC MOLECULE OF AMYLOID β-PEPTIDE |
WO2009056490A1 (en) | 2007-10-29 | 2009-05-07 | Innogenetics Nv | NEW ANTIBODIES SPECIFIC OF THE β-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS |
WO2009065054A2 (en) | 2007-11-16 | 2009-05-22 | The Rockefeller University | Antibodies specific for the protofibril form of beta-amyloid protein |
WO2009090650A2 (en) | 2008-01-16 | 2009-07-23 | Ben-Gurion University Of The Negev Research And Development Authority | Vaccine for alzheimer's disease |
WO2009095857A1 (en) | 2008-01-28 | 2009-08-06 | Consiglio Nazionale Delle Ricerche | Multimeric proteins able to induce an antibody response against the beta-amyloid and use thereof |
WO2009108550A1 (en) | 2008-02-28 | 2009-09-03 | Merck & Co., Inc. | 2-aminoimidazole beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2010012004A2 (en) | 2008-07-25 | 2010-01-28 | The Regents Of The University Of California | Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence |
WO2010011999A2 (en) | 2008-07-25 | 2010-01-28 | The Regents Of The University Of California | Methods and compositions for eliciting an amyloid-selective immune response |
WO2010011947A2 (en) | 2008-07-25 | 2010-01-28 | Abbott Laboratories | AMYLOID ß PEPTIDE ANALOGUES, OLIGOMERS THEREOF, PROCESSES FOR PREPARING AND COMPOSITIONS COMPRISING SAID ANALOGUES OR OLIGOMERS, AND THEIR USES |
WO2010016912A2 (en) | 2008-08-07 | 2010-02-11 | Mercia Pharma, Llc | Immunotherapeutic compositions for the treatment of alzheimer's disease |
WO2010021680A2 (en) | 2008-08-19 | 2010-02-25 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
WO2010026212A1 (en) | 2008-09-04 | 2010-03-11 | Probiodrug Ag | Novel inhibitors |
WO2010044464A1 (en) | 2008-10-16 | 2010-04-22 | 財団法人化学及血清療法研究所 | Modified amyloid beta peptide |
WO2010058333A1 (en) | 2008-11-23 | 2010-05-27 | Pfizer Inc. | Lactams as beta secretase inhibitors |
WO2010090954A1 (en) | 2009-02-06 | 2010-08-12 | Merck Sharp & Dohme Corp. | Novel trifluoromethylsulfonamide gamma secretase inhibitor |
WO2010094242A1 (en) | 2009-02-20 | 2010-08-26 | Merck Sharp & Dohme Corp. | Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease |
Non-Patent Citations (38)
Title |
---|
BATEMAN, R. C. ET AL., BIOCHEMISTRY, vol. 40, 2001, pages 11246 - 11250 |
BATEMAN, R. C. J., J NEUROSCI METHODS, vol. 30, 1989, pages 23 - 28 |
BECK A. ET AL., J PEPT RES, vol. 57, no. 6, 2001, pages 528 - 38 |
BHATIA, M., AM.J PHYSIOL GASTROINTEST.LIVER PHYSIOL, vol. 288, 2005, pages G1259 - G1265 |
BINDER, E. B. ET AL., BIOL PSYCHIATRY, vol. 50, 2001, pages 856 - 872 |
BOCKERS, T. M. ET AL., J NEUROENDOCRINOL, vol. 7, 1995, pages 445 - 453 |
BRINKMEIER H. ET AL., NATURE MEDICINE, vol. 6, 2000, pages 808 - 811 |
BUSBY, W. H. J. ET AL., J BIOL CHEM, vol. 262, 1987, pages 8532 - 8536 |
CLERICI, F., NEUROBIOL.AGING, vol. 27, 2006, pages 1763 - 1768 |
COLL, B. ET AL., CYTOKINE, vol. 34, 2006, pages 51 - 55 |
CONSALVO, A. P. ET AL., ANAL BIOCHEM, vol. 175, 1988, pages 131 - 138 |
DAHL, S. W. ET AL., PROTEIN EXPR PURIF, vol. 20, 2000, pages 27 - 36 |
DOCKRAY, G.J., J PHYSIOL, vol. 15, 1999, pages 315 - 324 |
EI MOUSSAOUI, A. ET AL., CELL MOL LIFE SCI, vol. 58, 2001, pages 556 - 570 |
FISCHER, W. H.; SPIESS, J., PROC NATL ACAD SCI U S A, vol. 84, 1987, pages 3628 - 3632 |
FRASER, L.R.; ADEOYA-OSIGUWA, S. A., VITAM HORM, vol. 63, 2001, pages 1 - 28 |
GALIMBERTI, D. ET AL., ARCH.NEUROL., vol. 63, 2006, pages 538 - 543 |
GOLOLOBOV, M. Y. ET AL., BIOL CHEM HOPPE SEYLER, vol. 377, 1996, pages 395 - 398 |
GONG, J. H. ET AL., J EXP.MED, vol. 186, 1997, pages 131 - 137 |
GOSLING, J. ET AL., J CLIN.LNVEST, vol. 103, 1999, pages 773 - 778 |
H. BUNDGAARD: "Design of Prodrugs", 1985, ELSEVIER |
HUSE J.T. ET AL., J. BIOL. CHEM., vol. 277, no. 18, 2002, pages 16278 - 16284 |
INOSHIMA, I. ET AL., AM.J PHYSIOL LUNG CELL MOL.PHYSIOL, vol. 286, 2004, pages L1038 - L1044 |
J.F.W. MCOMIE: "Protective Groups in Organic Chemistry", 1973, PLENUM PRESS |
KATABUCHI, H. ET AL., MED ELECTRON MICROSC., vol. 36, 2003, pages 253 - 262 |
LI, S. ET AL., J EXP.MED, vol. 202, 2005, pages 617 - 624 |
MESSER, M., NATURE, vol. 4874, 1963, pages 1299 |
MOL. CELL, vol. 2, 1998, pages 275 - 281 |
OGATA, H. ET AL., J PATHOL., vol. 182, 1997, pages 106 - 114 |
OHTA, M. ET AL., INT.J ONCOL., vol. 22, 2003, pages 773 - 778 |
PARK, I. W.; WANG, J. F.; GROOPMAN, J. E., BLOOD, vol. 97, 2001, pages 352 - 358 |
POHL, T. ET AL., PROC NATL ACAD SCI U S A, vol. 88, 1991, pages 10059 - 10063 |
SAIDO T.C., MEDICAL HYPOTHESES, vol. 54, no. 3, 2000, pages 427 - 429 |
SAIURA, A. ET AL., ARTERIOSCLER. THROMB. VASC. BIOL., vol. 24, 2004, pages 1886 - 1890 |
T.W. GREENE; P.G.M. WUTS: "Protective Groups in Organic Synthesis", 1991, JOHN WILEY & SONS |
WADA, T. ET AL., J AM.SOC.NEPHROL., vol. 15, 2004, pages 940 - 948 |
WHITE, F. A. ET AL., PROC. NATL. ACAD.SCI.U.S.A, 2005 |
YAMAMOTO, M. ET AL., AM.J PATHOL., vol. 166, 2005, pages 1475 - 1485 |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012123563A1 (en) * | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
JP2014508184A (en) * | 2011-03-16 | 2014-04-03 | プロビオドルグ エージー | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
US9610368B2 (en) | 2011-05-27 | 2017-04-04 | Probiodrug Ag | Radiolabelled glutaminyl cyclase (QC) inhibitors and uses of same |
US8945510B2 (en) | 2011-05-27 | 2015-02-03 | Probiodrug Ag | Radiolabeled glutaminyl cyclase (QC) inhibitors and uses of same |
JP2014515364A (en) * | 2011-05-27 | 2014-06-30 | プロビオドルグ エージー | Radiolabeled glutaminyl cyclase inhibitor |
WO2014140279A1 (en) * | 2013-03-15 | 2014-09-18 | Probiodrug Ag | Novel inhibitors |
AU2014230249B2 (en) * | 2013-03-15 | 2016-09-01 | Vivoryon Therapeutics N.V. | Novel inhibitors |
US9512115B2 (en) | 2013-03-15 | 2016-12-06 | Probiodrug Ag | Inhibitors |
EA029451B1 (en) * | 2013-03-15 | 2018-03-30 | Пробиодруг Аг | Novel inhibitors |
DE102015011780A1 (en) | 2015-09-16 | 2017-03-16 | Hochschule Anhalt | New glutaminyl cyclase inhibitors |
WO2017046256A1 (en) * | 2015-09-16 | 2017-03-23 | Hochschule Anhalt | Sulfolipids as new glutaminyl cyclase inhibitors |
WO2018178384A1 (en) * | 2017-03-31 | 2018-10-04 | Probiodrug Ag | Novel inhibitors |
IL269196B2 (en) * | 2017-03-31 | 2024-04-01 | Vivoryon Therapeutics N V | Heterocyclic glutaminyl cyclase inhibitors, uses therof as medicaments and pharmaceutical compositions comprising same |
IL269196B1 (en) * | 2017-03-31 | 2023-12-01 | Probiodrug Ag | Heterocyclic glutaminyl cyclase inhibitors, uses therof as medicaments and pharmaceutical compositions comprising same |
AU2018246382B2 (en) * | 2017-03-31 | 2022-06-16 | Vivoryon Therapeutics N.V. | Novel inhibitors |
US11339152B2 (en) | 2017-03-31 | 2022-05-24 | Vivoryon Therapeutics N.V. | Inhibitors |
WO2019022600A1 (en) | 2017-07-24 | 2019-01-31 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Treating pathological conditions by direct and indirect targeting of sirpa - cd47 interaction |
EP3658141B1 (en) | 2017-07-24 | 2022-11-16 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Treating pathological conditions by direct and indirect targeting of sirpalpha - cd47 interaction |
EP3747437A1 (en) | 2017-07-24 | 2020-12-09 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Treating pathological conditions by direct and indirect targeting of sirpa - cd47 interaction |
EP3747438A1 (en) | 2017-07-24 | 2020-12-09 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Treating pathological conditions by direct and indirect targeting of sirpa - cd47 interaction |
EA037862B1 (en) * | 2017-09-29 | 2021-05-28 | Виворайон Терапьютикс Аг | Inhibitors of glutaminyl cyclase |
WO2019063414A1 (en) * | 2017-09-29 | 2019-04-04 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
KR102251645B1 (en) | 2017-09-29 | 2021-05-14 | 비보리온 테라퓨틱스 아게 | Inhibitors of glutaminyl cyclase |
CN111315738A (en) * | 2017-09-29 | 2020-06-19 | 维沃永治疗股份公司 | Inhibitors of glutaminyl cyclase |
CN111315738B (en) * | 2017-09-29 | 2021-08-03 | 维沃永治疗股份公司 | Inhibitors of glutaminyl cyclase |
US11279690B2 (en) | 2017-09-29 | 2022-03-22 | Vivorian Therapeutics N.V | Inhibitors of glutaminyl cyclase |
AU2018340397B2 (en) * | 2017-09-29 | 2020-06-11 | Vivoryon Therapeutics N.V. | Inhibitors of glutaminyl cyclase |
KR20200074948A (en) * | 2017-09-29 | 2020-06-25 | 비보리온 테라퓨틱스 아게 | Inhibitors of glutamineyl cyclase |
EP3461819A1 (en) | 2017-09-29 | 2019-04-03 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
WO2019149689A1 (en) | 2018-01-31 | 2019-08-08 | Probiodrug Ag | Humanized and de-immunized antibodies |
EP3521308A1 (en) | 2018-01-31 | 2019-08-07 | Probiodrug AG | Humanized and de-immunized antibodies |
WO2022268179A1 (en) * | 2021-06-24 | 2022-12-29 | Insilico Medicine Ip Limited | Beta-lactam derivatives for the treatment of diseases |
US11834440B2 (en) | 2021-06-24 | 2023-12-05 | Insilico Medicine Ip Limited | Beta-lactam derivatives for the treatment of diseases |
EP4151207A1 (en) * | 2021-09-17 | 2023-03-22 | National Health Research Institutes | Benzimidazoles for use in the treatment of conditions involving cd47 upregulation or for increasing phagocytosis of a cell |
Also Published As
Publication number | Publication date |
---|---|
AU2010294214A1 (en) | 2012-03-29 |
AU2010294214B2 (en) | 2015-05-07 |
HK1175135A1 (en) | 2013-06-28 |
US8486940B2 (en) | 2013-07-16 |
CA2772488A1 (en) | 2011-03-17 |
US20160039795A1 (en) | 2016-02-11 |
EP2475428B1 (en) | 2015-07-01 |
ES2548913T3 (en) | 2015-10-21 |
CA2772488C (en) | 2018-04-17 |
IL218259A (en) | 2016-09-29 |
US20140065095A1 (en) | 2014-03-06 |
SG178953A1 (en) | 2012-04-27 |
IL218259A0 (en) | 2012-04-30 |
US20110092501A1 (en) | 2011-04-21 |
EA201200474A1 (en) | 2012-10-30 |
JP5934645B2 (en) | 2016-06-15 |
KR20120105421A (en) | 2012-09-25 |
DK2475428T3 (en) | 2015-09-28 |
US9650362B2 (en) | 2017-05-16 |
KR101755737B1 (en) | 2017-07-07 |
EP2475428A1 (en) | 2012-07-18 |
NZ598685A (en) | 2013-05-31 |
CN102695546B (en) | 2014-09-10 |
JP2013504544A (en) | 2013-02-07 |
EA022007B1 (en) | 2015-10-30 |
ZA201201366B (en) | 2013-09-25 |
BR112012008346A2 (en) | 2020-09-15 |
US9173885B2 (en) | 2015-11-03 |
PL2475428T3 (en) | 2015-12-31 |
CN102695546A (en) | 2012-09-26 |
MX2012002993A (en) | 2012-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9650362B2 (en) | Inhibitors | |
EP2545047B1 (en) | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) | |
EP2118101A1 (en) | Imidazo [1,5-a] pyridine derivatives as inhibitors of glutaminyl cyclase | |
EP2686313B1 (en) | Benzimidazole derivatives as inhibitors of glutaminyl cyclase | |
EP2142513A1 (en) | Nitrovinyl-diamine derivatives as glutaminyl cyclase inhibitors | |
WO2008128983A1 (en) | Cyano-guanidine derivatives as glutaminyl cyclase inhibitors | |
WO2010026212A1 (en) | Novel inhibitors | |
EP2542549A2 (en) | Inhibitors of glutaminyl cyclase | |
EP2560953A2 (en) | Novel inhibitors | |
BR112012008346B1 (en) | HETEROCYCLIC DERIVATIVES, THEIR PREPARATION PROCESS, AND PHARMACEUTICAL COMPOSITION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10751952 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 218259 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 416/KOLNP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2772488 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012528379 Country of ref document: JP Ref document number: MX/A/2012/002993 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010294214 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010751952 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2010294214 Country of ref document: AU Date of ref document: 20100913 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20127008546 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201200474 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012008346 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012008346 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120312 |